

## NICHOLAS JAMES SHAHEEN, M.D., M.P.H.

### Home Address

111 Edward Booth Ln.  
Durham, NC 27713  
(919) 819-0881  
e mail: nshaheen@med.unc.edu

### Work Address

University of North Carolina  
Division of Gastroenterology, CB #7080  
101 Manning Rd.  
Chapel Hill, NC 27599-7080  
(919) 819-0881

### Education

	<u>Location</u>	<u>Degree/Date</u>
1983-1987	Harvard University	B.A., 1987
1987-1991	University of Chicago, Pritzker School of Medicine	M.D., 1991
1996-1998	University of North Carolina	M.P.H., 1998

### Certification and Licensure

1991	Diplomate, National Board of Medical Examiners
1991	Illinois License No. 125026922
1994	North Carolina License No. 94-00634
1994	Diplomate, American Board of Internal Medicine
1997	BLS and ACLS certified, renewed through 2024
1998	Diplomate, ABIM Subspecialty of Gastroenterology (recertified through 2027)

### Professional Training

1991-1992 Intern, University of Chicago, Department of Medicine  
1992-1994 Resident, University of Chicago, Department of Medicine  
1994-1997 Clinical Fellow, University of North Carolina, Department of Medicine, Division of Digestive Diseases  
1997-1998 Research Fellow, National Institutes of Health Outcomes Training Program in Epidemiology (T32DK007634) at University of North Carolina

### Employment

2020-present Co-Director, North Carolina Translational & Clinical Sciences Institute (NC TraCS), home of UNC's CTSA Award  
2016-present Mary Kay & Eugene Bozymski and Linda & William Heizer Distinguished Professor of Medicine, University of North Carolina School of Medicine  
2013-present Chief, Division of Gastroenterology & Hepatology, University of North Carolina School of Medicine  
2009-2016 Professor of Medicine and Epidemiology (Tenured), University of North Carolina School of Medicine and School of Public Health  
2004-2009 Associate Professor of Medicine and Epidemiology (Tenured), University of North Carolina School of Medicine and School of Public Health  
1998-2004 Assistant Professor of Medicine and Epidemiology, University of North Carolina School of Medicine and School of Public Health  
1997-1998 Clinical Instructor, University of North Carolina School of Medicine

## Honors and Awards

2023	Master Endoscopist Award, American Society of Gastrointestinal Endoscopy
2020-present	Named Expertscape's Top Expert in the World in Barrett's Esophagus ( <a href="https://www.expertscape.com/ex/barrett+esophagus">https://www.expertscape.com/ex/barrett+esophagus</a> )
2020	Master, American College of Gastroenterology
2019	Theodore E. Woodward Award for best paper at the annual meeting of the American Clinical and Climatological Association
2018	Mentor of the Year, AGA Esophageal, Gastric and Duodenal Section
2018	ACG Governors' Award for Best Scientific Paper of the Meeting, ACG 2018
2017	Excellence in Mentoring Award, UNC GI Fellowship
2013	Emily Couric Honorary Lectureship, American College of Gastroenterology
2003-present	"Best Doctors in America," <sup>®</sup> elected biannually in every cycle
2011	Clinical Teacher of the Year, UNC Academy of Educators
2007-2011	Ray Hayworth '62 Medical Alumni Distinguished Teaching Professorship
2010	AGA Institute Master's Award in Gastroenterology Research
2010	Eugene Bozyski Award for Excellence in Endoscopy Teaching, UNC GI Fellowship
2008	Excellence in Mentoring Award, UNC GI Fellowship
2008	Fellow, University of North Carolina Academy of Educators
2007	White Coat Oration, University of North Carolina
2006-2007	President, North Carolina Society of Gastroenterology
2006	Fellow, American Gastroenterological Association
2005	Sophomore Basic Science Teaching Award, awarded by the 2 <sup>nd</sup> year class to the most outstanding teacher in the second year curriculum
2005	American Gastroenterological Association's Young Clinical Investigator Award, for "originality and innovative insight into a major problem in gastroenterology" (one awarded nationally)
2003	Research Excellence in Gastrointestinal and Liver (REGAL) Award, awarded for achievements in GI outcomes research (one of five awarded nationally)
2003	UNC GI Fellows' Excellence in Teaching Award
2002	Whitehead Medical Society Lectureship, selected by the student body of the medical school to give the honorary opening lecture of the school year
2002	Sophomore Basic Science Teaching Award, awarded by the 2 <sup>nd</sup> year class to the most outstanding teacher in the second year curriculum
2001	Dean's Excellence in Teaching Award
2001	Fellow, American College of Gastroenterology
2001	Fellow, American College of Physicians
2000	Hyman Battle Excellence in Teaching Award awarded by the 1 <sup>st</sup> and 2 <sup>nd</sup> year classes to the most outstanding teacher in the Basic Sciences
1999	American College of Gastroenterology Faculty Development Award (one of three awarded nationally)
1999	American Digestive Health Foundation Award for Outcomes Research (one of two awarded nationally)
1996	A.C.G. National Fellows Abstract Contest, Finalist
1993	Hilger Jenkins Perry Prize awarded annually by the senior class of the medical school to the outstanding member of the housestaff at the University of Chicago
1991-1993	Department of Internal Medicine Outstanding Clinical Teaching Award
1992	Alpha Omega Alpha Honorary Medical Fraternity, U. of Chicago
1988	NIH Research Award for Undergraduate Medical Education
1987	Magna Cum Laude, Harvard
1984	Dwight D. Eisenhower Congressional Summer Grant
1983	National Merit Scholar
1983	Valedictorian, R.B. Hayes High School

## Bibliography

### Contributions to Textbooks (26)

1. Wallace MB, Fockens P, Sung JJ. Gastroenterological Endoscopy, 3rd edition. **Shaheen NJ** associate editor. Thieme Publishing, Stuttgart, Germany, 2018.
2. Crockett SD, Dellon E, **Shaheen NJ**. Miscellaneous Diseases of the Esophagus. In: Yamada's Textbook of Gastroenterology, 6<sup>th</sup> edition. Wiley Publications, Hoboken, NJ, Yamada T, Alpers DH, Kalloo AN, Kaplowitz, Chung O, Powel DW, eds. 2015.
3. Kim HP, Crockett SD, **Shaheen NJ**. The Burden of Gastrointestinal Illness. Pgs. 3-16. In: GI Epidemiology: Diseases and Clinical Methodology, 2<sup>nd</sup> edition. Wiley Publishing, Oxford, UK. Talley NJ, Locke GR, Saito-Loftus YA, Eds.2014.
4. Bulsiewicz WJ, **Shaheen NJ**. Clinical features and endoscopic therapy in Barrett's esophagus. Pgs 306-316. In: Shackleford's Surgery of the Alimentary Tract, Ed 7. Yeo C, Ed. Elsevier, Maryland Heights, MO, 2013.
5. Bulsiewicz WJ, **Shaheen NJ**. Clinical features and endoscopic therapy in Barrett's esophagus. Pgs 306-316. In: Shackleford's Surgery of the Alimentary Tract, Ed 7. Yeo C, Ed. Elsevier, Maryland Heights, MO, 2013
6. **Shaheen NJ**. Symptoms and diagnosis of digestive disorders. Pgs 114-131. In: The Merck Manual of Medical Information – Home Edition, 3<sup>rd</sup> Edition. Porter RS, Kaplan JL, Homeier BP, eds. Merck Manual Publications, West Point, PA., 2009.
7. **Shaheen NJ**. Biology of the digestive system. Pgs 110-114. In: The Merck Manual of Medical Information – Home Edition, 3<sup>rd</sup> Edition. Porter RS, Kaplan JL, Homeier BP, eds. Merck Manual Publications, West Point, PA., 2009.
8. Long MD, **Shaheen NJ**. Epidemiology of Extra-Esophageal Reflux. Pgs. 1-18. In: Extra-Esophageal Reflux. Plural Publishing, San Diego, CA, 2009.
9. Palmer L, **Shaheen NJ**. Improving Screening Practices in Barrett's Esophagus. Pgs. 423-38. In: Barrett's Esophagus and Cancer. Surgical Clinics of North America. WB Saunders Co, Philadelphia, PA, 2009.
10. Dellon E, **Shaheen NJ**. Miscellaneous Diseases of the Esophagus. In: Yamada's Textbook of Gastroenterology, 5<sup>th</sup> edition. Wiley Publications, Hoboken, NJ, Yamada T, Alpers DH, Kalloo AN, Kaplowitz, Chung O, Powel DW, eds. 2008.
11. Dellon E, **Shaheen NJ**. Epidemiology of Gastro-Esophageal Cancer. In: Gastrointestinal Oncology: A Critical Multidisciplinary Approach. Lippincott, Blackwell Publishing, Oxford, UK. Jankowski, Sampliner, Kerr, and Fong, eds. publication pending, 34 type-written pgs.
12. Dellon E, **Shaheen NJ**. Esophageal Cancer: Epidemiology, Screening, and Prevention. Pages 157-166. In: Gastrointestinal Oncology: Principles and Practice, 2<sup>nd</sup> Ed. Lippincott, Williams and Wilkins Co., Philadelphia, PA. Kelsen D, Daly G, Kern AR, Levine B, Tepper J, and Van Cutsem N, Eds., 2008.
13. **Shaheen NJ**. Oropharyngeal dysphagia, achalasia and other esophageal motility problems: Clinical relevance and management. Pgs 7-16. In: Pathogenesis and Clinical Practice in Gastroenterology. Springer Publications, Dordrecht, The Netherlands, 2008.

14. **Shaheen NJ**. The Burden of Gastrointestinal Illness. Pgs. 8-16. In: Epidemiology of Gastroenterological Diseases. Blackwell Publishing, Oxford, UK. Talley NJ, Locke GR, Saito-Loftus YA, Eds., 2007.
15. Madanick RD, **Shaheen NJ**. Esophageal Disorders – Dysphagia. Pages 485-91. In: Netter's Textbook of Medicine, 2<sup>nd</sup> Ed. M.S. Runge, M.A. Greganti, Icon Publications, St. Louis, MO., 2007.
16. **Shaheen NJ**. Wire-Guided Dilatation. Pgs 164-168. In: Manual of Gastroenterologic Procedures. Lippincott Co., Philadelphia, PA. Drossman DA, **Shaheen NJ**, Grimm IS, Eds., 2005.
17. Wei JT, **Shaheen NJ**. Colonic Decompression. Pgs 156-160. In: Manual of Gastroenterologic Procedures. Lippincott Co., Philadelphia, PA. Drossman DA, **Shaheen NJ**, Grimm IS, Eds., 2005.
18. **Shaheen NJ**. Assorted Topics. In: AGA's Guidebook to ABIM Recertification, 2003. M DeLegge, P Schoenfeld, P Sharma, American Gastroenterological Association Publications, Bethesda, 2003.
19. **Shaheen NJ**, Rich M. Gastroesophageal Disease. In: Netter's Textbook of Medicine. Pgs. 303-309. M.S. Runge, M.A. Greganti, Icon Publications, St. Louis, MO., 2003
20. **Shaheen NJ**, Rich M. Peptic Ulcer Disease. In: Netter's Textbook of Medicine. Pgs. 340-347. M.S. Runge, M.A. Greganti, Eds. Icon Publications, St. Louis, MO., 2003.
21. Feder O, **Shaheen NJ**. Complications: Strictures, Ulcers, Bleeding. Pgs 55-82. In: Hot Topics in GERD and Dyspepsia. Hanley & Belfus, Inc., Philadelphia, PA, 2003.
22. Drossman DA, **Shaheen NJ**. Symptoms and diagnosis of digestive disorders. In: The Merck Manual of Medical Information – Home Edition. Pgs. 699-706. Merck Manual Publications, West Point, PA., 2003.
23. **Shaheen NJ**, Bozyski EM. Esophageal Complications of Reflux Disease. Pgs 193-218. In: Gastroesophageal Reflux Disease, R. Orlando et al, eds. Dekker Publishing, Philadelphia, 2000.
24. Grimm IS, **Shaheen NJ**. Therapy for Chronic Hepatitis. Pgs 913-920. In: Sexually Transmitted Diseases, Third Edition, W. Holmes et al, McGraw-Hill, Philadelphia, 1999.
25. Bozyski EM, **Shaheen NJ**. Peptic Ulcer Disease. Pgs 210-216. In: Clinical Problems in Adult Ambulatory Medicine, L Dornbrand et al., Little Brown, Boston, 1997.
26. Bozyski EM, **Shaheen NJ**. Dysphagia. Pgs 196-200. In: Clinical Problems in Adult Ambulatory Medicine, L Dornbrand et al., Little Brown, Boston, 1997.

### **Textbooks Authored, Edited (3)**

1. New Directions in Barrett's Esophagus (An edition of Gastrointestinal Endoscopy Clinics of North America). Elsevier, Amsterdam, Netherlands. **Shaheen NJ**, Ed., 2017.
2. Benign and Malignant Esophageal Diseases (An edition of Gastroenterology Clinics of North America). Elsevier, Amsterdam, Netherlands. **Shaheen NJ**, Ed., 2013.
3. Manual of Gastroenterologic Procedures. Lippincott, Williams and Wilkins Co., Philadelphia, PA. Drossman DA, **Shaheen NJ**, Grimm IS, Eds., 2005.

## Publications in Peer-Reviewed Journals (434)

### Original Research

1. Eluri S, Reddy S, Ketchem CC, Tappata M, Nettles HG, Watts AE, Cotton CC, Dellon ES, **Shaheen NJ**. Low prevalence of endoscopic screening for Barrett's esophagus in a screen-eligible primary care population. *Am J Gastroenterol*. 2022 Aug 12. doi: 10.14309/ajg.0000000000001935. Online ahead of print.
2. Gaber CE, **Shaheen NJ**, Edwards JK, Sandler RS, Nichols HB, Sanoff HK, Lund JL. Trimodality therapy vs definitive chemoradiation in older adults with locally advanced esophageal cancer. *JNCI Cancer Spectrum*. 2022 Oct 7;pkac069. doi: 10.1093/jncics/pkac069. Online ahead of print.
3. Gaber CE, **Shaheen NJ**, Sandler RS, Edwards JK, Nichols HB, Sanoff HK, Lund JL. Patterns of care amongst older adults diagnosed with locally advanced esophageal cancer: A cohort study. *J Geriatr Oncol*. 2022 Aug 22;S1879-4068(22)00200-4. doi: 10.1016/j.jgo.2022.08.009. Online ahead of print.
4. Blum AE, Ravillah D; BETRNet Consortium, Katabathula RM, Khalighi S, Varadan V, Guda K; BETRNet Contributors, Singh S, Miao Y, Kresak AM, Willis JE, Canto MI, Wang JS, **Shaheen NJ**, Chak A. HNF4A Defines Molecular Subtypes and Vulnerability to TGF $\beta$ -pathway Targeted Therapies in Cancers of the Distal Esophagus. *Gastroenterology*. 2022 Aug 4:S0016-5085(22)00830-7. doi: 10.1053/j.gastro.2022.07.073. Online ahead of print.
5. Schröder J, Chegwidan L, Maj C, Gehlen J, Speller J, Böhmer AC, Borisov O, Hess T, Kreuser N, Venerito M, Alakus H, May A, Gerges C, Schmidt T, Thieme R, Heider D, Hillmer AM, Reingruber J, Lyros O, Dietrich A, Hoffmeister A, Mehdorn M, Lordick F, Stocker G, Hohaus M, Reim D, Kandler J, Müller M, Ebigbo A, Fuchs C, Bruns CJ, Hölscher AH, Lang H, Grimminger PP, Dakkak D, Vashist Y, May S, Görg S, Franke A, Ellinghaus D, Galavotti S, Veits L, Weismüller J, Dommermuth J, Benner U, Rösch T, Messmann H, Schumacher B, Neuhaus H, Schmidt C, Wissinowski TT, Nöthen MM; Wellcome Trust Case Control Consortium 2 (WTCCC2); Esophageal Adenocarcinoma Genetics Consortium (EAGLE); **Barrett's and Esophageal Adenocarcinoma Consortium (BEACON)**, Dong J, Ong JS, Buas MF, Thrift AP, Vaughan TL, Tomlinson I, Whiteman DC, Fitzgerald RC, Jankowski J, Vieth M, Mayr A, Gharahkhani P, MacGregor S, Gockel I, Palles C, Schumacher J. GWAS meta-analysis of 16 790 patients with Barrett's oesophagus and oesophageal adenocarcinoma identifies 16 novel genetic risk loci and provides insights into disease aetiology beyond the single marker level. *Gut*. 2022 Jul 26;gutjnl-2021-326698. doi: 10.1136/gutjnl-2021-326698. Online ahead of print.
6. Muthusamy VR, Wani S, Gyawali CP, Komanduri S; **CGIT Barrett's Esophagus Consensus Conference Participants**. AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review. *Clin Gastroenterol Hepatol*. 2022 Jul 3:S1542-3565(22)00599-7. doi: 10.1016/j.cgh.2022.06.003. Online ahead of print.
7. Wang X, Gharahkhani P, Levine DM, Fitzgerald RC, Gockel I, Corley DA, Risch HA, Bernstein L, Chow WH, Onstad L, **Shaheen NJ**, Lagergren J, Hardie LJ, Wu AH, Pharoah PDP, Liu G, Anderson LA, Iyer PG, Gammon MD, Caldas C, Ye W, Barr H, Moayyedi P, Harrison R, Watson RP, Attwood S, Chegwidan L, Love SB, MacDonald D, deCaestecker J, Prenen H, Ott K, Moebus S, Venerito M, Lang H, Mayershofer R, Knapp M, Veits L, Gerges C, Weissmüller J, Reeh M, Nöthen MM, Izbicki JR, Manner H, Neuhaus H, Rösch T, Böhmer AC, Hölscher AH, Anders M, Pech O, Schumacher B, Schmidt C, Schmidt T, Noder T, Lorenz D, Vieth M, May A, Hess T, Kreuser N, Becker J, Ell C, Tomlinson I, Palles C, Jankowski JA, Whiteman DC, MacGregor S, Schumacher J, Vaughan TL, Buas MF, Dai JY. eQTL set-based association analysis identifies novel susceptibility loci for Barrett's

esophagus and esophageal adenocarcinoma. *Cancer Epidemiol Biomarkers Prev.* 2022 Jun 16;cebp.0096.2022-1-28 23:14:21.547. doi: 10.1158/1055-9965.EPI-22-0096. Online ahead of print.

8. Yu M, Moinova HR, Willbanks A, Cannon VK, Wang T, Carter K, Kaz A, Reddi D, Inadomi J, Luebeck G, Iyer PG, Canto MI, Wang JS, **Shaheen NJ**, Thota PN, Willis JE, LaFramboise T, Chak A, Markowitz SD, Grady WM. Novel DNA Methylation Biomarker Panel for Detection of Esophageal Adenocarcinoma and High-grade Dysplasia. *Clin Cancer Res.* 2022 Jun 15;clincanres.0445.2022-2-11 17:32:55.870. doi: 10.1158/1078-0432.CCR-22-0445. Online ahead of print.
9. Wani S, Souza RF, Durkalski VL, Serrano J, Hamilton F, **Shaheen NJ**; SURVENT TRIAL CONSORTIUM. Multicenter Randomized Controlled Trial of Surveillance Versus Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia: The SURVENT Trial: Study Rationale, Methodology, Innovation, and Implications. *Gastroenterology.* 2022 Jun 6:S0016-5085(22)00597-2. doi: 10.1053/j.gastro.2022.05.051. Online ahead of print.
10. **Shaheen NJ**, Falk GW, Iyer PG, Souza RF, Wani S. Guideline to Practice: Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. *Am J Gastroenterol.* 2022 Aug 1;117(8):1177-1180.
11. Cotton CC, **Shaheen NJ**, Thrift AP. Surveillance After Treatment of Barrett's Esophagus Benefits Those With High-Grade Dysplasia or Intramucosal Cancer Most. *Am J Gastroenterol.* 2022;117(7):1056-1062.
12. Walters KM, Jojic A, Pfaff ER, Rape M, Spencer DC, **Shaheen NJ**, Lamm B, Carey TS. Supporting research, protecting data: one institution's approach to clinical data warehouse governance. *J Am Med Inform Assoc.* 2022 Mar 15;29(4):707-712.
13. **Shaheen NJ**, Smith MS, Odze RD. Progression of Barrett's esophagus, crypt dysplasia, and low-grade dysplasia diagnosed by wide-area transepithelial sampling with 3-dimensional computer-assisted analysis: a retrospective analysis. *Gastrointest Endosc.* 2022 Mar;95(3):410-418.e1.
14. Ong JS, An J, Han X, Law MH, Nandakumar P; 23andMe Research team; **Esophageal cancer consortium**, Schumacher J, Gockel I, Bohmer A, Jankowski J, Palles C, Olsen CM, Neale RE, Fitzgerald R, Thrift AP, Vaughan TL, Buas MF, Hinds DA, Gharahkhani P, Kendall BJ, MacGregor S. Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett's oesophagus and provides insights into clinical heterogeneity in reflux diagnosis. *Gut* 2021 Jun 29;gutjnl-2020-323906. doi: 10.1136/gutjnl-2020-323906. Online ahead of print.
15. Bhatia S, Cotton CC, Kim E, Angle H, Watts AE, Eluri S, **Shaheen NJ**. Gender and Nationality Trends in Manuscripts Published in Prominent Gastroenterology Journals Between 1997 and 2017. *Dig Dis Sci* 2022 Feb;67(2):367-376.
16. Jones B, Williams JL, Komanduri S, Muthusamy VR, **Shaheen NJ**, Wani S. Racial Disparities in Adherence to Quality Indicators in Barrett's Esophagus: An Analysis Using the GIQuIC National Benchmarking Registry. *Am J Gastroenterol* 2021 Jun 1;116(6):1201-1210.
17. Glamour BK, Alaber O, Cioffi G, Chandar AK, Barnholtz-Sloan J, Brock W, Falk GW, Canto MI, Wang JS, Iyer PG, **Shaheen NJ**, Grady WM, Abrams JA, Thota PN, Chak A, Blum AE. Age of diagnosis in familial Barrett's associated neoplasia. *Fam Cancer* 2022 Jan;21(1):115-120.
18. Eluri S, Paterson A, Lauren BN, O'Donovan M, Bhandari P, di Pietro M, Lee M, Haidry R, Lovat L, Ragunath K, Hur C, Fitzgerald RC, **Shaheen NJ**. Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy.

Clin Gastroenterol Hepatol 2022 Feb;20(2):e51-e63. doi: 10.1016/j.cgh.2021.02.013. Epub 2021 Feb 10.

19. **Shaheen NJ**, Komanduri S, Muthusamy VR, Wani S, O'Donovan M, Kaushal R, Haydek JM. Acceptability and Adequacy of a Non-endoscopic Cell Collection Device for Diagnosis of Barrett's Esophagus: Lessons Learned. *Dig Dis Sci* 2022 Jan;67(1):177-186. doi: 10.1007/s10620-021-06833-6. Epub 2021 Feb 3.
20. Yang Z, Soltanian-Zadeh S, Chu KK, Zhang H, Moussa L, Watts AE, **Shaheen NJ**, Wax A, Farsi S. Connectivity-based deep learning approach for segmentation of the epithelium in vivo human esophageal OCT images. *Biomed Opt Express*. 2021 Sep 15;12(10):6326-6340.
21. Douville C, Moinova HR, Thota PN, **Shaheen NJ**, Iyer PG, Canto MI, Wang JS, Dumot JA, Faulx A, Kinzler KW, Papadopoulos N, Vogelstein B, Markowitz SD, Bettegowda C, Willis JE, Chak A. Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus. *Gastroenterology* 2021 May;160(6):2043-2054.
22. Peery AF, Crockett SD, Murphy CC, Jensen ET, Kim HP, Egberg MD, Lund JL, Moon AM, Pate V, Barnes EL, Schlusser CL, Baron TH, **Shaheen NJ**, Sandler RS. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2021. *Gastroenterology*. 2022 Feb;162(2):621-644
23. Cotton CC, Woosley JT, Moist SE, McGee SJ, Iuga A, **Shaheen NJ**, Dellon ES. Determination of a treatment response threshold for the Eosinophilic Esophagitis Endoscopic Reference Score. *Endoscopy*. 2021 Oct 21. doi: 10.1055/a-1675-7860. Online ahead of print.
24. Chang N, Raja S, Betancourt R, Randall C, Keene S, Lilly A, Fowler M, Woosley JT, **Shaheen NJ**, Dellon ES. Generic Measures of Quality of Life Are Not Correlated with Disease Activity in Eosinophilic Esophagitis. *Dig Dis Sci* 2021 Oct;66(10):3312-3321.
25. Dighe SG, Chen J, Yan L, He Q, Gharahkhani P, Onstad L, Levine DM, Palles C, Ye W, Gammon MD, Iyer PG, Anderson LA, Liu G, Wu AH, Dai JY, Chow WH, Risch HA, Lagergren J, **Shaheen NJ**, Bernstein L, Corley DA, Prenen H, deCaestecker J, MacDonald D, Moayyedi P, Barr H, Love SB, Chegwidden L, Attwood S, Watson P, Harrison R, Ott K, Moebus S, Venerito M, Lang H, Mayershofer R, Knapp M, Veits L, Gerges C, Weismüller J, Gockel I, Vashist Y, Nöthen MM, Izbicki JR, Manner H, Neuhaus H, Rösch T, Böhmer AC, Hölscher AH, Anders M, Pech O, Schumacher B, Schmidt C, Schmidt T, Noder T, Lorenz D, Vieth M, May A, Hess T, Kreuser N, Becker J, Ell C, Ambrosone CB, Moysich KB, MacGregor S, Tomlinson I, Whiteman DC, Jankowski J, Schumacher J, Vaughan TL, Madeleine MM, Hardie LJ, Buas MF. Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. *Carcinogenesis* 2021 Apr 17;42(3):369-377.
26. Ong JS, Dixon-Suen SC, Han X, An J; **Esophageal Cancer Consortium**; 23 and Me Research Team, Liyanage U, Dusingize JC, Schumacher J, Gockel I, Böhmer A, Jankowski J, Palles C, O'Mara T, Spurdle A, Law MH, Iles MM, Pharoah P, Berchuck A, Zheng W, Thrift AP, Olsen C, Neale RE, Gharahkhani P, Webb PM, MacGregor S. A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using Mendelian randomization. *Nat Commun* 2021 Jan 11;12(1):246. doi: 10.1038/s41467-020-20368-w.
27. Cotton CC, Betancourt R, Randall C, Perjar I, Bookhout C, Woosley JT, **Shaheen NJ**, Dellon ES. A Model Using Clinical and Endoscopic Characteristics Identifies Patients at Risk for Eosinophilic Esophagitis According to Updated Diagnostic Guidelines. *Clin Gastroenterol Hepatol* 2021 Sep;19(9):1824-1834
28. Canto MI, Trindade AJ, Abrams J, Rosenblum M, Dumot J, Chak A, Iyer P, Diehl D, Khara HS, Corbett FS, McKinley M, Shin EJ, Waxman I, Infantolino A, Tofani C, Samarasena J,

Chang K, Wang B, Goldblum J, Voltaggio L, Montgomery E, Lightdale CJ, Shaheen NJ. Multifocal Cryoballoon Ablation for Eradication of Barrett's Esophagus-Related Neoplasia: A Prospective Multicenter Clinical Trial. *Am J Gastroenterol* 2020 Nov;115(11):1879-1890.

29. Kamal A, Katzka DA, Achkar E, Carlson D, Clarke J, Fass R, Gyawali CP, Patel D, Penagini R, Rezaie A, Roman S, Savarino E, **Shaheen NJ**, Triadafilopoulos G. Development of a Preliminary Question Prompt List as a Communication Tool for Adults With Gastroesophageal Reflux Disease: A Modified Delphi Study. *Journal of Clinical Gastroenterology* 2020; epub ahead of print.
30. Wani S, Williams JL, Falk GW, Komanduri S, Muthusamy VR, **Shaheen NJ**. An Analysis of the GIQuIC Nationwide Quality Registry Reveals Unnecessary Surveillance Endoscopies in Patients With Normal and Irregular Z-Lines. *Am J Gastroenterol* 2020 Nov;115(11):1869-1878.
31. Eluri S, Corder SR, Kim E, Tappata M, Reed CC, **Shaheen NJ**, Dellon ES. Clinical features and time trends associated with an endoscopically normal esophagus in active eosinophilic esophagitis. *Endoscopy* 2021 Sep;53(9):886-892.
32. Gay CL, Neo DT, Devanathan AS, Kuruc JD, McGee KS, Schmitz JL, Sebastian J, **Shaheen NJ**, Ferrari G, McKellar M, Fiscus SA, Hicks CB, Robertson K, Kashuba ADM, Eron JJ, Margolis DM. Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. *AIDS* 2020 Nov 1;34(13):1923-1931.
33. Dong J, Maj C, Tsavachidis S, Ostrom QT, Gharahkhani P, Anderson LA, Wu AH, Ye W, Bernstein L, Borisov O, Schröder J, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA, May A, Gerges C, Anders M, Venerito M, Schmidt T, Izbicki JR, Hölscher AH, Schumacher B, Vashist Y, Neuhaus H, Rösch T, Knapp M, Krawitz P, Böhmer A, Iyer PG, Reid BJ, Lagergren J, **Shaheen NJ**, Corley DA, Gockel I, Fitzgerald RC, Cook MB, Whiteman DC, Vaughan TL, Schumacher J, Thrift AP; Stomach and Oesophageal Cancer Study (SOCS) consortium. Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. *Gastroenterology* 2020 Dec;159(6):2065-2076.
34. Henn AJ, Song KY, Gravely AA, Mesa H, Sultan S, **Shaheen NJ**, Shaukat A, Hanson BJ. Persistent indefinite for dysplasia in Barrett's esophagus is a risk factor for dysplastic progression to low-grade dysplasia. *Diseases of the Esophagus* 2020; epub ahead of print.
35. Eluri S, Iglesia EGA, Massaro M, Peery AF, **Shaheen NJ**, Dellon ES. Practice patterns and adherence to clinical guidelines for diagnosis and management of eosinophilic esophagitis among gastroenterologists. *Diseases of the Esophagus* 2020; epub ahead of print.
36. Purkayastha BPD, Chan ER, Ravillah D, Ravi L, Gupta R, Canto MI, Wang JS, **Shaheen NJ**, Willis JE, Chak A, Varadan V, Guda K. Genome-Scale Analysis Identifies Novel Transcript-Variants in Esophageal Adenocarcinoma. *Cell Mol Gastroenterol Hepatol*. 2020;10(3):652-654.
37. Wani S, Williams JL, Komanduri S, Muthusamy VR, **Shaheen NJ**. Time Trends in Adherence to Surveillance Intervals and Biopsy Protocol Among Patients With Barrett's Esophagus. *Gastroenterology*. 2020 Feb;158(3):770-772.
38. Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, Gebhart JH, Galanko JA, Baron JA, **Shaheen NJ**. Rapid Recurrence of Eosinophilic Esophagitis Activity After Successful Treatment in the Observation Phase of a Randomized, Double-Blind, Double-Dummy Trial. *Clinical Gastroenterology & Hepatology* 2020 Jun;18(7):1483-1492.
39. Eluri S, Tappata M, Huang KZ, Koutlas NT, Robey BS, Fan C, Reed CC, **Shaheen NJ**, Dellon ES. Distal esophagus is the most commonly involved site for strictures in patients with



eosinophilic esophagitis. *Dis Esophagus*. 2020 Mar 5;33(2):doz088. doi: 10.1093/dote/doz088.

40. Dellon ES, Woosley JT, McGee SJ, Moist SE, **Shaheen NJ**. Utility of major basic protein, eotaxin-3, and mast cell tryptase staining for prediction of response to topical steroid treatment in eosinophilic esophagitis: analysis of a randomized, double-blind, double dummy clinical trial. *Diseases of the Esophagus*. 2020 Jun 15;33(6):doaa003.
41. Srinivas N, Cottrell M, Maffuid K, Prince HA, Nelson JAE, White N, Sykes C, Dellon ES, Madanick RD, **Shaheen NJ**, Gonzalez D, Kashuba ADM. Translational Approach to Predicting the Efficacy of Maraviroc-Based Regimens as HIV Preexposure Prophylaxis. *Antimicrobial Agents & Chemotherapy*. 2020 Jan 27;64(2):e01729-19.
42. Yadlapati R, Triggs J, Quader F, Eluri S, Bhatia S, Kaizer A, Pandolfino JE, Komanduri S, Gyawali P, **Shaheen NJ**, Menard-Katcher P, Wani S. Reduced Esophageal Contractility Is Associated with Dysplasia Progression in Barrett's Esophagus: A Multicenter Cohort Study. *Digestive Diseases and Sciences* 2020; epub ahead of print.
43. Eluri S, Perjar I, Betancourt R, Randall C, Raja S, Woosley JT, **Shaheen NJ**, Dellon ES. Heartburn and dyspepsia symptom severity improves after treatment and correlates with histology in adults with eosinophilic esophagitis. *Diseases of the Esophagus* 2019 Nov 13;32(9):doz028. doi: 10.1093/dote/doz028.
44. Wani S, Williams JL, Komanduri S, Muthusamy VR, **Shaheen NJ**. Endoscopists systematically undersample patients with long-segment Barrett's esophagus: an analysis of biopsy sampling practices from a quality improvement registry. *Gastrointestinal Endoscopy* 2019;90(5):732-741.
45. Song KY, Henn AJ, Gravely AA, Mesa H, Sultan S, **Shaheen NJ**, Shaukat A, Hanson BJ. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort. *Diseases of the Esophagus*. 2020 Mar 5;33(2):doz061. doi: 10.1093/dote/doz061.
46. Eluri S, Earasi AG, Moist SE, Dellon ES, **Shaheen NJ**. Prevalence and Incidence of Intestinal Metaplasia and Dysplasia of Gastric Cardia in Patients With Barrett's Esophagus After Endoscopic Therapy. *Clinical Gastroenterology & Hepatology* 2020;18(1):82-88.
47. Thompson CG, Rosen EP, Prince HMA, White N, Sykes C, de la Cruz G, Mathews M, Deleage C, Estes JD, Charlins P, Mulder LR, Kovarova M, Adamson L, Arora S, Dellon ES, Peery AF, **Shaheen NJ**, Gay C, Muddiman DC, Akkina R, Garcia JV, Luciw P, Kashuba ADM. Heterogeneous antiretroviral drug distribution and HIV/SHIV detection in the gut of three species. *Sci Transl Med*. 2019 Jul 3;11(499).
48. Xie SH, Fang R, Huang M, Dai J, Thrift AP, Anderson LA, Chow WH, Bernstein L, Gammon MD, Risch HA, **Shaheen NJ**, Reid BJ, Wu AH, Iyer PG, Liu G, Corley DA, Whiteman DC, Caldas C, Pharoah PD, Hardie LJ, Fitzgerald RC, Shen H, Vaughan TL, Lagergren J. Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. *Clinical Gastroenterology & Hepatology* 2019 Nov 19;S1542-3565(19)31317-5.
49. An J, Gharakhani P, Law MH, Ong JS, Han X, Olsen CM, Neale RE, Lai J, Vaughan TL, Gockel I, Thieme R, Böhmer AC, Jankowski J, Fitzgerald RC, Schumacher J, Palles C; **BEACON**; 23andMe Research Team, Whiteman DC, MacGregor S. Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases. *Nat Commun*. 2019;10(1):4219. doi: 10.1038/s41467-019-11968-2.

50. Reed CC, Tappata M, Eluri S, **Shaheen NJ**, Dellon ES. Combination Therapy with Elimination Diet and Corticosteroids is Effective for Adults with Eosinophilic Esophagitis. *Clinical Gastroenterology & Hepatology* 2019;17(13):2800-2802.
51. Parasa S, Desai M, Vittal A, Chandrasekar VT, Pervez A, Kennedy KF, Gupta N, **Shaheen NJ**, Sharma P. Estimating neoplasia detection rate (NDR) in patients with Barrett's oesophagus based on index endoscopy: a systematic review and meta-analysis. *Gut*. 2019 Dec;68(12):2122-2128.
52. Dellon ES, Woosley JT, Arrington A, McGee SJ, Covington J, Moist SE, Gebhart JH, Tylicki AE, Shoyoye SO, Martin CF, Galanko JA, Baron JA, **Shaheen NJ**. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial. *Gastroenterology*. 2019 Jul;157(1):65-73.
53. Wani S, Williams JL, Komanduri S, Muthusamy VR, **Shaheen NJ**. Over-Utilization of Repeat Upper Endoscopy in Patients with Non-dysplastic Barrett's Esophagus: A Quality Registry Study. *Am J Gastroenterol*. 2019 Aug;114(8):1256-1264.
54. Blum AE, Venkitachalam S, Ravillah D, Chelluboyina AK, Kieber-Emmons AM, Ravi L, Kresak A, Chandar AK, Markowitz SD, Canto MI, Wang JS, **Shaheen NJ**, Guo Y, Shyr Y, Willis JE, Chak A, Varadan V, Guda K. Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor- $\beta$  and JNK Signaling Pathways in Esophageal Cancer. *Gastroenterology*. 2019 May;156(6):1761-1774.
55. Dong J, Gharahkhani P, Chow WH, Gammon MD, Liu G, Caldas C, Wu AH, Ye W, Onstad L, Anderson LA, Bernstein L, Pharoah PD, Risch HA, Corley DA, Fitzgerald RC; Stomach and Esophageal Cancer Study Consortium, Iyer PG, Reid BJ, Lagergren J, **Shaheen NJ**, Vaughan TL, MacGregor S, Love S, Palles C, Tomlinson I, Gockel I, May A, Gerges C, Anders M, Böhmer AC, Becker J, Kreuser N, Thieme R, Noder T, Venerito M, Veits L, Schmidt T, Schmidt C, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Mayershofer R, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, Jankowski J, Schumacher J, Neale RE, Whiteman DC, Thrift AP. No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. *Clinical Gastroenterology & Hepatology* 2019;17(11):2227-2235.
56. Petrick JL, Li N, Anderson LA, Bernstein L, Corley DA, El Serag HB, Hardikar S, Liao LM, Liu G, Murray LJ, Rubenstein JH, Schneider JL, **Shaheen NJ**, Thrift AP, van den Brandt PA, Vaughan TL, Whiteman DC, Wu AH, Zhao WK, Gammon MD, Cook MB. Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium. *Cancer* 2019;125(23):4210-4223.
57. Ferrer-Torres D, Nancarrow DJ, Steinberg H, Wang Z, Kuick R, Weh KM, Mills RE, Ray D, Ray P, Lin J, Chang AC, Reddy RM, Orringer MB, Canto MI, **Shaheen NJ**, Kresty LA, Chak A, Wang TD, Rubenstein JH, Beer DG. Constitutively Higher Level of GSTT2 in Esophageal Tissues From African Americans Protects Cells Against DNA Damage. *Gastroenterology* 2019;156(5):1404-1415.
58. Duits LC, Lao-Sirieix P, Wolf WA, O'Donovan M, Galeano-Dalmau N, Meijer SL, Offerhaus GJA, Redman J, Crawte J, Zeki S, Pouw RE, Chak A, **Shaheen NJ**, Bergman JGGHM, Fitzgerald RC. A biomarker panel predicts progression of Barrett's esophagus to esophageal adenocarcinoma. *Dis Esophagus*. 2019 Jan 1;32(1):doy102. doi: 10.1093/dote/doy102.
59. Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, Jensen ET, **Shaheen NJ**, Barritt AS, Lieber SR, Kochar B, Barnes EL, Fan YC, Pate V, Galanko J, Baron TH, Sandler RS. Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018. *Gastroenterology*. 2019 Jan;156(1):254-272.

60. Pouw RE, Beyna T, Belghazi K, Koch AD, Schoon EJ, Haidry R, Weusten BL, Bisschops R, **Shaheen NJ**, Wallace MB, Marcon N, Heise-Ginsburg R, Gotink AW, Wang KK, Leggett CL, Ortiz-Fernández-Sordo J, Rangunath K, DiPietro M, Pech O, Neuhaus H, Bergman JJ. A prospective multicenter study using a new multiband mucosectomy device for endoscopic resection of early neoplasia in Barrett's esophagus. *Gastrointest Endosc.* 2018 Oct;88(4):647-654.
61. Eluri S, Selitsky SR, Perjar I, Hollyfield J, Betancourt R, Randall C, Rusin S, Woosley JT, **Shaheen NJ**, Dellon ES. Clinical and Molecular Factors Associated With Histologic Response to Topical Steroid Treatment in Patients With Eosinophilic Esophagitis. *Clinical Gastroenterology & Hepatology* 2019;17(6):1081-1088.
62. Machicado JD, Han S, Yadlapati RH, Simon VC, Qumseya BJ, Sultan S, Kushnir VM, Komanduri S, Rastogi A, Muthusamy VR, Haidry R, Rangunath K, Singh R, Hammad HT, **Shaheen NJ**, Wani S. A Survey of Expert Practice and Attitudes Regarding Advanced Imaging Modalities in Surveillance of Barrett's Esophagus. *Digestive Diseases & Sciences* 2018;63(12):3262-3271.
63. Han S, Yadlapati R, Simon V, Ezekwe E, Early DS, Kushnir V, Hollander T, Brauer BC, Hammad H, Edmundowicz SA, Wood M, **Shaheen NJ**, Muthusamy RV, Komanduri S, Wani S. Dysplasia severity is associated with poor quality of life in patients with Barrett's esophagus referred for endoscopic eradication therapy. *Diseases of the Esophagus* 2019;32(1):doy086. doi: 10.1093/dote/doy086.
64. Januszewicz W, Tan WK, Lehovsky K, Debiram-Beecham I, Nuckcheddy T, Moist S, Kadri S, di Pietro M, Boussioutas A, **Shaheen NJ**, Katzka DA, Dellon ES, Fitzgerald RC; BEST1 and BEST2 study investigators. Safety and Acceptability of a Nonendoscopic Esophageal Sampling Device - Cytosponge: A Systematic Review of Multicenter Data. *Clinical Gastroenterology & Hepatology* 2019;17(4):647-656.
65. Weber MD, Andrews E, Prince HA, Sykes C, Rosen EP, Bay C, **Shaheen NJ**, Madanick RD, Dellon ES, De Paris K, Nelson JA, Gay CL, Kashuba AD. Virological and immunological responses to raltegravir and dolutegravir in the gut-associated lymphoid tissue of HIV-infected men and women. *Antiviral Therapy* 2018;23(6):495-504.
66. Eluri S, Klaver E, Duits LC, Jackson SA, Bergman JJ, **Shaheen NJ**. Validation of a biomarker panel in Barrett's esophagus to predict progression to esophageal adenocarcinoma. *Dis Esophagus.* 2018 Nov 1;31(11). doi: 10.1093/dote/doy026. PubMed PMID: 29635420.
67. Chan MQ, Blum AE, Chandar AK, Emmons AMLK, Shindo Y, Brock W, Falk GW, Canto MI, Wang JS, Iyer PG, **Shaheen NJ**, Grady WM, Abrams JA, Thota PN, Guda KK, Chak A. Association of sporadic and familial Barrett's esophagus with breast cancer. *Dis Esophagus.* 2018 Apr 1;31(4). doi: 10.1093/dote/doy007. PubMed PMID: 29528378; PubMed Central PMCID: PMC6005759.
68. **Shaheen NJ**, Mukkada V, Eichinger CS, Schofield H, Todorova L, Falk GW. Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course. *Dis Esophagus.* 2018 Aug 1;31(8). doi: 10.1093/dote/doy015. PubMed PMID: 29617744; PubMed Central PMCID: PMC6102800.
69. Cotton CC, Haidry R, Thrift AP, Lovat L, **Shaheen NJ**. Development of Evidence-Based Surveillance Intervals After Radiofrequency Ablation of Barrett's Esophagus. *Gastroenterology* 2018;155(2):316-326.
70. Dong J, Buas MF, Gharahkhani P, Kendall BJ, Onstad L, Zhao S, Anderson LA, Wu AH, Ye W, Bird NC, Bernstein L, Chow WH, Gammon MD, Liu G, Caldas C, Pharoah PD, Risch HA,

Iyer PG, Reid BJ, Hardie LJ, Lagergren J, **Shaheen NJ**, Corley DA, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) consortium, Whiteman DC, Vaughan TL, Thrift AP. Determining Risk of Barrett's Esophagus and Esophageal Adenocarcinoma Based on Epidemiologic Factors and Genetic Variants. *Gastroenterology* 2018, 2018;154(5):1273-1281.

71. Sawas T, Iyer PG, Alsawas M, Cotton CC, Leggett CL, Murad MH, Wang KK, **Shaheen NJ**, Katzka DA. Higher Rate of Barrett's Detection in the First Year After Successful Endoscopic Therapy: Meta-analysis. *Am J Gastroenterol.* 2018;113(7):959-971.
72. Abrams JA, Komanduri S, **Shaheen NJ**, Wang Z, Rothstein RI. Radiofrequency ablation for the treatment of weight regain after Roux-en-Y gastric bypass surgery. *Gastrointestinal Endoscopy* 2018;87(1):275-279.
73. Canto MI, **Shaheen NJ**, Almario JA, Voltaggio L, Montgomery E, Lightdale CJ. Multifocal nitrous oxide cryoballoon ablation with or without EMR for treatment of neoplastic Barrett's esophagus (with video). *Gastrointest Endosc.* 2018;88(3):438-446.
74. Wang Z, **Shaheen NJ**, Whiteman DC, Anderson LA, Vaughan TL, Corley DA, El-Serag HB, Rubenstein JH, Thrift AP. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. *Am J Gastroenterol.* 2018;113(8):1148-1155.
75. Codipilly DC, Chandar AK, Singh S, Wani S, **Shaheen NJ**, Inadomi JM, Chak A, Iyer PG. The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis. *Gastroenterology.* 2018;154(8):2068-2086.
76. Dong J, Levine DM, Buas MF, Zhang R, Onstad L, Fitzgerald RC; Stomach and Oesophageal Cancer Study (SOCS) Consortium, Corley DA, **Shaheen NJ**, Lagergren J, Hardie LJ, Reid BJ, Iyer PG, Risch HA, Caldas C, Caldas I, Pharoah PD, Liu G, Gammon MD, Chow WH, Bernstein L, Bird NC, Ye W, Wu AH, Anderson LA, MacGregor S, Whiteman DC, Vaughan TL, Thrift AP. Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus. *Clin Gastroenterol Hepatol.* 2018;16(10):1598-1606.
77. Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, Brock W, De la Cruz Cabrera O, Guda K, Barnholtz-Sloan JS, Iyer PG, Canto MI, Wang JS, **Shaheen NJ**, Thota PN, Willis JE, Chak A, Markowitz SD. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. *Sci Transl Med.* 2018 Jan 17;10(424). pii: eao5848.
78. Mukkada V, Falk GW, Eichinger CS, King D, Todorova L, **Shaheen NJ**. Health-Related Quality of Life and Costs Associated With Eosinophilic Esophagitis: A Systematic Review. *Clin Gastroenterol Hepatol.* 2018;16(4):495-503.
79. Jovov B, Reed CC, **Shaheen NJ**, Pruitt A, Ferrell K, Orlando GS, Djukic Z, Orlando RC. Fragments of e-Cadherin as Biomarkers of Non-erosive Reflux Disease. *Digestive Diseases and Sciences* 2018;63(3):628-635.
80. Koutlas NT, Eluri S, Rusin S, Perjar I, Hollyfield J, Woosley JT, **Shaheen NJ**, Dellon ES. Impact of smoking, alcohol consumption, and NSAID use on risk for and phenotypes of eosinophilic esophagitis. *Dis Esophagus.* 2018;31(1):1-7.
81. Vennalaganti PR, Kaul V, Wang KK, Falk GW, **Shaheen NJ**, Infantolino A, Johnson DA, Eisen G, Gerson LB, Smith MS, Iyer PG, Lightdale CJ, Schnoll-Sussman F, Gupta N, Gross SA, Abrams J, Haber GB, Chuttani R, Pleskow DK, Kothari S, Goldblum JR, Zhang Y, Sharma P. Increased detection of Barrett's esophagus-associated neoplasia using wide-area

trans-epithelial sampling: a multicenter, prospective, randomized trial. *Gastrointest Endosc.* 2018;87(2):348-355.

82. Yadlapati R, Vaezi MF, Vela MF, Spechler SJ, **Shaheen NJ**, Richter J, Lacy BE, Katzka D, Katz PO, Kahrilas PJ, Gyawali CP, Gerson L, Fass R, Castell DO, Craft J, Hillman L, Pandolfino JE. Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel. *Am J Gastroenterol.* 2018;113(7):980-986.
83. Peery AF, **Shaheen NJ**, Cools KS, Baron TH, Koruda M, Galanko JA, Grimm IS. Morbidity and mortality after surgery for nonmalignant colorectal polyps. *Gastrointest Endosc.* 2018;87(1):243-250.
84. Reed CC, Fan C, Koutlas N, Stefanadis Z, Eluri S, **Shaheen NJ**, Dellon ES. Compounded Oral Viscous Budesonide is Effective and Provides a Durable Response in Eosinophilic Esophagitis. *HSOA J Gastroenterol Hepatol Res.* 2018;7(1):2509-2515.
85. Schlottmann F, Luckett DJ, Fine J, **Shaheen NJ**, Patti MG. Laparoscopic Heller Myotomy Versus Peroral Endoscopic Myotomy (POEM) for Achalasia: A Systematic Review and Meta-analysis. *Ann Surg.* 2018; 267(3):451-460.
86. Cotton CC, Wolf WA, Overholt BF, Li N, Lightdale CJ, Wolfsen HC, Pasricha S, Wang KK, **Shaheen NJ**. Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report of the Ablation in Intestinal Metaplasia Containing Dysplasia Trial. *Gastroenterology* 2017 Sep;153(3):681-688.
87. Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, Brock W, De la Cruz Cabrera O, Guda K, Barnholtz-Sloan JS, Iyer PG, Canto MI, Wang JS, **Shaheen NJ**, Thota PN, Willis JE, Chak A, Markowitz SD. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. *Science Translational Medicine* 2017; 17;10(424).
88. Sun X, Chandar AK, Canto MI, Thota PN, Brock M, **Shaheen NJ**, Beer DG, Wang JS, Falk GW, Iyer PG, Abrams JA, Venkat-Ramani M, Veigl M, Miron A, Willis J, Patil DT, Nalbantoglu I, Guda K, Markowitz SD, Zhu X, Elston R, Chak A. Genomic regions associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture study. *PLoS One.* 2017;12(10):e0184962.
89. Runge TM, Eluri S, Woosley JT, **Shaheen NJ**, Dellon ES. Control of inflammation decreases the need for subsequent esophageal dilation in patients with eosinophilic esophagitis. *Diseases of the Esophagus* 2017;30(7):1-7.
90. Li N, Petrick JL, Steck SE, Bradshaw PT, McClain KM, Niehoff NM, Engel LS, **Shaheen NJ**, Corley DA, Vaughan TL, Gammon MD. Dietary sugar/starches intake and Barrett's esophagus: a pooled analysis. *European Journal of Epidemiology* 2017;32(11):1007-1017.
91. Li N, Petrick JL, Steck SE, Bradshaw PT, McClain KM, Niehoff NM, Engel LS, **Shaheen NJ**, Risch HA, Vaughan TL, Wu AH, Gammon MD. A pooled analysis of dietary sugar/carbohydrate intake and esophageal and gastric cardia adenocarcinoma incidence and survival in the USA. *Int J Epidemiol.* 2017;46(6):1836-1846.
92. Tsai FC, Ghorbani S, Greenwald BD, Jang S, Dumot JA, McKinley MJ, **Shaheen NJ**, Habr F, Wolfsen HC, Abrams JA, Lightdale CJ, Nishioka NS, Johnston MH, Zfass A, Coyle WJ. Safety and efficacy of endoscopic spray cryotherapy for esophageal cancer. *Diseases of the Esophagus.* 2017;30(11):1-7.
93. Reed CC, Wolf WA, Cotton CC, Rusin S, Perjar I, Hollyfield J, Woosley JT, **Shaheen NJ**, Dellon ES. Optimal Histologic Cutpoints for Treatment Response in Patients With

Eosinophilic Esophagitis: Analysis of Data From a Prospective Cohort Study. *Clinical Gastroenterology & Hepatology* 2017;16(2):226-233.

94. Guthikonda A, Cotton CC, Madanick RD, Spacek MB, Moist SE, Ferrell K, Dellon ES, **Shaheen NJ**. Clinical Outcomes Following Recurrence of Intestinal Metaplasia After Successful Treatment of Barrett's Esophagus With Radiofrequency Ablation. *American Journal of Gastroenterology* 2017;112(1):87-94.
95. Erichsen R, Horvath-Puho E, Lund JL, Dellon ES, **Shaheen NJ**, Pedersen L, Davey Smith G, Sørensen HT. Mortality and cardiovascular diseases risk in patients with Barrett's oesophagus: a population-based nationwide cohort study. *Aliment Pharmacol Ther* 2017 Apr;45(7):973-982.
96. Duits LC, van der Wel MJ, Cotton CC, Phoa KN, Ten Kate FJ, Seldenrijk CA, Offerhaus GJ, Visser M, Meijer SL, Mallant-Hent RC, Krishnadath KK, Pouw RE, Tijssen JG, **Shaheen NJ**, Bergman JJ. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia. *Gastroenterology* 2017;152(5):993-1001.
97. Reed CC, Fan C, Koutlas NT, **Shaheen NJ**, Dellon ES. Food elimination diets are effective for long-term treatment of adults with eosinophilic oesophagitis. *Aliment Pharmacol Ther*. 2017;46(9):836-844.
98. Katzka DA, Smyrk TC, Alexander JA, Geno DM, Beitia RA, Chang AO, **Shaheen NJ**, Fitzgerald RC, Dellon ES. Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study. *Am J Gastroenterol*. 2017;112(10):1538-1544.
99. Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, **Shaheen NJ**, Spechler SJ, Rubenstein JH, Nishioka NS, Meltzer SJ, Hazelton WD, van Ballegooijen M, Tramontano AC, Gazelle GS, Luebeck EG, Inadomi JM, Hur C. Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. *Clin Gastroenterol Hepatol*. 2017;15(9):1471-1474.
100. Eluri S, Runge TM, Hansen J, Kochar B, Reed CC, Robey BS, Woosley JT, **Shaheen NJ**, Dellon ES. Diminishing Effectiveness of Long-Term Maintenance Topical Steroid Therapy in PPI Non-Responsive Eosinophilic Esophagitis. *Clinical and Translational Gastroenterology* 2017;8(6):e97.
101. Wani S, Muthusamy VR, **Shaheen NJ**, Yadlapati R, Wilson R, Abrams JA, Bergman J, Chak A, Chang K, Das A, Dumot J, Edmundowicz SA, Eisen G, Falk GW, Fennerty MB, Gerson L, Ginsberg GG, Grande D, Hall M, Harnke B, Inadomi J, Jankowski J, Lightdale CJ, Makker J, Odze RD, Pech O, Sampliner RE, Spechler S, Triadafilopoulos G, Wallace MB, Wang K, Waxman I, Komanduri S. Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. *Gastrointestinal Endoscopy* 2017;86(1):1-17.
102. Wani S, Muthusamy VR, **Shaheen NJ**, Yadlapati R, Wilson R, Abrams JA, Bergman J, Chak A, Chang K, Das A, Dumot J, Edmundowicz SA, Eisen G, Falk GW, Fennerty MB, Gerson L, Ginsberg GG, Grande D, Hall M, Harnke B, Inadomi J, Jankowski J, Lightdale CJ, Makker J, Odze RD, Pech O, Sampliner RE, Spechler S, Triadafilopoulos G, Wallace MB, Wang K, Waxman I, Komanduri S. Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett's Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. *American Journal of Gastroenterology* 2017 Jul;112(7):1032-1048.

103. Murphy CC, Claire Yang Y, **Shaheen NJ**, Hofstetter WL, Sandler RS. An age-period-cohort analysis of obesity and incident esophageal adenocarcinoma among white males. *Diseases of the Esophagus* 2017; 1;30(3):1-8.
104. Cotton CC, Erim D, Eluri S, Palmer SH, Green DJ, Wolf WA, Runge TM, Wheeler S, **Shaheen NJ**, Dellon ES. Cost Utility Analysis of Topical Steroids Compared to Dietary Elimination for Treatment of Eosinophilic Esophagitis. *Clinical Gastroenterology and Hepatology* 2017; 15(6):841-849
105. Wolf WA, Piazza NA, Gebhart JH, Rusin S, Covey S, Higgins LL, Beitia R, Speck O, Woodward K, Cotton CC, Runge TM, Eluri S, Woosley JT, **Shaheen NJ**, Dellon ES. Association Between Body Mass Index and Clinical and Endoscopic Features of Eosinophilic Esophagitis. *Digestive Diseases and Sciences* 2017; 62(1):143-149.
106. Runge TM, Eluri S, Cotton CC, Burk CM, Woosley JT, **Shaheen NJ**, Dellon ES. Causes and Outcomes of Esophageal Perforation in Eosinophilic Esophagitis. *Journal of Clinical Gastroenterology* 2017;51(9):805-813.
107. Ghorbani S, Tsai FC, Greenwald BD, Jang S, Dumot JA, McKinley MJ, **Shaheen NJ**, Habr F, Coyle WJ. Safety and efficacy of endoscopic spray cryotherapy for Barrett's dysplasia: results of the National Cryospray Registry. *Dis Esophagus*. 2017;30(11):1-7.
108. Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, Gharahkhani P, Palles C, Lagergren J, Fitzgerald RC, Ye W, Caldas C, Bird NC, **Shaheen NJ**, Bernstein L, Gammon MD, Wu AH, Hardie LJ, Pharoah PD, Liu G, Iyer P, Corley DA, Risch HA, Chow WH, Prenen H, Chegwidden L, Love S, Attwood S, Moayyedi P, MacDonald D, Harrison R, Watson P, Barr H, deCaestecker J, Tomlinson I, Jankowski J, Whiteman DC, MacGregor S, Vaughan TL, Madeleine MM. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. *Gut*. 2017; 66(10):1739-1747.
109. Runge TM, **Shaheen NJ**, Djukic Z, Hallquist S, Orlando RC. Cleavage of E-Cadherin Contributes to Defective Barrier Function in Neosquamous Epithelium. *Dig Dis Sci*. 2016 Nov;61(11):3169-3175.
110. Banerjee B, **Shaheen NJ**, Martinez JA, Hsu CH, Trowers E, Gibson BA, Della'Zanna GJ, Richmond E, Chow HS. Clinical Study of Ursodeoxycholic Acid in Barrett's Esophagus Patients. *Cancer Prev Res (Phila)*. 2016; 9(7):528-33.
111. Thrift AP, Anderson LA, Murray LJ, Cook MB, **Shaheen NJ**, Rubenstein JH, El-Serag HB, Vaughan TL, Schneider JL, Whiteman DC, Corley DA. Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus. *Am J Gastroenterol*. 2016;111(11):1528-35.
112. Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON); Esophageal Adenocarcinoma GenEtics Consortium (EAGLE); Wellcome Trust Case Control Consortium 2 (WTCCC2), Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RG, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, **Shaheen NJ**, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WH, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J. Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. *Lancet Oncol*. 2016; 17(10):1363-1373.

113. Blum A, Venkitachalam S, Guo Y, Kieber-Emmons AM, Ravi L, Chandar AK, Iyer PG, Canto MI, Wang JS, **Shaheen NJ**, Barnholtz-Sloan JS, Markowitz SD, Willis JE, Shyr Y, Chak A, Varadan V, Guda K. RNA Sequencing Identifies Transcriptionally-Viable Gene Fusions in Esophageal Adenocarcinomas. *Cancer Res.* 2016;76(19):5628-5633.
114. Runge TM, Eluri S, Cotton CC, Burk CM, Woosley JT, **Shaheen NJ**, Dellon ES. Outcomes of Esophageal Dilatation in Eosinophilic Esophagitis: Safety, Efficacy, and Persistence of the Fibrostenotic Phenotype. *Am J Gastroenterol.* 2016 Feb;111(2):206-13.
115. Kendall BJ, Rubenstein JH, Cook MB, Vaughan TL, Anderson LA, Murray LJ, **Shaheen NJ**, Corley DA, Chandar AK, Li L, Greer KB, Chak A, El-Serag HB, Whiteman DC, Thrift AP. Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis. *Clin Gastroenterol Hepatol.* 2016; 14(10):1412-1419
116. Cottrell ML, Prince HM, Allmon A, Mollan KR, Hudgens MG, Sykes C, White N, Malone S, Dellon ES, Madanick RD, **Shaheen NJ**, Patterson KB, Kashuba AD. Cervicovaginal and Rectal Fluid as a Surrogate Marker of Antiretroviral Tissue Concentration: Implications for Clinical Trial Design. *J Acquir Immune Defic Syndr.* 2016; 15;72(5):498-506
117. Sun X, Elston RC, Barnholtz-Sloan JS, Falk GW, Grady WM, Faulx A, Mittal SK, Canto M, **Shaheen NJ**, Wang JS, Iyer PG, Abrams JA, Tian YD, Willis JE, Guda K, Markowitz SD, Chandar A, Warfe JM, Brock W, Chak A. Predicting Barrett's esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. *Cancer Epidemiol Biomarkers Prev.* 2016; 25(5):727-35.
118. Sun X, Elston R, Falk GW, Grady WM, Faulx A, Mittal SK, Canto MI, **Shaheen NJ**, Wang JS, Iyer PG, Abrams JA, Willis JE, Guda K, Markowitz S, Barnholtz-Sloan JS, Chandar A, Brock W, Chak A. Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas. *Mol Genet Genomic Med.* 2016 Mar 14;4(4):407-19.
119. Dai JY, Tapsoba Jde D, Buas MF; **BEACON Consortium**, Risch HA, Vaughan TL. Constrained Score Statistics Identify Genetic Variants Interacting with Multiple Risk Factors in Barrett's Esophagus. *Am J Hum Genet.* 2016 Aug 4;99(2):352-65.
120. Cottrell ML, Yang KH, Prince HM, Sykes C, White N, Malone S, Dellon ES, Madanick RD, **Shaheen NJ**, Hudgens MG, Wulff J, Patterson KB, Nelson JA, Kashuba AD. A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine. *J Infect Dis.* 2016;214(1):55-64.
121. Dellon ES, Cotton CC, Gebhart JH, Higgins LL, Beitia R, Woosley JT, **Shaheen NJ**. Accuracy of the Eosinophilic Esophagitis Endoscopic Reference Score in Diagnosis and Determining Response to Treatment. *Clinical Gastroenterology & Hepatology* 2016;14(1):31-39.
122. Ek WE, Lagergren K, Cook M, Wu AH, Abnet CC, Levine D, Chow WH, Bernstein L, Risch HA, **Shaheen NJ**, Bird NC, Corley DA, Hardie LJ, Fitzgerald RC, Gammon MD, Romero Y, Liu G, Ye W, Vaughan TL, MacGregor S, Whiteman DC, Westberg L, Lagergren J. Polymorphisms in genes in the androgen pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. *International Journal of Cancer* 2016;138(5):1146-52.
123. Eluri S, Runge TM, Cotton CC, Burk CM, Wolf WA, Woosley JT, **Shaheen NJ**, Dellon ES. The Extreme Narrow-Caliber Esophagus is a Treatment Resistant Sub-Phenotype of Eosinophilic Esophagitis. *Gastrointestinal Endoscopy* 2016; 83(6):1142-8.
124. Gharahkhani P, Tung J, Hinds D, Mishra A; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), Vaughan TL, Whiteman DC, MacGregor S; **BEACON study investigators**; Barrett's and Esophageal Adenocarcinoma Consortium BEACON. *Chronic*



- gastroesophageal reflux disease shares genetic background with esophageal adenocarcinoma and Barrett's esophagus. *Human Molecular Genetics* 2016; 25(4):828-35.
125. Dellon ES, Gebhart JH, Higgins LL, Hathorn KE, Woosley JT, **Shaheen NJ**. The esophageal biopsy "pull" sign: a highly specific and treatment-responsive endoscopic finding in eosinophilic esophagitis (with video). *Gastrointestinal Endoscopy* 2016;83(1):92-100.
126. Li N, Pasricha S, Bulsiewicz WJ, Pruitt RE, Komanduri S, Wolfsen HC, Chmielewski GW, Corbett FS, Chang KJ, **Shaheen NJ**. Effects of preceding endoscopic mucosal resection on the efficacy and safety of radiofrequency ablation for treatment of Barrett's esophagus: results from the United States Radiofrequency Ablation Registry. *Diseases of the Esophagus* 2016; 29(6):537-43.
127. Wolf WA, Cotton CC, Green DJ, Hughes JT, Woosley JT, **Shaheen NJ**, Dellon ES. Evaluation of Histologic Cutpoints for Treatment Response in Eosinophilic Esophagitis. *J Gastroenterol Hepatol Res.* 2015 Oct 1;4(10):1780-1787.
128. Wolf WA, Pasricha S, Cotton C, Li N, Triadafilopoulos G, Muthusamy VR, Chmielewski GW, Corbett FS, Camara DS, Lightdale CJ, Wolfsen H, Chang KJ, Overholt BF, Pruitt RE, Ertan A, Komanduri S, Infantolino A, Rothstein RI, **Shaheen NJ**. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus. *Gastroenterology* 2015;149(7):1752-61.
129. Mlombe YB, Rosenberg NE, Wolf LL, Dzamalala CP, Chalulu K, Chisi J, **Shaheen NJ**, Hosseinipour MC, Shores CG. Environmental Risk Factors for Oesophageal Cancer in Malawi: A case-control study. *Malawi Medical Journal* 2015;27(3):88-92.
130. Cotton CC, Duits LC, Wolf WA, Peery AF, Dellon ES, Bergman JJ, **Shaheen NJ**. Spatial Predisposition of Dysplasia in Barrett's Esophagus Segments: A Pooled Analysis of the SURF and AIM Dysplasia Trials. *American Journal of Gastroenterology* 2015;110(10):1412-19.
131. Dellon ES, Rusin S, Gebhart JH, Covey S, Speck O, Woodward K, Higgins LL, Beitia R, Madanick RD, Levinson S, Woosley JT, **Shaheen NJ**. A Clinical Prediction Tool Identifies Cases of Eosinophilic Esophagitis Without Endoscopic Biopsy: A Prospective Study. *American Journal of Gastroenterology* 2015;110(9):1347-54.
132. Dai JY, de Dieu Tapsoba J, Buas MF, Onstad LE, Levine DM, Risch HA, Chow WH, Bernstein L, Ye W, Lagergren J, Bird NC, Corley DA, **Shaheen NJ**, Wu AH, Reid BJ, Hardie LJ, Whiteman DC, Vaughan TL. A Newly Identified Susceptibility Locus near FOXP1 Modifies the Association of Gastroesophageal Reflux with Barrett's Esophagus. *Cancer Epidemiology, Biomarkers & Prevention* 2015;24(11):1739-47.
133. Peery AF, Crockett SD, Barritt AS, Dellon ES, Eluri S, Gangarosa LM, Jensen ET, Lund JL, Pasricha S, Runge T, Schmidt M, **Shaheen NJ**, Sandler RS. Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States. *Gastroenterology* 2015;149(7):1731-41.
134. Lagergren K, Ek WE, Levine D, Chow WH, Bernstein L, Casson AG, Risch HA, **Shaheen NJ**, Bird NC, Reid BJ, Corley DA, Hardie LJ, Wu AH, Fitzgerald RC, Pharoah P, Caldas C, Romero Y, Vaughan TL, MacGregor S, Whiteman D, Westberg L, Nyren O, Lagergren J. Polymorphisms in Genes of Relevance for Oestrogen and Oxytocin Pathways and Risk of Barrett's Oesophagus and Oesophageal Adenocarcinoma: A Pooled Analysis from the BEACON Consortium. *PLoS One* 2015;10(9): e0138738.
135. Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, **Shaheen NJ**, Souza RF, Spechler SJ, Vennalaganti P, Wang K. Quality Indicators for the Management of Barrett's

Esophagus, Dysplasia, and Esophageal Adenocarcinoma: International Consensus Recommendations from the American Gastroenterological Association Symposium. *Gastroenterology* 2015;149(6):1599-1606.

136. Almario CV, May FP, **Shaheen NJ**, Murthy R, Gupta K, Jamil LH, Lo SK, Spiegel BM. Cost Utility of Competing Strategies to Prevent Endoscopic Transmission of Carbapenem-Resistant Enterobacteriaceae. *American Journal of Gastroenterology* 2015;110(12):1666-74.
137. Pasricha S, Cotton C, Hathorn KE, Li N, Nulsiewicz WJ, Wolf WA, Muthusamy VR, Komanduri S, Wolfsen HC, Pruitt RE, Ertan A, Chmielewski GW, **Shaheen NJ**. Effects of learning curve on efficacy of radiofrequency ablation for Barrett's esophagus. *Gastroenterology* 2015;149(4):890-96.
138. Yu M, O'Leary RM, Kaz AM, Morris SM, Carter KT, Chak A, Chandar A, Willis JE, Moinova HR, Markowitz SD, Brenner DE, Anandabapasathy S, Westerhoff M, Wong CJ, **Shaheen NJ**, Chen Y, Barnholtz-Sloan JS, Grady WM. Methylated B3GAT2 and ZNF793 Are Potential Detection Biomarkers for Barrett's Esophagus. *Cancer Epidemiology, Biomarkers and Prevention* 2015;24(12):1890-97.
139. Lee E, Stram DO, Ek WE, Onstad LE, MacGregor S, Gharahkhani P, Ye W, Lagergren J, **Shaheen NJ**, Murray LJ, Hardie LJ, Gammon MD, Chow WH, Risch HA, Corley DA, Levine DM, Whiteman DC, Bernstein L, Bird NC, Vaughan TL, Wu AH. Pleiotropic Analysis of Cancer Risk Loci on Esophageal Adenocarcinoma Risk. *Cancer Epidemiology, Biomarkers and Prevention* 2015;24(11):1801-03.
140. Buas MF, Onstad L, Levine DM, Risch HA, Chow WH, Liu G, Fitzgerald RC, Bernstein L, Ye W, Bird NC, Romero Y, Casson AG, Corley DA, **Shaheen NJ**, Wu AH, Gammon MD, Reid BJ, Hardie LJ, Peters U, Whiteman DC, Vaughan TL. MiRNA-Related SNPs and Risk of Esophageal Adenocarcinoma and Barrett's Esophagus: Post Genome-Wide Association Analysis in the BEACON Consortium. *PLoS One*. 2015;10(6):e0128617.
141. Eluri S, Brugge WR, Daglilar ES, Jackson SA, Styn MA, Callenberg KM, Welch DC, Barr TM, Duits LC, Bergman JJ, **Shaheen NJ**. The Presence of Genetic Mutations at Key Loci Predicts Progression to Esophageal Adenocarcinoma in Barrett's Esophagus. *Am J Gastroenterol*. 2015;110(6):828-34.
142. Pasricha S, Li N, Bulsiewicz WJ, Rothstein RI, Infantolino A, Ertan A, Camara DS, Dellon ES, Triadafilopoulos G, Lightdale CJ, Madanick RD, Lyday WD, Muthusamy RV, Overholt BF, **Shaheen NJ**. Sex and race and/or ethnicity differences in patients undergoing radiofrequency ablation for Barrett's esophagus: results from the U.S. RFA Registry. *Gastrointest Endosc*. 2015;82(2):276-84.
143. Wolf WA, Cotton CC, Green DJ, Hughes JT, Woosley JT, **Shaheen NJ**, Dellon ES. Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients. *Clinical Gastroenterology and Hepatology* 2015;13(3):452-58.
144. Dellon ES, Rusin S, Gebhart JH, Covey S, Higgins LL, Beitia R, Speck O, Woodward K, Woosley JT, **Shaheen NJ**. Utility of a Noninvasive Serum Biomarker Panel for Diagnosis and Monitoring of Eosinophilic Esophagitis: A Prospective Study. *Am J Gastroenterol*. 2015;110(6):821-27.
145. Cotton CC, Wolf WA, Pasricha S, Li N, Madanick RD, Spacek MB, Ferrell K, Dellon ES, **Shaheen NJ**. Recurrent intestinal metaplasia after radiofrequency ablation for Barrett's esophagus: endoscopic findings and anatomic location. *Gastrointest Endosc*. 2015 Jun;81(6):1362-9.
146. **Shaheen NJ**, Adler J, Dedrie S, Johnson D, Malfertheiner P, Miner P, Meulemans A, Poole L, Tack J, Thielemans L, Troy S, Vakil N, Zerbib F, Ruth M. Randomised clinical trial: the 5-

- HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapy. *Aliment Pharmacol Ther.* 2015 Apr;41(7):649-61.
147. Dellon ES, Erichsen R, Baron JA, **Shaheen NJ**, Vyberg M, Sorensen HT, Pedersen L. The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population-based estimates from Denmark. *Aliment Pharmacol Ther.* 2015 Apr;41(7):662-70.
148. Rizk MK, Sawhney MS, Cohen J, Pike IM, Adler DG, Dominitz JA, Lieb JG, Lieberman DA, Park WG, **Shaheen NJ**, Wani S. Quality indicators common to all endoscopic procedures. *Am J Gastroenterol* 2015; 110(1):48-59.
149. Park WG, **Shaheen NJ**, Rizk MK, Sawhney MS, Cohen J, Pike IM, Adler DG, Dominitz JA, Lieb JG, Lieberman DA, Wani S. Quality indicators for EGD. *Am J Gastroenterol* 2015;110(1):60-71.
150. Rex DK, Schoenfeld PS, Rizk MK, Sawhney MS, Cohen J, Pike IM, Adler DG, Dominitz JA, Lieb JG, Lieberman DA, Park WG, **Shaheen NJ**, Wani S. Quality indicators for colonoscopy. *Am J Gastroenterol* 2015;11(1):72-90.
151. Wani S, Wallace MB, Cohen J, Pike IM, Adler DG, Dominitz JA, Lieb JG, Lieberman DA, Park WG, Rizk MK, Sawhney MS, **Shaheen NJ**, Tokar JL. Quality indicators for EUS. *Am J Gastroenterol* 2015;110(1):102-113.
152. Adler DG, Lieb JG, Cohen J, Pike IM, Park WG, Rizk MK, Sawhney MS, Scheiman JM, **Shaheen NJ**, Sherman S, Wani S. Quality indicators for ERCP. *Am J Gastroenterol* 2015;110(1):91-101.
153. Palles C, Chegwidden L, Li X, Findlay J, Farnham G, Giner FC, Peppelenbosch MP, Kovac M, Adams CL, Prenen H, Briggs Sanders HR, MacDonald D, Haigh C, Tucker A, Love S, Nanji M, deCaestecker J, D Ferry, B Rathbone, J Hapeshi, H Barr, B Zietek, N Maroo, L Gay, T Underwood, L Boulter, H McMurtry, D Monk, P Patel, K Raganath, D Al Dulaimi, I Murray, K Koss, A Veitch, N Trudgill, C Nwokolo, B Rembacken, P Atherfold, E Green, Y Ang, EJ Kuipers, W Chow, S Paterson, S Kadri, I Beales, C Grimley, P Mullins, C Beckett, M Farrant, A Dixon, S K, Matthew Johnson, Shahjehan W, A Dhar, E Sawyer, R Roylance, L Onstad, MD Gammon, DA Corley, **NJ Shaheen**, NC Bird, LJ Hardie, BJ Reid, W Ye, G Liu, Y Romero, L Bernstein, AH Wu, AG Casson, R Fitzgerald, DC Whiteman, HA Risch, DM Levine, TL. Vaughan, AP. Verhaar, J van den Brande, Eelke L. Toxopeus, Manon C. Spaander, Bas P.L. Wijnhoven, Luc JW. van der Laan, K Krishnadath, C Wijmenga, G Trynka, R McManus, JV Reynolds, J O'Sullivan, P MacMathuna, SA McGarrigle, D Kelleher, S Vermeire, I Cleynen, R Bisschops, I Tomlinson, J Jankowski. Polymorphisms Near *TBX5* and *GDF7* are Associated with Increased Risk for Barrett's Esophagus. *Gastroenterology* 2015;148(2):367-78.
154. Wolf WA, Cotton CC, Green DJ, Hughes JT, Woosley JT, **Shaheen NJ**, Dellon ES. Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients. *Clinical Gastroenterology & Hepatology.* 2015;13(3):452-8.
155. Buas MF, Levine DM, Makar KW, Utsugi H, Onstad L, Li X, Galipeau PC, **Shaheen NJ**, Hardie LJ, Romero Y, Bernstein L, Gammon MD, Casson AG, Bird NC, Risch HA, Ye W, Liu G, Corley DA, Blount PL, Fitzgerald RC, Whiteman DC, Wu AH, Reid BJ, Vaughan TL. Integrative post-genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. *Carcinogenesis* 2014;35(12):2740-47.
156. Thrift AP, **Shaheen NJ**, Gammon MD, Bernstein L, Reid BJ, Onstad L, Risch HA, Lui G, Bird NC, Wu AH, Corley DA, Romero Y, Chanock S, Chow WH, Casson AG, Levine D, Zhang R, Ek WE, MacGregor S, Ye W, Hardie LJ, Vaughan TL, Whiteman DC. Obesity and

risk of esophageal adenocarcinoma and Barrett's esophagus: a Mendelian randomization study. *JNCI* 2014;106(11).

157. Pasricha S, Bulsiewicz WJ, Hathorn KE, Komanduri S, Muthusamy VR, Rothstein RI, Wolfsen HC, Lightdale CJ, Overholt BF, Camara DS, Dellon ES, Lyday WD, Ertan A, Chmielewski GW, **Shaheen NJ**. Durability and predictors of successful radiofrequency ablation for Barrett's esophagus. *Clinical Gastroenterology and Hepatology* 2014; 12(11):1840-47.
158. Thrift AP, Cook MB, Vaughn TL, Anderson LA, Murray LJ, Whiteman DC, **Shaheen NJ**. Alcohol and the risk of Barrett's Esophagus: A pooled analysis from the international BEACON consortium. *American Journal of Gastroenterology* 2014;109(10):1586-94.
159. Dellon ES, Speck O, Woodward K, Covey S, Rusin S, **Shaheen NJ**, Woosley JW. Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. *Modern Pathology* 2015;28(3):383-90.
160. Thrift AP, Risch HA, Onstad L, **Shaheen NJ**, Casson AG, Bernstein L, Corley DA, Levine DM, Chow WH, Reid BJ, Romero Y, Hardie LJ, Liu G, Wu AH, Bird NC, Gammon MD, Ye W, Whiteman DC, Vaughan TL. Risk of Esophageal Adenocarcinoma Decreases With Height, Based on Consortium Analysis and Confirmed by Mendelian Randomization. *Clinical Gastroenterology & Hepatology* 2014;12(10):1667-76.
161. Dellon ES, Speck O, Woodward K, Covey S, Rusin S, Gebhart JH, Chen X, Woosley JT, **Shaheen NJ**. Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump-inhibitor responsive esophageal eosinophilia: A prospective study. *Clinical Gastroenterology & Hepatology* 2014;12(12):2015-22.
162. Jensen ET, Hoffman K, **Shaheen NJ**, Genta RM, Dellon ES. Esophageal eosinophilia is increased in rural areas with low population density: Results from a national pathology database. *American Journal of Gastroenterology*.2014; 109(5):668-75.
163. Dellon ES, Jensen EC, Martin CF, **Shaheen NJ**, Kappelman MD. The prevalence of eosinophilic esophagitis in the United States. *Clinical Gastroenterology and Hepatology* 2014;12(4):589-96.
164. Chen H, Hu Y, Djukic Z, Yamamoto M, **Shaheen N**, Orlando R, Chen X. Nrf2 deficiency attenuates the barrier function of mouse esophageal epithelium. *Gut* 2014;63(5):711-19.
165. Wolf WA, Jerath MR, Sperry SLW, **Shaheen NJ**, Dellon ES. Dietary elimination therapy is an effective option for adults with eosinophilic esophagitis. *Clinical Gastroenterology and Hepatology* 2014;12(8):1272-9.
166. Dellon ES, Kim HP, Sperry SLW, Rybnicek DA, Woosley JT, **Shaheen NJ**. A phenotypic analysis shows eosinophilic esophagitis is a progressive fibrostenotic disease. *Gastrointestinal Endoscopy* 2014;79(4):577-585.
167. Lu Y, Ek WE, Whiteman D, Vaughan TL, Spurdle AB, Easton DF, Pharoah PD, Thompson DJ, Dunning AM, Hayward NK, Chenevix-Trench G; Q-MEGA and AMFS Investigators; ANECS-SEARCH; UKOPS-SEARCH; BEACON Consortium, Macgregor S. Most common 'sporadic' cancers have a significant germline genetic component. *Hum Mol Genet*. 2014;23(22):6112-8.
168. Rybnicek DA\*, Hathorn KE\*, Pfaff ER, Bulsiewicz WJ, **Shaheen NJ**, Dellon ES. Administrative coding is specific, but not sensitive, for identifying eosinophilic esophagitis. *Diseases of the Esophagus* 2014; 27(8):703-8.

169. Ren D, Zheng G, Bream S, Tevebaugh W, **Shaheen NJ**, Chen X. Single nucleotide polymorphisms of caudal type homeobox 1 and 2 are associated with Barrett's esophagus. *Digestive Diseases and Sciences* 2014;59(1):57-63.
170. Dellon ES, Speck O, Woodward K, Gebhart JH, Madanick RD, Levinson S, Fritchie KJ, Woosley JT, **Shaheen NJ**. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: A Prospective Cohort Study. *American Journal of Gastroenterology* 2013;108(12):1854-60.
171. Trembath DG, **Shaheen NJ**, O'Neill S, Weck K, Greene KG. Metastatic melanoma in an esophagus demonstrating Barrett esophagus with high-grade dysplasia. *BMC Research Notes* 2013;13(6):457.
172. Ek WE, Levine DM, D'Amato M, Pedersen NL, Magnusson PKE, Bresso F, Onstad LE, Schmidt PT, Törnblom H, Nordenstedt H, Romero Y, Chow W, Murray LJ, Gammon MD, Liu G, Bernstein L, Casson AG, Risch HA, **Shaheen NJ**, Bird NC, Reid BJ, Corley DA, Hardie LJ, Ye W, Wu AH, Zucchelli M, Spector TD, Hysi P, Vaughan TL, Whiteman DC, MacGregor S on behalf of the BEACON study investigators. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus and gastroesophageal reflux. *JNCI* 2013;105(22):1711-18.
173. Levine D, Ek WE, Zhang R, Liu X, Onstad L, Sather C, Lao-Sirieix P, Gammon MD, Corley DA, **Shaheen NJ**, Bird NC, Hardie LJ, Murray LJ, Reid BJ, Chow W, Risch HA, Nyrén O, Ye W, Liu G, Romero Y, Bernstein L, Wu AH, Casson AG, Chanock S, Harrington P, Caldas I, Debiram-Beecham I, Caldas C, Hayward NK, Pharoah P, Fitzgerald R, MacGregor S, Whiteman DC, Vaughan TL. A Genome-Wide Association Study Identifies New Susceptibility Loci for Esophageal Adenocarcinoma and Barrett's Esophagus. *Nature Genetics* 2013;45(12):1487-93.
174. **Shaheen NJ**, Denison H, Bjorck K, Silberg DG. Esophageal mucosal breaks in gastroesophageal reflux partially responsive to proton pump inhibitor therapy. *American Journal of Gastroenterology* 2013;108(4):529-34.
175. Garman KS, Owzar K, Hauser ER, Westfall K, Anderson BR, Souza RF, Diehl AM, Provenzale D, **Shaheen NJ**. MicroRNA Expression Differentiates Squamous Epithelium from Barrett's Esophagus and Esophageal Cancer. *Digestive Diseases and Sciences* 2013;58(11):3178-88.
176. Nason KS, Murphy T, Schindler J, Schipper PH, Hoppo T, Diggs BS, Sauer DA, **Shaheen NJ**, Morris CD, Jobe BA. A cross-sectional analysis of the prevalence of Barrett's esophagus in otolaryngology patients with laryngeal symptoms. *J Clin Gastroenterol* 2013;47(9):762-68.
177. Fang Y, Chen H, Hu Y, Tevebaugh W, **Shaheen NJ**, Orlando RC, Hu J, Chen X.. Gastroesophageal reflux activates the NFkB pathway and impairs esophageal barrier function in mice *American Journal of Physiology – Gastrointestinal and Liver Physiology* 2013;305(1):G58-65.
178. Greener BN, Patterson KB, Prince HMA, Sykes C, Adams JL, Dumond JB, **Shaheen NJ**, Cohen MS, Kashuba ADM. Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV Negative Men After Single and Multiple Dosing. *JAIDS* 2013;64(1):39-44.
179. Orman ES, Li N, **Shaheen NJ**. Efficacy and durability of radiofrequency ablation for Barrett's esophagus: A systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology* 2013;11(10):1245-55.
180. Chen H, Fang Y, Li W, Orlando RC, **Shaheen N**, Chen XL. NFkB and Nrf2 in esophageal epithelial barrier function. *Tissue Barriers* 2013;1 (1): e27463.

181. Bulsiewicz WJ, **Shaheen NJ**, Hansen MB, Pruitt A, Orlando RC. Effect of Amiloride on Experimental Acid-induced Heartburn in Non-Erosive Reflux Disease. *Digestive Diseases and Sciences* 2013;58(7):1955-59.
182. Bulsiewicz WJ, Kim HP, Dellon ES, Cotton CC, Pasricha S, Madanick RD, Spacek MB, Bream SE, Chen X, Orlando RC, **Shaheen NJ**. Safety and Efficacy of Endoscopic Mucosal Therapy with Radiofrequency Ablation for Patients with Neoplastic Barrett's Esophagus. *Clin Gastroenterol Hepatol* 2013; 11(6):636-42.
183. Patterson KB, Prince HA, Stevens T, **Shaheen NJ**, Dellon ES, Madanick R, Jennings S, Cohen MS, Kashuba ADM. Differential Penetration of Raltegravir throughout Gastrointestinal Tissue: Implications for Eradication and Cure. *AIDS* 2013;27(9):1413-19.
184. Kubo A, Cook MB, **Shaheen NJ**, Vaughan TL, Whiteman DC, Murray L, Corley DA. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's esophagus: a pooled analysis from the international BEACON consortium. *Gut* 2013;62(12):1684-91.
185. Dellon ES, Erichsen R, Pedersen L, **Shaheen NJ**, Baron JA, Sorensen HT, Vyberg M. Development and validation of a registry-based case definition of eosinophilic esophagitis in the linked health registries in Denmark. *World J Gastroenterol* 2013;19(4):503-10..
186. Jovov B, **Shaheen NJ**, Orlando GS, Djukic Z, Orlando RC. Defective barrier function in neosquamous epithelium. *American Journal of Gastroenterology* 2013;108(3):386-91.
187. Dellon ES, Jones PD, Martin NB, Kelly M, Kim SC, Freeman KL, Dellon EP, Ferris ME, **Shaheen NJ**. Health care transition from pediatric to adult-focused gastroenterology in patients with eosinophilic esophagitis. *Diseases of the Esophagus* 2013;26(1):7-13.
188. Ladabaum U, Brill JV, Sonnenberg A, **Shaheen NJ**, Inadomi J, Wilcox CM, Park WG, Hur C, Pasricha PJ. How to value technological innovation: A proposal for determining relative clinical value. *Gastroenterology*2013;144(1):5-8.
189. **Shaheen NJ**, Denison H, Björck K, Karlsson M, Silberg DG. Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial. *Gut* 2013; 62(9):1248-55.
190. Orman ES, Kim HP, Bulsiewicz WJ, Cotton CC, Dellon ES, Spacek MB, Chen X, Madanick RD, Pashricha S, **Shaheen NJ**. Intestinal Metaplasia Recurs Infrequently in Patients Successfully Treated for Barrett's Esophagus with Radiofrequency Ablation. *American Journal of Gastroenterology* 2013;108(2):187-95.
191. **Shaheen NJ**, Kim HP, Bulsiewicz WJ, Lyday WD, Triadafilopoulos G, Wolfsen HC, Komanduri S, Chmielewski GW, Ertan A, Corbett FS, Camara DS, Rothstein RI, Overholt BF. Prior fundoplication does not improve the safety or efficacy outcomes of radiofrequency ablation: Results from the U.S. RFA Registry. *Journal of Gastrointestinal Surgery* 2013;17(1):21-9.
192. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, DiBonaventura MD, Carroll CF, Allen MA, Cook SF, Sandler RS, Kappelman MD, **Shaheen NJ**. Burden of gastrointestinal disease in the United States: 2012 update. *Gastroenterology* 2012;143(5):1179-87.
193. Su Z, Gaye LJ, Strange A, ...**Shaheen NJ**, ..., Jankowski JA. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. *Nature Genetics* 2012;44(10):1131-36.

194. Chassany O, **Shaheen NJ**, Karlsson M, Hughes N, Rydén A. Systematic review: symptom assessment using patient-reported outcomes in gastro-oesophageal reflux disease and dyspepsia. *Scandinavian Journal of Gastroenterology* 2012;47(12):1412-21.
195. Dellon ES, Chen X, Miller CR, Woosley JT, **Shaheen NJ**. Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. *American Journal of Gastroenterology* 2012;107(10):1503-11.
196. Kim HP, Vance RB, **Shaheen NJ**, Dellon ES. The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: A meta-analysis. *Clinical Gastroenterology and Hepatology* 2012;10(9):988-96.
197. Dellon ES, Sheikh A, Speck O, Woodward K, Whitlow AB, Hores JM, Ivanovic M, Chau A, Woosley JT, Madanick RD, Orlando RC, **Shaheen NJ**. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. *Gastroenterology* 2012;143(2):321-24.
198. Kim HP, Bulsiewicz WJ, Cotton CC, Dellon ES, Spacek MB, Chen X, Madanick RD, Pasricha S, **Shaheen NJ**. Focal endoscopic mucosal resection prior to radiofrequency ablation is equally effective and safe compared to RFA alone for the eradication of Barrett's esophagus with advanced neoplasia. *Gastrointestinal Endoscopy* 2012;76(4):733-39.
199. Bennett C, Vakil N, Bergman JJ, ..**Shaheen NJ**, ..., Jankowski J. Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. *Gastroenterology* 2012;143(2):336-46.
200. Crockett SD, Sperry SLW, Miller CB, **Shaheen NJ**, Dellon ES. Emergency care of esophageal foreign body impactions: timing, treatment modalities, and resource utilization. *Diseases of the Esophagus* 2012;26(2):105-12.
201. Cook MB, **Shaheen NJ**, Anderson LA, Giffen C, Chow WH, Vaughan TL, Whiteman DC, Corley DA. Cigarette smoking increases risk of Barrett's esophagus: A pooled analysis from the international BEACON consortium. *Gastroenterology* 2012; 142(4):744-53.
202. McNeill MB, Sperry SLW, Crockett SD, Miller CB, **Shaheen NJ**, Dellon ES. Epidemiology and management of esophageal coin impaction in children. *Digestive and Liver Diseases* 2012;44(6):482-6.
203. Bulsiewicz WJ, Dellon ES, Rogers AJ, Pasricha S, Madanick RD, Grimm IS, **Shaheen NJ**. The impact of endoscopic ultrasound findings on clinical decision-making in Barrett's esophagus with high-grade dysplasia or early esophageal adenocarcinoma. *Diseases of the Esophagus* 2014; 27(5):409-17.
204. Peery AF, Hoppo T, Garman KS, Dellon ES, Daugherty N, Bream S, Sanz AF, Spacek MB, Connors D, Faulx AL, Chak A, Luketich JD, **Shaheen NJ**, Jobe BA. Feasibility, safety, acceptability, and yield of office-based transnasal endoscopy. *Gastrointestinal Endoscopy* 2012;75(5):945-53.
205. Chak A, Chen Y, Vengoechea J, Canto MI, Elston R, Falk GW, Grady WM, Guda K, Kinnard M, Markowitz S, Mittal S, Prasad GA, **Shaheen NJ**, Willis JE, Barnholtz-Sloan, J. Variation in age at cancer diagnosis in familial versus non-familial Barrett's esophagus. *Cancer Epidemiology, Biomarkers and Prevention* 2012;21(2):376-83.
206. Dorn SD, David Wei, Nilay D. Shah, Joel F. Farley, **Shaheen NJ**, Robert S. Sandler, Michael Kappelman. Impact of the 2008-2009 Economic Recession on Colonoscopy Utilization Among the Insured. *Clinical Gastroenterology & Hepatology* 2012;10(3):278-84..

207. Halsey KD, Manish A, Heath J, Bulsiewicz WJ, Petullo B, Madanick RD, Dellon ES, **Shaheen NJ**, Greenwald BD. Eosinophilic infiltration of the esophagus following endoscopic ablation of Barrett's neoplasia. *Diseases of the Esophagus* 2012; 75(5):945-953.
208. Brown KC, Patterson KB, Jennings, SH, Malone SA, **Shaheen, NJ**, Asher-Prince HM, Spacek M, Cohen MS, Kashuba ADM. Single and multiple dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men. *Journal of the Acquired Immune Deficiency Syndrome* 2012;61(2):138-44.
209. Sperry SLW, Woosley JT, **Shaheen NJ**, Dellon ES. Influence of race and gender on the presentation of eosinophilic esophagitis. *American Journal of Gastroenterology* 2012;107(2):215-21.
210. Dellon ES, Bower JJ, Keku TO, Chen X, Miller CR, Woosley JT, Orlando RC, **Shaheen NJ**. Markers of tyrosine kinase activity in eosinophilic esophagitis: A pilot study of the FIP1L1-PDGFR $\alpha$  fusion gene, pERK 1/2, and pSTAT5. *Diseases of the Esophagus* 2012;25(2):166-74.
211. Crockett SD, Lipkus IM, Bright SD, Sampliner RE, Wang KK, Boolchand V, Lutzke LS, **Shaheen NJ**. Overutilization of endoscopic surveillance in non-dysplastic Barrett's esophagus: A multi-center study. *Gastrointestinal Endoscopy* 2012; 44(6):482-6.
212. Hoppo T, Sanz A, Nason KS, Carroll TL, Rosen C, Normolle DP, **Shaheen NJ**, Luketich JD, Jobe BA. How Much Pharyngeal Exposure is "Normal?" Normative Data for Laryngopharyngeal Reflux Events Using Hypopharyngeal Multichannel Intraluminal Impedance (HMII). *Journal of Gastrointestinal Surgery* 2012;16(1):16-24.
213. Patterson KB, Cohen MS, Jenkins A, Kraft E, Prince HM, Rooney J, **Shaheen NJ**, Kashuba ADM. Penetration of tenofovir and emtricitabine in mucosal tissues: Implications for prevention of HIV-1 transmission. *Science Translational Medicine* 2011;3(112):112re4.
214. Sperry SL, Crockett SD, Miller CB, **Shaheen NJ**, Dellon ES. Esophageal foreign-body impactions: epidemiology, time trends and the impact of the increasing prevalence of eosinophilic esophagitis. *Gastrointestinal Endoscopy* 2011; 74(5):985-91.
215. Dellon ES, Peery AP, **Shaheen NJ**, Morgan DM, Hurrell JM, Lash RH, Genta RM. Inverse association of esophageal eosinophilia with *Helicobacter pylori* infection based on analysis of a US pathology database. *Gastroenterology* 2011;141(5):1586-92.
216. **Shaheen NJ**, Overholt BF, Sampliner RE, Wolfsen HC, Wang, KK, Fleischer DE, Sharma VK, Eisen GM, Fennerty MB, Hunter JG, Bronner MP, Goldblum JR, Bennett AE, Mashimo H, Rothstein RI, Gordon SR, Edmundowicz SA, Madanick RD, Muthusamy R, Chang KJ, Kimmey MB, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Dumot J, Falk GW, Galanko JA, Jobe BA, Hawes RH, Hoffman BJ, Sharma P, Chak A, Lightdale CJ. Durability of radiofrequency ablation for Barrett's esophagus with dysplasia. *Gastroenterology* 2011;141(2):460-68.
217. Perry AF, Cao H, Diminik R, **Shaheen NJ**, Dellon ES. Variable reliability of endoscopic findings in eosinophilic esophagitis with white light and narrow band imaging. *Clinical Gastroenterology and Hepatology* 2011; 9(6):475-80.
218. Brown KC, Patterson KB, Malone S, **Shaheen NJ**, Prince H, Dumond J, Spacek M, Cohen M, Kashuba ADM. Single and Multiple Dose Pharmacokinetics of Maraviroc in Saliva, Semen, and Rectal Tissue of HIV-Negative Men. *Journal of Infectious Diseases* 2011; 203(10):1484-90.



219. Sperry S, **Shaheen NJ**, Dellon ES. Toward uniformity in the diagnosis of Eosinophilic Esophagitis (EoE): The effect of guidelines variability of diagnostic criteria for EoE. *American Journal of Gastroenterology* 2011;106(5):824-32.
220. **Shaheen NJ**, Crockett SD, Bright SD, Madanick RD, Buckmire R, Couch M, Dellon ES, Galanko JA, Sharpless G, Morgan DR, Spacek MB, Heidt-Davis P, Henke D. Randomized clinical trial: High-dose acid suppression for chronic cough – a double-blind, placebo-controlled study. *Alimentary Pharmacology & Therapeutics* 2011;33(2):225-34.
221. Terry NG, Zhu Y, Rinehart MT, Brown WJ, Gebhart S, Bright S, Carretta E, Ziefle CW, Panjehpour M, Madanick RD, Dellon ES, Goldblum J, Bennett A, Overholt BF, Woosley JT, **Shaheen NJ**, Wax A. Detection of dysplasia in Barrett's esophagus with in vivo depth-resolved nuclear morphology measurements. *Gastroenterology* 2011; 140(1):42-50.
222. Long MD, Martin C, Sandler RS, **Shaheen NJ**, Herfarth H, Dellon ES. Reduced polyp detection as endoscopy shift progresses. *Journal of Clinical Gastroenterology* 2011; 45(3):253-258.
223. Zhu Y, Terry NG, Woosley JT, **Shaheen NJ**, Wax A. Design and validation of an angle-resolved low coherence interferometry fiber probe for in vivo clinical measurements of depth-resolved nuclear morphology. *Journal of Biomedical Optics* 2011; 16(1):011003.
224. Dellon ES, Chen X, Miller CR, Fritchie KJ, Rubinas TC, Woosley JT, **Shaheen NJ**. Tryptase staining of mast cells may differentiate eosinophilic esophagitis from gastroesophageal reflux disease. *American Journal of Gastroenterology* 2011;106:264-71.
225. Madanick RD, **Shaheen NJ**, Dellon ES. A novel balloon pull-through technique for esophageal dilation in eosinophilic esophagitis. *Gastrointestinal Endoscopy* 2011; 73: 138-142.
226. Peery AF, **Shaheen NJ**, Dellon ES. Practice patterns for the evaluation and treatment of eosinophilic esophagitis. *Alimentary Pharmacology & Therapeutics* 2010;32(11-12) 1373-82.
227. Rothlein LR, Shaheen AW, Vavalle JP, Smith SV, Renner JB, **Shaheen NJ**, Tarrant TK. Sclerosing mesenteritis successfully treated with a TNF antagonist. *BMJ Case Reports* Dec 20;2010. doi:pii: bcr0720103145.
228. **Shaheen NJ**, Peery AF, Hawes RH et al. Quality of life following radiofrequency ablation of dysplastic Barrett's esophagus. *Endoscopy* 2010;42(10): 790-99.
229. **Shaheen NJ**, Peery AF, Overholt BF, Lightdale CJ, Chak A, Wang KK, Hawes RH, Fleischer DE, Goldblum JR. Biopsy depth following radiofrequency ablation of dysplastic Barrett's esophagus. *Gastrointestinal Endoscopy* 2010; 72(3):490-96.
230. Dellon ES, Gibbs WB, Rubinas TC, Fritchie KJ, Madanick RD, Woosley JT, **Shaheen NJ**. Esophageal dilation in eosinophilic esophagitis: Safety and predictors of clinical response and complications. *Gastrointestinal Endoscopy* 2010; 71:706-12.
231. Greenwald BD, Dumot JA, Abrams JA, Lightdale CJ, David DS, Nishioka NS, Yachimski P, Johnston MH, **Shaheen NJ**, Zfass AM, Smith JO, Gill KRS, Burdick SJ, Mallat D, Wolfsen HC. Endoscopic spray cryotherapy for esophageal cancer: Safety and efficacy. *Gastrointestinal Endoscopy* 2010; 71:686-93.
232. **Shaheen NJ**, Greenwald BD, Peery AF, Dumot JA, Nishioka NS, Wolfsen HC, Burdick SJ, Abrams JA, Wang KK, Mallat DB, Johnston MH, Zfass AM, Smith JO, Barthel JS, Lightdale CJ. Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. *Gastrointestinal Endoscopy* 2010; 71:680-685.

233. Dellon ES, Farrell TM, Bozyski EM, **Shaheen NJ**. Diagnosis of eosinophilic esophagitis after fundoplication for “refractory reflux”: Implications for pre-operative evaluation. *Diseases of the Esophagus* 2010; 23:191-95.
234. Wang J, Qin R, Ma Y, Wu H, Peters H, Tyska M, **Shaheen NJ**, Chen X. Differential gene expression in normal esophagus and Barrett’s esophagus. *Journal of Gastroenterology* 2009; 44:897-911.
235. Dellon ES, Cullen NR, Madanick RD, Buckmire RA, Grimm IS, Weissler MC, Couch ME, **Shaheen NJ**. Outcomes of a combined antegrade and retrograde approach for dilation of radiation induced esophageal strictures. *Gastrointestinal Endoscopy* 2010; 71(7):1122-29.
236. Dellon ES, Gibbs WB, Fritchie KJ, Rubinas T, Wilson LA, Woosley JT, **Shaheen NJ**. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. *Clinical Gastroenterology and Hepatology* 2009; 7(12):1305-13.
237. Lippmann QK, Crockett SD, Dellon ES, **Shaheen NJ**. Quality of life in GERD and Barrett’s esophagus is related to gender and manifestation of disease. *American Journal of Gastroenterology* 2009; 104:2695-703.
238. Dellon ES, Fritchie KJ, Rubinas TC, Woosley JT, **Shaheen NJ**. Inter- and intra-observer reliability and validation of a new method for determination of eosinophil counts in patients with esophageal eosinophilia. *Digestive Diseases and Sciences* 2010; 55(7):1940-9.
239. Levesque MC, Moody MA, Hwang KK, Marshall D, Whitesides J, Amos J, Gurley T, Allgood S, Kuraoka M, Haynes BB, Parker DC, **Shaheen NJ**, Plonk S, Cohen M, Tomaras G, Goepfert P, Shaw G, Eron J, Hicks CB, Liao HX, Markowitz M, Kelsoe G, Margolis DM, Hatnes BF. Transmitted/Founder HIV-1 induces B cell polyclonal differentiation and apoptosis with massive gastrointestinal tract germinal center loss In the earliest stages of infection. *PLoS Medicine* 2009 Jul 7;6(7):e1000107.
240. **Shaheen NJ**, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Galanko JA, Bronner MP, Goldblum JR, Bennett AE, Jobe BA, Eisen GM, Fennerty MB, Hunter JG, Fleischer DE, Sharma VK, Hawes RH, Hoffman BJ, Rothstein RI, Gordon SR, Mashimo H, Chang KJ, Muthasamy VR, Edmundowicz SA, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Falk GW, Kimmey MB, Madanick RD, Chak A, Lightdale CJ. A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for Barrett’s esophagus (BE) containing dysplasia. *New England Journal of Medicine* 2009; 360: 2277-88.
241. Rubenstein JH, Kao JY, Madanick RD, Zhang M, Wang M, Spacek MB, Donovan J, Bright SD, **Shaheen NJ**. Association of adiponectin multimers with Barrett’s esophagus. *Gut* 2009; 58:1583-89.
242. Inadomi JM, Samsouk M, Madanick RD, **Shaheen NJ**. A cost-utility analysis of ablative therapy for Barrett’s esophagus. *Gastroenterology* 2009; 136: 2101-14.
243. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Olaru AV, Paun BC, Yang J, Kan T, Ito T, Hamilton JP, Selaru FM, Mori Y, Agarwal R, David S, Abraham JM, Wolfsen HC, Wallace MB, **Shaheen NJ**, Washington K, Wang J, Canto M, Bhattacharyya A, Nelson M, Wagner P, Romero Y, Wang KK, Feng Z, Sampliner RE, Meltzer SJ. A multicenter, double-blind, pre-validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. *Cancer Research*, 2009; 69: 4112-15.
244. Crockett SD, Lippmann Q, Dellon ES, **Shaheen NJ**. Health-related quality of life in patients with Barrett’s esophagus: A systematic review. *Clinical Gastroenterology & Hepatology* 2009; 7: 613-23.

245. Crockett SD, Dellon ES, Bright SD, **Shaheen NJ**. A 25 year analysis of the American College of Gastroenterology research grant program: Factors associated with publication and advancement in academics. *American Journal of Gastroenterology* 2009;104: 1097-1105.
246. Dellon ES, Lippmann QK, Galanko JA, Sandler RS, **Shaheen NJ**. The effect of GI endoscopy nurse experience on screening colonoscopy outcomes. *Gastrointestinal Endoscopy* 2009; 70(2):331-43.
247. Sharma P, **Shaheen NJ**, Perez MC, Pilmer BL, Lee M, Atkinson S, Peura D. Healing of erosive esophagitis with TAK-390MR, a proton pump inhibitor with a novel dual delayed release formulation: Results from 2 randomized controlled trials. *Alimentary Pharmacology and Therapeutics* 2009; 29:731-41.
248. Dellon ES, Grimm IS, Hawk J, **Shaheen NJ**. The use of carbon dioxide for insufflation during gastrointestinal endoscopy: A systematic review. *Gastrointestinal Endoscopy*, 2009; 69: 843-49.
249. Wani S, Puli SR, **Shaheen NJ**, Westhoff B, Slehria S, Bansal A, Rastogi A, Sayana H, Sharma P. Esophageal adenocarcinoma in Barrett's esophagus post endoscopic ablative therapy: A meta-analysis and systematic review. *American Journal of Gastroenterology* 2009;104:502-13.
250. Chen X, Qin R, Liu B, Ma Y, Su Y, Yang CS, Glickman JN, Odze RD, **Shaheen NJ**. Multilayered epithelium in a rat model and human Barrett's esophagus: Expression patterns of transcription factors and differentiation markers. *BMC Gastroenterology* 2008; 8: 1.
251. Brown A, Young B, Morton J, Behrns K, **Shaheen N**. Are health related outcomes in acute pancreatitis improving? An analysis of national trends in the U.S. from 1997 to 2003. *JOP*. 2008 Jul 10;9(4):408-14.
252. Ganz RA, Overholt BF, Sharma VK, Fleischer DE, **Shaheen NJ**, et al. Circumferential ablation is safe and effective for the treatment of Barrett's esophagus with high-grade dysplasia: A U.S. multi-center registry. *Gastrointestinal Endoscopy* 2008;68:35-40.
253. Dellon ES, Lippmann Q, Sandler RS, **Shaheen NJ**. GI endoscopy nurse experience and polyp detection during screening colonoscopy. *Clinical Gastroenterology and Hepatology* 2008; 6: 1342-47.
254. Kahrilas P, **Shaheen NJ**, Vaezi MF. AGA Technical Review on gastroesophageal reflux disease. *Gastroenterology* 2008;135:1392-1413.
255. Kahrilas P, **Shaheen NJ**, Vaezi MF. AGA Medical Position Paper on gastroesophageal reflux disease. *Gastroenterology* 2008;135:1383-1391 .
256. Fisher DA, Johnson MR, **Shaheen NJ**. Fecal occult blood testing completion in a VA population: Low and strongly related to race. *Journal of Clinical Outcomes Management* 2007; 14: 93-98.
257. Fisher DA, Galanko J, Dudley TK, **Shaheen NJ**. Impact of comorbidity on colorectal cancer screening in the Veterans' Healthcare System. *Clinical Gastroenterology and Hepatology*. 2007 Aug;5(8):991-6.
258. Dellon ES, Aderoju A, Woosley JT, Sandler RS, **Shaheen NJ**. Variability in diagnostic criteria for eosinophilic esophagitis: a systematic review. *American Journal of Gastroenterology* 2007; 102: 1-14.

259. Jovov B, Italie V, **Shaheen NJ**, Carson J, Gambling T, Anderson JA, Orlando RC. Claudin-18: A dominant tight junction protein in Barretts esophagus and likely contributor to its acid resistance. *American Journal of Physiology* 2007 Dec;293(6):G1106-13.
260. **Shaheen NJ**, Madanick RD, Alattar M, Morgan DR, Davis P, Galanko JA, Spacek MB, Vaughn BV. Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: prevalence and response to therapy. *Digestive Diseases and Sciences* 2007; 53: 1493-1499.
261. Schindler BA, Novak, D, Wong D, **Shaheen NJ**, Drossman D. The impact of the changing health care environment on the health and well-being of faculty at four medical schools. *Academic Medicine* 2006; 81:27-34.
262. Austin GL, Thiny MT, Westman EC, Yancy WS, **Shaheen NJ**. A very low carbohydrate diet improves gastroesophageal reflux and its symptoms. *Digestive Diseases and Sciences* 2006;51:1307-12.
263. Austin GL, **Shaheen NJ**, Sandler RS. Use of inflammatory bowel disease serologic markers. *American Journal of Gastroenterology* 2006; 101: 413-16.
264. **Shaheen NJ**, Hansen R, Morgan DR, Thiny MT, Gangarosa LM, Ringel Y, Russo MW, Sandler RS. Digestive disease and liver statistics, 2006. *American Journal of Gastroenterology* 2006;101:2128-38.
265. Brown A, Schmitz SM, **Shaheen NJ**. The association of industry sponsorship to published outcomes in GI clinical research. *Clinical Gastroenterology and Hepatology* 2006;4:1445-51.
266. **Shaheen NJ**, Stuart S, Schmitz SM, Mitchell KL, Fried MW, Zacks S, Russo MW, Galanko J, Shrestha R. Pantoprazole reduces the size of post-banding ulcers after elective endoscopic variceal band ligation: a randomized, controlled trial. *Hepatology* 2005;41:588-594.
267. **Shaheen NJ**, Dulai, GS, Ascher B, Mitchell KL, Schmitz SM. The effect of a new diagnosis of Barrett's esophagus on insurance status. *American Journal of Gastroenterology* 2005; 100: 577-80.
268. Hansen RA, **Shaheen NJ**, Schommer JC. Therapeutic switching: the relationship between diagnosis, insurance, direct-to-consumer advertising, and switching between two proton pump inhibitors. *Clinical Therapeutics* 2005; 27: 1-10.
269. **Shaheen NJ**, Green B, Medapalli RK, Wei J, Schmitz SM, Mitchell KL, Provenzale D. Perceived risk of esophageal adenocarcinoma in subjects with Barrett's esophagus. *Gastroenterology* 2005; 129: 429-36.
270. Russo MW, Wei JT, Thiny MT, Gangarosa LM, Brown A, Ringel Y, **Shaheen NJ**, Sandler RS. Digestive disease and liver statistics, 2004. *Gastroenterology* 2004; 126:1448-54.
271. Sharma P, McQuaid K, Dent J, Fennerty B, Sampliner R, Spechler S, Cameron A, Corley D, Falk G, Goldblum J, Hunter J, Jankowski J, Lundell L, Reid B, **Shaheen NJ**, Sonnenberg A, Wang K, Weinstein W. A critical review of the diagnosis and management of Barrett's esophagus: The AGA Chicago workshop. *Gastroenterology* 2004; 127: 310-330.
272. **Shaheen NJ**, Inadomi J, Overholt B, Sharma P. What is the best management for Barrett's esophagus with high-grade dysplasia? A cost-effectiveness analysis. *Gut* 2004; 53(12):1736-44.

273. **Shaheen NJ**, Silverman LM, Keku T, Lawrence LB, Rohlfs EM, Martin CF, Galanko JA, Sandler RS. "Hemochromatosis Gene" (*HFE*) mutations and the risk of colon cancer. *Journal of the National Cancer Institute* 2003; 95: 154-60.
274. Heider TR, Behrns KE, Koruda MJ, **Shaheen NJ**, Lucktong TA, Bradshaw B, Farrell TM. Fundoplication improves disordered esophageal motility. *Journal of Gastrointestinal Surgery*, 2003;7:159-163.
275. **Shaheen NJ**, Lawrence LB, Bacon BR, Barton JC, Barton NH, Galanko JA, Martin CF, Sandler RS. Insurance and employment consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage. *American Journal of Gastroenterology* 2003;98:1175-80.
276. Goodgame B, **Shaheen NJ**, Galanko J, El-Serag HB. The risk of cirrhosis and hepatocellular carcinoma among persons infected with Hepatitis C virus: publication bias? *American Journal of Gastroenterology* 2003; 98: 2535-2542.
277. Corey KE, Schmitz SM, **Shaheen NJ**. Does a surgical anti-reflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A Meta-analysis. *American Journal of Gastroenterology* 2003; 98: 2390-2394.
278. Lucktong TA, Morton JM, **Shaheen NJ**, Farrell TM. Resection of benign esophageal stricture through a minimally invasive endoscopic and transgastric approach. *American Surgeon* 2002;8:720-3.
279. Robertson DJ, Lawrence LB, **Shaheen NJ**, Halabi S, Baron JA, Paskett E, Petrelli NJ, Sandler RS. Quality of colonoscopy reporting: a process of care study. *American Journal of Gastroenterology* 2002;97:2651-2656.
280. Ofman JJ, **Shaheen NJ**, Desai AA, Moody B, Bozymski EM, Weinstein WM. Assessing process of care in Barrett's esophagus. *American Journal of Gastroenterology* 2001; 96: 876-881.
281. O'Malley MS, **Shaheen NJ**, Crosby MA, Murray SC, Klenzak JS, Galanko JA, Singla A, Ransohoff DF, Sandler RS, Gaither J, Paskett ED. Colorectal cancer screening in North Carolina: Community clinicians' perspectives. *North Carolina Medical Journal* 2001; 62: 292-298.
282. **Shaheen NJ**, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? *Gastroenterology* 2000; 119: 333-338.
283. **Shaheen NJ**, Crosby MA, O'Malley MS, Murray SC, Sandler RS, Galanko JA, Ransohoff DF, Klenzak JS. The practices and attitudes of primary care nurse practitioners and physician assistants with respect to colorectal cancer screening. *American Journal of Gastroenterology* 2000; 95: 3259-3265.
284. **Shaheen NJ**, Robertson DJ, Crosby MA, Furs SJ, May DT, Harlan WR, Grimm IS, Isaacs KL, Bozymski EM. Hyoscyamine as an antispasmodic in elective colonoscopy; A randomized, double-blinded, placebo-controlled trial. *American Journal of Gastroenterology* 1999; 94: 2905-2908.
285. Behrns KE, **Shaheen NJ**, Grimm I. Type I choledochal cyst in association with Familial Adenomatous Polyposis. *American Journal of Gastroenterology* 1998; 93: 1377-1379.
286. **Shaheen NJ**, Bacon BR, Grimm IS. Clinical characteristics of patients with hereditary hemochromatosis who lack the Cys282Tyr mutation. *Hepatology* 1998; 28: 526-530.

287. Rohlf EM, **Shaheen NJ**, Silverman LM. Is the hemochromatosis gene a modifier locus for cystic fibrosis? *Genetic Testing* 1998; 2: 85-88.
288. Warshauer DM, **Shaheen NJ**, Ferlesi PJ. Sclerosing mesenteritis. A CT demonstration. *Journal of Computer Assisted Tomography* 1997; 21: 108-109.
289. Kopp VJ, Mayer DC, **Shaheen NJ**. Intravenous erythromycin promotes gastric emptying prior to emergency anesthesia. *Anesthesiology* 1997; 87: 703-705.
290. **Shaheen NJ**, Cosby MA, Grimm IS, Isaacs KL. The use of percutaneous endoscopic gastrostomy in pregnancy. *Gastrointestinal Endoscopy* 1997; 46: 564-565.
291. **Shaheen NJ**, Grimm IS. Fulminant hepatic failure associated with clarithromycin. *American Journal of Gastroenterology* 1996; 91: 394-395.
292. **Shaheen NJ**, Grimm IS. Comparison of the Caldwell Needle/Cannula with the angiocath needle for large volume paracentesis. *American Journal of Gastroenterology* 1996;91:1731-1733.
293. Dozer D, **Shaheen NJ**, Goldberg M, Spiegel A. Mucinous pancreatic neoplasms mistaken for chronic pancreatitis. *Practical Gastroenterology* 1995; 19: 48H-48K.
294. Lashner BA, **Shaheen NJ**, Hanauer SB, Kirschner BS. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. *American Journal of Gastroenterology* 1993; 88(3): 356-359.

#### Other Peer-Reviewed Articles

295. **Shaheen NJ**, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. *Am J Gastroenterol.* 2022 Apr 1;117(4):559-587.
296. **Shaheen NJ**. Endoscopic treatment of esophageal neoplasia: A decade of evolution. *Trans Am Clin Climatol Assoc* 2020;131:297-314.
297. Peery AF, Arora S, **Shaheen NJ**. Reviving Routine Gastrointestinal Endoscopy in the COVID-19 Era. *Am J Gastroenterol* 2020 Sep;115(9):1376-1379.
298. Greenberg SB, **Shaheen NJ**. Endoscopic Surveillance of Barrett's Esophagus: Using Old Principles and New Technology to Improve Care. *Am J Gastroenterol.* 2022 Feb 1;117(2):201-204.
299. Watts AE, Cotton CC, **Shaheen NJ**. Radiofrequency Ablation of Barrett's Esophagus: Have We Gone Too Far, or Not Far Enough? *Current Gastroenterology Reports* 2020: epub ahead of print.
300. Vaezi MF, **Shaheen NJ**, Muthusamy VR. State of Evidence in Minimally Invasive Management of Gastroesophageal Reflux: Findings of a Scoping Review. *Gastroenterology.* 2020 Oct;159(4):1504-1525.
301. Kahn A, **Shaheen NJ**, Iyer PG. Approach to the Post-Ablation Barrett's Esophagus Patient. *American Journal of Gastroenterology* 2020 Jun;115(6):823-831.
302. Sharma P, **Shaheen NJ**, Katzka D, Bergman JJGHM. AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review. *Gastroenterology.* 2020 Feb;158(3):760-769.

303. Shaheen NJ. Risk of cancer in patients with Barrett Esophagus. *Gastroenterol Hepatol (N Y)*. 2019 Dec;15(12):688-690.
304. **Shaheen NJ**. Endoscopic treatment of esophageal neoplasia: A decade of evolution. *Transactions of the American Clinical & Climatological Association* 2020;131:297-314.
305. Peery AF, Arora S, **Shaheen NJ**. Reviving Routine Gastrointestinal Endoscopy in the COVID-19 Era. *Am J Gastroenterol* 2020 Sep;115(9):1376-1379.
306. Reed CC, **Shaheen NJ**. Management of Barrett Esophagus Following Radiofrequency Ablation. *Gastroenterol Hepatol (N Y)*. 2019 Jul;15(7):377-386.
307. Peters Y, Al-Kaabi A, **Shaheen NJ**, Chak A, Blum A, Souza RF, Di Pietro M, Iyer PG, Pech O, Fitzgerald RC, Siersema PD. Barrett oesophagus. *Nat Rev Dis Primers*. 2019 May 23;5(1):35.
308. Reed CC, **Shaheen NJ**. Durability of Endoscopic Treatment for Dysplastic Barrett's Esophagus. *Curr Treat Options Gastroenterol*. 2019 Jun;17(2):171-186.
309. Ramay FH, Vareedayah AA, Visrodia K, Iyer PG, Wang KK, Eluri S, **Shaheen NJ**, Reddy R, Martin LW, Greenwald BD, Edwards MA. What Constitutes Optimal Management of T1N0 Esophageal Adenocarcinoma? *Ann Surg Oncol*. 2019 Mar;26(3):714-731.
310. **Shaheen NJ**, Sandler RS. How to Promote the Academic Success of Junior Faculty Physicians in Gastroenterology. *Gastroenterology* 2018;155(5):1293-1297.
311. **Shaheen NJ**, Fennerty MB, Bergman JJ. Less Is More: A Minimalist Approach to Endoscopy. *Gastroenterology*. 2018;154(7):1993-2003
312. **Shaheen NJ**. Endoscopic Management of Barrett Esophagus. *Gastroenterol Hepatol (NY)*. 2018;14(7):433-435.
313. Goldblum JR, **Shaheen NJ**, Vennalaganti PR, Sharma P, Lightdale CJ. WATS for Barrett's surveillance. *Gastrointest Endosc*. 2018 Jul;88(1):201-202.
314. Shafa S, **Shaheen NJ**. How I Approach It: Care of the Post-Ablation Barrett's Esophagus Patient. *Am J Gastroenterol*. 2017;112(10):1487-1490.
315. Reed CC, **Shaheen NJ**. Natural History of the Post-ablation Esophagus. *Dig Dis Sci*. 2018;63(8):2136-2145.
316. Eluri S, **Shaheen NJ**. Importance of an Irregular Z Line: Is Barrett's in the Eye of the Beholder? *Dig Dis Sci*. 2018;63(6):1378-1380..
317. Spechler SJ, Merchant JL, Wang TC, Chandrasoma P, Fox JG, Genta RM, Goldenring JR, Hayakawa Y, Kuipers EJ, Lund PK, McKeon F, Mills JC, Odze RD, Peek RM Jr., Pham T, Que J, Rustgi AK, **Shaheen NJ**, Shivdasani RA, Souza RF, Storz P, Todisco A, Wang DH, Wright NA. A Summary of the 2016 James W. Freston Conference of the American Gastroenterological Association: Intestinal Metaplasia in the Esophagus and Stomach: Origins, Differences, Similarities and Significance. *Gastroenterology*. 2017;153(1):e6-e13.
318. Eluri S, **Shaheen NJ**. Endoscopic Eradication Therapy in Barrett's Esophagus. *Tech Gastrointest Endosc*. 2017 Jul;19(3):137-142.
319. Shaheen NJ. New Directions in Barrett's Esophagus. *Gastrointest Endosc Clin N Am*. 2017 Jul;27(3):xv-xvi.

320. Katzka DA, Smyrk TC, Alexander JA, Geno DM, Beitia RA, Chang AO, Shaheen NJ, Fitzgerald RC, Dellon ES. Corrigendum: Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study. *Am J Gastroenterol*. 2017 Dec 19. doi: 10.1038/ajg.2017.474.
321. Patti MG, **Shaheen NJ**. ISS Symposium From Heartburn to Barrett's Esophagus, and Beyond. *World J Surg*. 2017; 41(7):1665.
322. Schlottmann F, **Shaheen NJ**, Madanick RD, Patti MG. The role of Heller myotomy and POEM for nonachalasia motility disorders. *Dis Esophagus*. 2017 Apr 1;30(4):1-5.
323. Vaezi MF, Pandolfino JE, Vela MF, **Shaheen NJ**. AGA White Paper: Optimal Strategies to Define and Diagnose Gastroesophageal Reflux Disease. *Clin Gastroenterol Hepatol*. 2017; 15(8):1162-1172.
324. Schlottmann F, Patti MG, **Shaheen NJ**. Endoscopic Treatment of High-Grade Dysplasia and Early Esophageal Cancer. *World J Surg*. 2017; 41(7):1705-1711.
325. Schlottmann F, Patti MG, **Shaheen NJ**. From Heartburn to Barrett's Esophagus, and Beyond. *World J Surg*. 2017; 41(7):1698-1704.
326. Gould JC, Wendling MR, Oeschlager BK, Mittal SK, Komanduri S, Perry KA, Cleary S, Galandiuk S, Scott DJ, Fisichella PM, **Shaheen NJ**, Haisley KR, Hunter JG. Advances in the Diagnosis and Treatment of Barrett's Esophagus and Early Esophageal Cancer; Summary of the Kelly and Carlos Pellegrini SSAT/SAGES Luncheon Symposium. *J Gastrointest Surg*. 2017; doi: 10.1007/s11605-017-3390-5.
327. Eluri S, **Shaheen NJ**. Barrett's esophagus: diagnosis and management. *Gastrointest Endosc*. 2017 May;85(5):889-903.
328. Reed CC, **Shaheen NJ**. Endoscopic Treatment of High-Grade Dysplasia and Intramucosal Esophageal Adenocarcinoma. *J Laparoendosc Adv Surg Tech A*. 2016;26(10):768-772.
329. Hachem C, **Shaheen NJ**. Diagnosis and Management of Functional Heartburn. *American Journal of Gastroenterology* 2016; 111(1):53-61.
330. **Shaheen NJ**. Response to Braillon et al. *Am J Gastroenterol*. 2016 Jun;111(6):900.
331. Shafa S, **Shaheen NJ**. Buried Barrett's Esophagus-a Sheep in Sheep's Clothing. *J Gastrointest Surg*. 2016 Jul;20(7):1281-3. doi: 10.1007/s11605-016-3165-4.
332. **Shaheen NJ**, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. *American Journal of Gastroenterology* 2016; Jan;111(1):30-50.
333. Rubenstein JH, **Shaheen NJ**. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. *Gastroenterology* 2015;149(2):302-317.
334. Runge TM, Abrams JA, **Shaheen NJ**. Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma. *Gastroenterol Clin North Am*. 2015 Jun;44(2):203-231.
335. Abrams JA, Appelman HD, Beer DG, Berry LD, Chak A, Falk GW, Fitzgerald RC, Ginsberg GG, Grady WM, Joshi BP, Lynch JP, Markowitz S, Richmond E, Rustgi AK, Seibel EJ, **Shaheen NJ**, Shyr Y, Umar A, Wang KK, Wang TD, Wang TC, Yassin R. Barrett's Esophagus Translational Research Network (BETRNet): The pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. *Gastroenterology* 2014;146(7):1586-90.



336. **Shaheen NJ**. Advances in GERD. *Gastroenterol Hepatol* 2013;9(6):377-79.
337. **Shaheen NJ**. Highlights from the new ACG guidelines for the diagnosis and management of GERD. *Gastroenterology & Hepatology* 2013;9(6):377-79.
338. **Shaheen NJ**. Benign and malignant esophageal diseases. *Gastroenterology Clinics of North America* 2013;42(1):xiii-xiv.
339. **Shaheen NJ**, Weinberg DS, Denberg TD, Chou R, Qassem A, for the Guidelines Committee of the American College of Physicians. Upper endoscopy for gastroesophageal reflux disease: Best practice advice from the American College of Physicians. *Ann Intern Med* 2012;157:808-815.
340. Chen H, Fang Y, Tevebaugh W, Orlando RC, **Shaheen NJ**, Chen X. Molecular mechanisms of Barrett's esophagus. *Dig Dis Sci* 2011;56(12): 3405-20.
341. Greenwald BD, Lightdale CJ, Abrams JA, Horwhat JD, Chuttani R, Komanduri S, Upton MP, Appelman HD, Shields HM, **Shaheen NJ**, Sontag SJ. Barrett's esophagus: endoscopic treatments. *Annals of the New York Academy of Science* 2011; 1232(1):156-74.
342. Wax A, Terry NG, Dellon ES, **Shaheen NJ**. Angle Resolve Low Coherence Interferometry for Detection of Dysplasia in Barrett's Esophagus. *Gastroenterology* 2011;141(2):443-47.
343. Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, Burks AW, Cheade M, Collins MH, Dellon ES, Dohil R, Falk GW, Gonsalves N, Gupta SK, Katzka DA, Lucendo AJ, Markowitz JE, Noel RJ, Odze RD, Putnam PE, Richter JE, Romero Y, Ruchelli E, Sampson HA, Schoepfer A, **Shaheen NJ**, Sicherer SH, Spechler S, Spergel JM, Straumann A, Wershil BK, Rothenberg ME, Aceves SS. Eosinophilic esophagitis: Updated consensus recommendations for children and adults. *Journal of Allergy and Clinical Immunology* 2011;128(1):3-20..
344. Scholl S, Dellon ES, **Shaheen NJ**. Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions. *American Journal of Gastroenterology* 2011;106(3):386-92.
345. Peery AF, **Shaheen NJ**. Esophagus: Endoscopic therapy for flat, dysplastic Barrett Esophagus. *Nature Reviews of Gastroenterology & Hepatology* 2011; 8(4): 186-87.
346. Spechler SJ, Sharma P, Souza, RF, Inadomi JM, **Shaheen NJ**. American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus. *Gastroenterology* 2011; 140(3): e18-52.
347. Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association Medical Position Statement on the Management of Barrett's Esophagus. *Gastroenterology* 2011; 140(3):1084-91.
348. Garman KS, **Shaheen NJ**. Ablative therapies for Barrett's esophagus. *Current Gastroenterology Reports* 2011;13(3):226-39.
349. Crockett SD, **Shaheen NJ**. Reflux and Barrett's esophagus. *Endoscopy essentials. Endoscopy* 2011;43(1):21-25.
350. Bulsiewicz WJ, **Shaheen NJ**. The role of radiofrequency ablation in the management of Barrett's esophagus. *Gastrointestinal Endoscopy Clinics of North America* 2011; 21(1):95-109.

351. Newton WP, Stone K, Dent GA, **Shaheen NJ**, Byerly J, Gilliland KO, Rao K, Farrell T, Cross A. The University of North Carolina at Chapel Hill School of Medicine Curriculum. *Academic Medicine* 2010;85 (9 Suppl): S424-29.
352. Dellon ES, **Shaheen NJ**. Persistent symptoms in the PPI era: the changing face of GERD. *Gastroenterology* 2010;139(1):7-13.
353. Frantz DF, **Shaheen NJ**. When to consider endoscopic ablation for Barrett's Esophagus. *Current Opinion in Gastroenterology* 2010;26(4):361-66.
354. Crockett SD, Barritt AS, **Shaheen NJ**. A 52-year-old man with heartburn: Should he undergo screening for Barrett's esophagus? *Clinical Gastroenterology and Hepatology* 2010; 8(7):565-71.
355. Kanaly T, **Shaheen NJ**, Vaughn BV. Gastrointestinal issues in sleep and sleep disorders. *Current Opinion in Pulmonary Medicine* 2009; 15: 571-77.
356. **Shaheen NJ**, Palmer LB. Improving screening practices for Barrett's esophagus. *Surgical Oncology Clinics of North America* 2009; 18: 423-37.
357. **Shaheen NJ**, Richter JE. Barrett's Esophagus: A Lancet Seminar. *Lancet* 2009; 373: 850-861.
358. **Shaheen NJ**, Spechler SJ. Total endoscopic eradication of Barrett's esophagus: study methodology, candidate selection, and clinical outcomes. *Endoscopy* 2008; 12: 994-999.
359. Long MD, **Shaheen NJ**. Extra-Esophageal GERD: clinical dilemma of epidemiology versus clinical practice. *Current Gastroenterology Reports* 2007; 9: 195-202.
360. Johnson DA, **Shaheen N**, Sarles H et al. Pay for performance: An ACG guideline for physicians. *American Journal of Gastroenterology* 2007; 102:2119-2122.
361. Madanick RD, **Shaheen NJ**. Is intestinal metaplasia of the gastroesophageal junction (IMAGE) Really Barrett's Esophagus? *Current GERD Reports* 2007;1:137-43.
362. Cassara JE, **Shaheen NJ**. Endoscopic antireflux devices: a year of challenges and change. *Current Opinion in Gastroenterology* 2006; 22: 423-428.
363. **Shaheen NJ**. Barrett Esophagus: disease management and patient perceptions. *Gastroenterology & Hepatology* 2006; 2: 468-71.
364. **Shaheen NJ**. Advances in Barrett's esophagus and esophageal adenocarcinoma. *Gastroenterology* 2005; 128 (6): 1554-1566.
365. Dellon E, **Shaheen NJ**. Does screening for Barrett's esophagus and adenocarcinoma of the esophagus prolong survival? *Journal of Clinical Oncology* 2005; 23: 1-5.
366. **Shaheen NJ**. The impact of antireflux surgery on Barrett's esophagus. *Gastroenterology* 2004; 126:351-52.
367. **Shaheen N**. Endoscopy for Barrett's esophagus and esophageal adenocarcinoma. *American Family Physician* 2004;69(9):2060-61.
368. **Shaheen NJ**. Endoscopic screening for barrett's esophagus and cancer in patients with reflux disease: too big a haystack, too few needles. *American Family Physician* 2004; 69: 2060-2061.

369. Brown A, **Shaheen NJ**. Screening for upper gastrointestinal malignancy. *Seminars in Oncology* 2004;31: 487-97.
370. **Shaheen N**, Provenzale D. The epidemiology of gastroesophageal reflux disease. *American Journal of Medical Sciences* 2003; 326: 264-273.
371. Wei J, **Shaheen N**. The changing epidemiology of esophageal adenocarcinoma. *Seminars in Gastrointestinal Disease* 2003; 14: 112-27.
372. **Shaheen NJ**, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with NSAID's. *Cancer* 2002; 4: 950-963.
373. **Shaheen NJ**, Provenzale D, Sandler RS. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: A review of the evidence. *American Journal of Gastroenterology* 2002; 97: 1319-27.
374. **Shaheen NJ**. What is the right age cutoff for immediate endoscopic investigation of dyspepsia? *Gastroenterology* 2002; 123: 2149-2150.
375. **Shaheen N**, Ransohoff DF. Gastroesophageal reflux, Barrett's esophagus and esophageal cancer: Scientific review. *JAMA* 2002; 287: 1972-81.
376. **Shaheen N**, Ransohoff DF. Gastroesophageal reflux, Barrett's esophagus and esophageal cancer: Clinical applications. *JAMA* 2002; 287: 1982-86.
377. **Shaheen NJ**, Provenzale D. Screening strategies in gastroesophageal reflux disease: Early identification of esophageal adenocarcinoma. *Advances in Internal Medicine* 2001; 47: 137-57.
378. Grimm IS, **Shaheen NJ**. Can interferon prevent hepatocellular carcinoma in hepatitis C virus - induced cirrhosis? *Gastroenterology* 1996; 110: 2019-2021.

#### Editorials and Letters

379. Eluri S, **Shaheen NJ**. Measuring Quality in Barrett's Endoscopy. *Clin Gastroenterol Hepatol* 2021 May;19(5):889-891.
380. Tan WK, **Shaheen NJ**. Random biopsy of the neosquamous epithelium is a waste of time and money. *Gastrointest Endosc.* 2019 Sep;90(3):404-406.
381. An J, Gharakhani P, Law MH, Ong JS, Han X, Olsen CM, Neale RE, Lai J, Vaughan TL, Gockel I, Thieme R, Böhmer AC, Jankowski J, Fitzgerald RC, Schumacher J, Palles C; **BEACON**; 23andMe Research Team. Author Correction: Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases. *Nature Communications* 2019 Dec 4;10(1):5617.
382. **Shaheen NJ**. New Data on an Old Weapon: Is APC Adequate Treatment for Dysplastic Barrett's Esophagus? *Endoscopy* 2021 Feb;53(2):133-135.
383. Eluri S, **Shaheen NJ**. Measuring Quality in Barrett's Endoscopy. *Clinical Gastroenterology & Hepatology* 2020; epub ahead of print.
384. Cotton CC, Shaheen NJ. Overutilization of Endoscopic Surveillance in Barrett's Esophagus: The Perils of Too Much of a Good Thing. *American Journal of Gastroenterology* 2020 Jul;115(7):1019-1021.

385. **Shaheen NJ**. Where is the finish line for endoscopic eradication therapy in Barrett's esophagus? *Gastrointestinal Endoscopy* 2019 May;89(5):926-928.
386. **Shaheen NJ**, Falk GW, Iyer PG, Gerson LB. Corrigendum: ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. *Am J Gastroenterol*. 2016 Jul;111(7):1077.
387. **Shaheen NJ**. Response to Braillon et al. *Am J Gastroenterol*. 2016 Jun;111(6):900. doi: 10.1038/ajg.2016.131. PubMed PMID: 27249989.
388. Otaki F, **Shaheen NJ**. Stratifying Risk in Barrett's Esophagus With Low-Grade Dysplasia: Making the Best of a (Not So) Bad Situation. *Clin Gastroenterol Hepatol*. 2016; 14(7):963-5.
389. **Shaheen NJ**. "Rightsizing" use of upper endoscopy. *Annals of Internal Medicine* 2014;160(3):205.
390. **Shaheen NJ**. Presentation of the Julius M. Friedenwald Medal to Robert S. Sandler, MD, MPH. *Gastroenterology*. 2015 Jun;148(7):1466-9.
391. Adler DG, Lieb JG, Cohen J, Pike IM, Park WG, Rizk MK, Sawhney MS, Scheiman JM, **Shaheen NJ**, Sherman S, Wani S. Corrigendum: quality indicators for ERCP. *Am J Gastroenterol*. 2015 Apr;110(4):608. doi: 10.1038/ajg.2015.75. PubMed PMID: 25853209.
392. **Shaheen NJ**. What is behind the remarkable increase in esophageal adenocarcinoma? *American Journal of Gastroenterology* 2014;109(3):345-47.
393. **Shaheen NJ**. Choosing weapons in Barrett's esophagus. *Endoscopy* 2013;45:866-868.
394. **Shaheen NJ**, Hur C. Garlic, silver bullets, and surveillance endoscopy for Barrett's esophagus. *Gastroenterology* 2013;145(2):273-76..
395. **Shaheen NJ**, Weinberg DS. Upper endoscopy for gastroesophageal reflux disease. *Annals of Internal Medicine* 2013;158(6):502-503 (letter reply).
396. **Shaheen NJ**. Predicting the risk of Barrett's esophagus: Does the BERET fit? *American Journal of Gastroenterology* 2013;108(3):363-365.
397. Wani S, Sayana H, **Shaheen N**, Sharma P. Response to Desai et al. *American Journal of Gastroenterology* 2011; 106(7):1365-6.
398. **Shaheen NJ**, Peery AF. Letter reply. *Endoscopy* 2011;43(3):245.
399. **Shaheen NJ**. Should women with heartburn undergo screening upper endoscopy for prevention of cancer? *American Journal of Gastroenterology* 2011; 106(2):261-63.
400. Madanick RD, Long MD, **Shaheen NJ**. Ascertainment bias increases estimate of risk of GERD in depressed patients. *Alimentary Pharmacology and Therapeutics* 2010; 32(3):508-09.
401. **Shaheen NJ**. Risk and reason in Barrett's Esophagus. *Clinical Gastroenterology & Hepatology* 2010; 8:231-34.
402. Peery AF, **Shaheen NJ**. Optical coherence tomography in Barrett's esophagus: the road to clinical utility. *Gastrointestinal Endoscopy* 2010; 71:231-34.
403. **Shaheen NJ**. More on reports of esophageal cancer with oral bisphosphonate use (Letter). *New England Journal of Medicine* 2009; 360: 1790-91.

404. Dellon ES, **Shaheen NJ**. Barrett's Esophagus and the Costs of "Doing Something." *Gastrointestinal Endoscopy* 2007; 65:31-35.
405. Vish S, **Shaheen NJ**. Adipose deposition and Barrett's esophagus: Is all fat created equal? A Selected Summary. *Gastroenterology*. 2006;131:967-9.
406. **Shaheen NJ**. The rise and fall (and rise?) of endoscopic anti-reflux procedures. *Gastroenterology*. 2006 Sep;131(3):952-4.
407. **Shaheen NJ**. Barrett's Esophagus: The AGA Teaching Slide Series. A Review. *Gastroenterology* 2005; 128: 1140-41.
408. Wanamaker RC, **Shaheen NJ**. Does acid suppression cause community-acquired pneumonia? A Selected Summary. *Gastroenterology* 2005; 128: 1130-32.
409. **Shaheen NJ**, Dulai GS, Ascher B, Mitchell KL, Schmitz SM. Effect of a new diagnosis of Barrett's esophagus on insurance status. *Am J Gastroenterol*. 2005 Mar;100(3):577-80.
410. **Shaheen NJ**. Does fundoplication change the risk of cancer in the setting of Barrett's esophagus? *American Journal of Gastroenterology* 2005; 100: 1009-1011.
411. **Shaheen NJ**. Raising the bar in studies of endoscopic anti-reflux procedures. *Gastroenterology* 2005; 128: 779-82.
412. **Shaheen NJ**. Should We Worry About the Length of Barrett's Esophagus? *Gastrointestinal Endoscopy* 2005; 62: 682-85.
413. **Shaheen NJ**. What is the best management strategy for achalasia? A Selected Summary. *Gastroenterology* 2004;127:1850-2.
414. Mitchell KL, **Shaheen NJ**. Preventive therapy in perforated colonic diverticular disease? Calcium channel blockers may hold the key. A Selected Summary. *Gastroenterology*. 2004;127(2):680-2.
415. **Shaheen NJ**. Is Bigger better? Re-exploring the relationship between hospital volume and surgical outcomes. A Selected Summary. *Gastroenterology* 2004; 126: 924-26.
416. **Shaheen NJ**. Separating bad from worse in Barrett's esophagus. *Gastroenterology*. 2003;125:260-1; discussion 261-2.
417. **Shaheen NJ**. Can gastrografin heal the obstructed bowel? A Selected Summary. *Gastroenterology*. 2003;124:852-3.
418. Wei JT, **Shaheen NJ**. Dollars and sense in preventing esophageal cancer. *Gastroenterology*. 2003;125:1268-70.
419. **Shaheen NJ**. The AGA Gastroenterology Teaching Project Review. *Gastroenterology* 2003; 125: 987.
420. **Shaheen NJ**. Is there a Barrett's iceberg? *Gastroenterology* 2002; 123: 636-639.
421. **Shaheen NJ**. Awakening the sleeping postsurgical abdomen. A Selected Summary. *Gastroenterology* 2002; 122: 1178-79.
422. Thiny MT, **Shaheen NJ**. Is Stretta ready for primetime? *Gastroenterology* 2002; 123: 643-645.

423. Ringel Y, **Shaheen NJ**, Drossman DA. Functional pain of presumed esophageal origin (Letter to the Editor). *Archives of Internal Medicine* 2002; 162: 365-66.
424. **Shaheen NJ**. Does surveillance endoscopy improve life expectancy in those with Barrett's esophagus? A Selected Summary. *Gastroenterology* 2001; 121: 1516-1522.
425. **Shaheen NJ**, Rich M. Helicobacter pylori and nonulcer dyspepsia: looking beyond the bug. A Selected Summary. *Gastroenterology* 2001; 121: 735-737.
426. **Shaheen NJ**, Bozymski EM. Can antireflux surgery alter the natural history of Barrett's esophagus? *American Journal of Gastroenterology* 1999; 94: 11-13.
427. **Shaheen NJ**, Ransohoff DF. Sigmoidoscopy costs and the limits of altruism. *American Journal of Medicine* 1999;107:286-287.
428. Bozymski EM, **Shaheen NJ**. Barrett's esophagus: acid suppression, but no regression. An Editorial. *American Journal of Gastroenterology* 1997; 92: 556-558.
429. **Shaheen NJ**, Bozymski EM. Open access endoscopy: cognition, technician, or some of both? An Editorial. *Gastrointestinal Endoscopy* 1997; 46: 84-87.
430. Grimm IS, **Shaheen NJ**. The value of endoscopy in H. pylori positive dyspepsia. A Selected Summary. *Gastroenterology* 1997; 113: 1801-1803.
431. Grimm IS, **Shaheen NJ**, Bozymski EM. Surveillance for Barrett's esophagus: are we saving lives? A Selected Summary. *Gastroenterology* 1997; 112: 661-662.
432. Bozymski EM, **Shaheen NJ**. Wire-guided esophageal dilatation and fluoroscopy: is seeing believing? An Editorial. *American Journal of Gastroenterology* 1996: 91:1486-1487.
433. Grimm IS, **Shaheen NJ**. Calcium channel blockers and gi bleeding: more bad press? A Selected Summary. *Gastroenterology* 1996;111:1391-1393.
434. Grimm IS, **Shaheen NJ**. Small bowel bacterial overgrowth: epiphenomenon or bad actor in cirrhosis? A Selected Summary. *Gastroenterology* 1996; 110: 955-956.

#### **Unrefereed Works, Including Book Reviews (14)**

1. **Shaheen NJ**. Endoscopic therapy for Barrett's esophagus. *Journal of Digestive Endoscopy* 2012; 3(Suppl): S17-22.
2. **Shaheen NJ**, Sartor RB. Our New President – Robert S. Sandler. *Gastroenterology* 2008; 134: 1596-1600.
3. Barritt AS, **Shaheen NJ**. Should patients with Barrett's oesophagus be kept under surveillance? The case against. *Best Pract Res Clin Gastroenterol.* 2008;22(4):741-50.
4. Dellon ES, **Shaheen NJ**. The role of surgery in the management of Barrett's esophagus. *Oncology* 2007; 21:1392-94.
5. **Shaheen NJ**. Gastroesophageal Reflux. In: Focused Clinical Updates. AGA Institute, Cirque Med Ed, Pocopson, PA. M Donowitz, Ed., 2006.
6. **Shaheen NJ**. Endoscopic screening for Barrett's esophagus and esophageal adenocarcinoma: too few needles, too big a haystack. *AGA Perspectives*, June/July, 2005;1: pgs. 4-12.

7. **Shaheen NJ.** Injectable co-polymer improved symptoms, but not esophageal acid exposures, when compared to a sham procedure in subjects with reflux. Evidence Based Gastroenterology 2005; 6: 70-72.
8. **Shaheen NJ.** The Esophagus. A book review. Gastroenterology 2004; 127: 1012-13.
9. **Shaheen NJ.** Should we be screening for esophageal adenocarcinoma? Evidence Based Gastroenterology 2003; 4: 84-86.
10. **Shaheen NJ.** NSAIDs in Barrett's Esophagus: An aspirin a day keeps the surgeon away? Evidence Based Gastroenterology 2003; 4: 124-125.
11. **Shaheen NJ.** What is the prevalence of Barrett's esophagus in asymptomatic populations? Evidence Based Gastroenterology 2002; 2: 110-112.
12. **Shaheen NJ.** Endoscopic evaluation and treatment of swallowing disorders. A Book Review. Gastroenterology 2002; 122: 585.
13. **Shaheen NJ.** Gastroesophageal reflux disease symptoms were associated with increased risk for adenocarcinomas of the esophagus and gastric cardia. ACP Journal Club 1999; 131: 52.
14. Grimm IS, **Shaheen NJ.** Gastrointestinal physiology. A Book Review. Hepatology 1996;24: 973-974.

## Abstracts and Presentations

### *Published Abstracts (328)*

1. Alabdulwahhab M, Al-Shakhshir H, Moinova H, Thota PN, **Shaheen, NJ**, Canto MI, Wang JS, Iyer PG, Markowitz SD, Grady WM, Ghanoum M, Chak A. Distal Esophageal Microbiome And Mycobiome In Barrett's Esophagus (BE) & Esophageal Adenocarcinoma (EAC). Gastroenterology 2022;162(7, Suppl. SUPPL):S333-S334.
2. Chak A, Moinova H, Canto MI, Thota PN, **Shaheen, NJ**, Iyer PG, Wang JS, Dumot JA, Faulx AL, Thomas S, Willis J, Markowitz SD. Accuracy Of A Non-Endoscopic Esophageal Sampling Device And Biomarker Panel For Detection Of Barrett's Esophagus (BE). Gastroenterology 2022;162(7, Suppl. SUPPL):S719-S719.
3. Chandar AK, Keerthy KS, Gupta R, Grady WM, Canto MI, **Shaheen NJ**, Thota, PN, Iyer PG, Wang JS, Falk GW, Abrams JA, Dumot JA, Faulx AJ, Markowitz SD, Willis J, Moinova H, Guda K, Brock W, Chak A Patients With Esophageal Adenocarcinoma With Prior Gerd Symptoms Are Similar To Those Without GERD: A Prospective Cross-Sectional Study. Gastroenterology 2022;162(7, Suppl. SUPPL):S173-S173.
4. Eluri S, Narick C, Finkelstein S, Watts AE, Santiago-Mejia A, **Shaheen NJ.** Mutational load increases with worsening dysplasia grade and normalizes after endoscopic treatment of dysplastic Barrett's esophagus. Gastroenterology 2022;162(7, Suppl. SUPPL):S718-S718.
5. Gaber CE, Lund JL, Cotton CC, Eluri S, Dellon ES, **Shaheen NJ.** Patterns And Predictors Of Adherence To Prescription Proton Pump Inhibitor Therapy In A Population Of Commercially Insured Barrett's Esophagus Patients. Gastroenterology 2022;162(7, Suppl. SUPPL):S1060-S1061.

6. McGill SK, Commins SP, Keku TO, Galanko J, **Shaheen NJ**, Peery AF, Sandler R. Alpha-Gal Sensitization Is Common In A Colonoscopy Screening Population. *Gastroenterology* 2022;162(7, Suppl. SUPPL):S156-S156.
7. Verheij EP, Van Munster S, Nieuwenhuis E, Cotton CC, Weusten BL, Herrero LA, Alkhalaf A, Schenk BE, Schoon EJ, Curvers W, Koch, AD, De Jonge PJF, Tang TJ, Nagengast WB, Westerhof J, Houben MH, **Shaheen NJ**, Bergman J, Pouw RE.. All-Cause Mortality After Successful Endoscopic Eradication Therapy For Barrett's Related Neoplasia In A Nationwide Cohort Of 1154 Patients. *Gastroenterology* 2022;162(7, Suppl. SUPPL):S172-S172.
8. Eluri S, Reddy S, Corey K, Tappata M, Nettles HG, Watts AE, Cotton CC, Dellon ES, **Shaheen NJ**. Low prevalence of screening endoscopy for Barrett's esophagus in high-risk GERD patients in a large primary care population. *Gastrointest Endosc.* June 2021; Volume 93, Issue 6, Supplement, Page AB287-288. Virtual DDW, 2021.
9. Eluri S, Cotton CC, C Watts AE, Chaletsky, DM, Moloney B, Malik ZA, Trindade AJ, Gordon, SR, Yachimski, P, Khan AR, Schnoll-Sussman F, Shafa, S, Smith MS, Odze R, **Shaheen NJ**. Wide area transepithelial sample biopsy with 3-dimensional computer-assisted analysis (WTAS3D) nearly doubles the detection of disease recurrence in post-ablation surveillance of Barrett's esophagus. *Gastrointest Endosc.* June 2021; Volume 93, Issue 6, Supplement, Page AB303-304. Virtual DDW, 2021.
10. Greenberg SB, Croglio MP, Shore B, Nettles HG, Dellon ES, **Shaheen NJ**, Eluri S. Clinical characteristics and treatment outcomes in patients with functional esophagogastric junction outflow obstruction. *Gastroenterology.* May 2021; Volume 160, Issue 6, Supplement, Page S-455. Virtual DDW, 2021.
11. Cotton CC, Watts AE, Eluri S, Chaletsky, DM., Moloney B, Malik ZA, Gordon, SR, Yachimski, P, Khan AR, Schnoll-Sussman F, Shafa, S, **Shaheen NJ**. Analysis of a multicenter post-ablation cohort suggests radiofrequency ablation for non-dysplastic Barrett's esophagus remains commonplace. *Gastroenterology.* May 2021; Volume 160, Issue 6, Supplement, Page S-178. Virtual DDW, 2021.
12. Cotton CC, Watts AE, Eluri S, Chaletsky, DM., Moloney B, Malik ZA, Trindade AJ, Gordon, SR, Yachimski, P, Khan AR, Schnoll-Sussman F, Shafa, S, Smith MS, Odze R, **Shaheen NJ**. Wide-area transepithelial sampling with three-dimensional computer-assisted analysis (wats3d) commonly detects crypt dysplasia not identified by forceps biopsies in the surveillance of treatment-naïve barrett's esophagus. *Gastroenterology.* May 2021; Volume 160, Issue 6, Supplement, Page S-637-638. Virtual DDW, 2021.
13. Xue Z, Cotton CC, Eluri S, Dellon ES, **Shaheen NJ**. Fundoplication is rarely required for complete eradication of intestinal metaplasia in patients undergoing radiofrequency ablation for dysplastic Barrett's esophagus. *Gastrointest Endosc.* June 2021; Volume 93, Issue 6, Supplement, Page AB278-279. Virtual DDW, 2021.
14. Watts AE, Eluri S, Cotton CC, Chaletsky, DM, Moloney B, Malik ZA, Trindade AJ, Gordon, SR, Yachimski, P, Khan AR, Schnoll-Sussman F, Shafa, S, Smith MS, Odze R, **Shaheen NJ**. The addition of wide-area transepithelial sampling with three-dimensional computer-assisted analysis (WATS3D) to forceps biopsy in screening exams of GERD patients with columnar epithelium increases detection of intestinal metaplasia. *Gastrointest Endosc.* June 2021; Volume 93, Issue 6, Supplement, Page AB286-287. Virtual DDW, 2021.
15. Eluri S, Kaul V, Sharma NR, Gordon SR, Kachaamy T, Smallfield G, Samarasena J, Trindade A, Willingham FF, Zolotarevsky E, Barber J, Kothari S, Weber J, Chang KJ, Benias P, McKinley MJ, **Shaheen NJ**. Palliative endoscopic spray cryotherapy to prevent worsening of dysphagia and improve quality of life in esophageal cancer. 2021; Volume 39, Issue 3, Supplement. Virtual DDW, 2021.



16. Dellon ES, Woosley JT, McGee SJ, Moist SE, **Shaheen NJ**. Utility of major basic protein, eotaxin-3, and mast cell tryptase staining for prediction of response to topical steroid treatment in eosinophilic esophagitis: Analysis of a randomized, double-blind, double-dummy clinical trial. *Gastroenterology* 2020;158(6): S837-838. Virtual DDW, 2020.
17. Cotton CC, Woosley JT, Moist SE, McGee SJ, **Shaheen NJ**, Dellon ES. Determination of an endoscopic response threshold for the eosinophilic esophagitis endoscopic reference score: analysis of a randomized comparative clinical trial of topical steroids. *Gastroenterology* 2020;158(6): S819-820. Virtual DDW, 2020.
18. Cotton CC, Woosley JT, Moist SE, McGee SJ, **Shaheen NJ**, Dellon ES. Dysphagia in eosinophilic esophagitis improves with topical steroid treatment independent of improvement in endoscopic and histologic measures of mucosal inflammation: Analysis of a randomized comparative effectiveness clinical trial. *Gastroenterology* 2020;158(6): S820. Virtual DDW, 2020.
19. Alaber OA, ... **Shaheen, NJ**, ... Chak, A. Tolerability of a non-endoscopic distal esophagus sampling device. *Gastroenterology* 2020;158(6): S310. Virtual DDW, 2020.
20. Kamal A,... **Shaheen NJ**, Triadafilopoulos G. High rate of concordance between physicians and patients on shared decision questions for development of a gastroesophageal reflux disease (GERD) question prompt list (QPL). *Gastroenterology* 2020;158(6): S882. Virtual DDW, 2020.
21. Chang NC...**Shaheen, NJ**... Dellon ES. Impact of eosinophilic esophagitis disease activity on quality of life: results from a prospective patient registry. *Gastroenterology* 2020;158(6): S831-832. Virtual DDW, 2020.
22. Canto MI, Trindade AJ, Abrams J, ...**Shaheen NJ**. Safety and efficacy of multifocal cryoballoon ablation for eradication of previously untreated Barrett's neoplasia: preliminary results of a large multicenter American trial. *Gastrointestinal Endoscopy* 2019;89:AB98-AB. Presented at DDW 2019, San Diego, CA.\*
23. Chandar AK, Alaber O, Dumot JA, ... **Shaheen NJ**, Triadafilopoulos G. Modifications in non-endoscopic distal esophagus sampling devices improve ability to swallow and DNA yield. *Gastrointestinal Endoscopy* 2019;89:AB448-AB. Presented at DDW 2019, San Diego, CA.
24. Cotton CC, Meyers MH, King W, ...**Shaheen NJ**, Eluri S. Total daily opioid dose is associated with higher distal contractile integral among opioid users undergoing high resolution esophageal manometry. *Gastroenterology* 2019;156:S1004-S. Presented at DDW 2019, San Diego, CA.
25. Dellon ES, Woosley JT, Arrington A, ...**Shaheen NJ**. Rapid recurrence of symptoms, endoscopic findings, and esophageal eosinophilia without maintenance therapy after successful initial treatment: results from the observation phase of a randomized, double-blind, double dummy clinical trial. *Gastroenterology* 2019;156:S713-S4. Presented at DDW 2019, San Diego, CA.\*
26. Dellon ES, Woosley JT, Arrington A, ... **Shaheen NJ**. Oral viscous budesonide versus swallowed fluticasone inhaler for initial treatment of adolescents and adults with eosinophilic esophagitis: a randomized, double-blind, double-dummy clinical trial. *Gastroenterology* 2019;156:S72-S3. Presented at DDW 2019, San Diego, CA.\*
27. Eluri S, Bhatia S, Shoyoye SO, ... **Shaheen NJ**. High prevalence of dysphagia and associated poor health related quality of life in a prospective cohort of chronic opioid users. *Gastroenterology* 2019;156:S988-S. Presented at DDW 2019, San Diego, CA.

28. Eluri S, Kaul V, McKinley M, ... **Shaheen NJ**. Durability of successful eradication of Barrett's esophagus with liquid nitrogen spray cryotherapy: results of a US multicenter registry. *Gastrointestinal Endoscopy* 2019;89:AB98-AB9. Presented at DDW 2019, San Diego, CA.\*
29. Eluri S, Kaul V, McKinley M, ... **Shaheen NJ**. Liquid nitrogen spray cryotherapy eradicates dysplasia in 87% and intestinal metaplasia in 65% of patients with Barrett's esophagus: results of a US multicenter registry. *Gastroenterology* 2019;156:S280-S1. Presented at DDW 2019, San Diego, CA.
30. Eluri S, Kaul V, Sharma NR, ... **Shaheen NJ**. Liquid nitrogen spray cryotherapy is safe for palliation of esophageal cancer: interim results from a prospective multicenter study. *Gastrointestinal Endoscopy* 2019;89:AB199-AB.
31. Glamour B, Alaber O, Cioffi G, ... **Shaheen NJ**...Blum A. Age of diagnosis in familial esophageal adenocarcinoma. *Gastroenterology* 2019;156:S287-S. Presented at DDW 2019, San Diego, CA.
32. Kamal A, Katzka DA, Achkar E,... **Shaheen NJ**...Triadafilopoulos G. "Let's Make Your Clinic Visit a Little Simpler"-Development of a Question Prompt List for Adult Patients With Gastroesophageal Reflux Disease: a Modified Delphi Study. *Gastroenterology* 2019;157:E25-E6. Presented at DDW 2019, San Diego, CA.
33. Moinova H, LaFramboise T, Lutterbaugh J, ...**Shaheen NJ**...Chak A. Neosquamous epithelium following endoscopic ablation of Barrett's esophagus is not epigenetically normal. *Gastroenterology* 2019;156:S284-S. Presented at DDW 2019, San Diego, CA.
34. **Shaheen NJ**, Haydek JM, Komanduri S, Muthusamy VR, Wani SB, Kaushal R. A multicenter study of the adequacy and accuracy of Cytosponge (tm): first report in an American population with Barrett's esophagus and GERD. *Gastroenterology* 2019;156:S222-S3. Presented at DDW 2019, San Diego, CA.\*
35. **Shaheen NJ**, Haydek JM, Komanduri S, Muthusamy VR, Wani SB, Kaushal R. A Multicenter study of the safety and acceptability of Cytosponge (tm): first report in an American population with Barrett's esophagus and GERD. *Gastroenterology* 2019;156:S474-S. Presented at DDW 2019, San Diego, CA.
36. Venkitachalam S, Blum A, Ravillah D, ...**Shaheen NJ**...Guda K. Molecular dependencies in esophageal adenocarcinoma: a systems biology approach. *Gastroenterology* 2019;156:S498-S9. Presented at DDW 2019, San Diego, CA.
37. Wani SB, Williams JL, Komanduri S, Muthusamy VR, **Shaheen NJ**. Adherence to appropriate surveillance intervals in Barrett's esophagus has improved over time but adherence to the Seattle biopsy protocol has not: an analysis using the GIQuIC national quality benchmarking registry. *Gastrointestinal Endoscopy* 2019;89:AB139-AB40. Presented at DDW 2019, San Diego, CA.
38. SB Wani, JL Williams, S Komanduri, VR Muthusamy, **NJ Shaheen**. Factors Associated With Over-Utilization of Repeat Upper Endoscopy in Patients With Non-Dysplastic Barrett's Esophagus (NDBE): A Study Using the GI Quality Improvement Consortium (GIQuIC) National Registry. Presented at ACG National Meeting, Philadelphia, PA. *American Journal of Gastroenterology* 2018;113(10 Suppl):2.\*
39. **NJ Shaheen**, MS Smith, JR Goldblum, RD Odze. Progression of Barrett's Esophagus (BE) and Dysplasia Detected by Wide Area Transepithelial Sampling With Computer-Assisted 3D Analysis (WATS3D) Confirms the Clinical Significance of Crypt Dysplasia. Presented at ACG National Meeting, Philadelphia, PA. *American Journal of Gastroenterology* 2018;113(10 Suppl):3.\*

40. S Eluri, M Massaro, A Peery, **NJ Shaheen**, ES Dellon. Comparing Current Practice Patterns and Practice Guidelines for the Diagnosis and Management of Eosinophilic Esophagitis in the United States. Presented at ACG National Meeting, Philadelphia, PA. *American Journal of Gastroenterology* 2018;113(10 Suppl):P1162.
41. M Tappata, S Eluri, KZ Huang, N Koutlas, B Robey, C Fan, **NJ Shaheen**, ES Dellon. Intralesional Triamcinolone Injection as Adjunct Therapy in Eosinophilic Esophagitis Patients With Stricture Disease. Presented at ACG National Meeting, Philadelphia, PA. *American Journal of Gastroenterology* 2018;113(10 Suppl):P1163.
42. S Bhatia, S Eluri, E Kim, H Angle, ES Dellon, **NJ Shaheen**. High Impact Research in Digestive Diseases Is Becoming More Multi-National and Is Performed by Larger Teams: A Trend Analysis of Publications From 1997-2017. Presented at ACG National Meeting, Philadelphia, PA. *American Journal of Gastroenterology* 2018;113(10 Suppl):P2521.
43. S Bhatia, S Eluri, E Kim, H Angle, ES Dellon, **NJ Shaheen**. Trends in Female Authorship of High Impact Publications in Gastroenterology Journals, 1997-2017. Presented at ACG National Meeting, Philadelphia, PA. *American Journal of Gastroenterology* 2018;113(10 Suppl):P2520.
44. SB Wani, JL Williams, S Komanduri, VR Muthusamy, **NJ Shaheen**. Over-Utilization of Repeat upper Endoscopy in Patients with Non-Dysplastic Barrett's Esophagus: A Population-Based Study Using a National Benchmarking Registry. Presented at DDW 2018, Washington, DC. *Gastroenterology* 2018;154(6), S-28–S-29.
45. CC Reed, M Tappata, S Eluri, **NJ Shaheen**, ES Dellon. Outcomes of Combined Treatment with Food Elimination Diet and Topical Corticosteroids in Adult Patients with Eosinophilic Esophagitis. Presented at DDW 2018, Washington, DC. *Gastroenterology* 2018;154(6): S-248.
46. W King, CC Cotton, S Eluri, SE Moist, ES Dellon, **NJ Shaheen**. Efficacy of Endoscopic Eradication Therapy for Intramucosal Esophageal Adenocarcinoma: A Single Center us Experience. Presented at DDW 2018, Washington, DC. *Gastroenterology* 2018;154(6): S-907.
47. S Eluri, A Paterson, M O'Donovan, P Bhandari, M Di Pietro, R Haidry, L Lovat, K Ragunath, RC Fitzgerald, **NJ Shaheen**. Efficacy of Cytosponge to Assess for Recurrent or Residual Barrett's Esophagus Following Endoscopic Eradication Therapy. Presented at DDW 2018, Washington, DC. *Gastroenterology* 2018;154(6): S-897.
48. S Eluri, M Tappata, KZ Huang, NT Koutlas, B Robey, C Fan, CC Reed, **NJ Shaheen**, ES Dellon. The Distal Esophagus is the Most Commonly Involved Site for Strictures in Patients with Eosinophilic Esophagitis Presented at DDW 2018, Washington, DC. *Gastroenterology* 2018;154(6): S-251–S-252
49. T Sawas, PG Iyer, CC Cotton, M Alsawas, CL Leggett, M Murad, KK Wang, **NJ Shaheen**, D Katzka. The Main Effect of Endoscopic Barrett's Therapy is in Eradicating Prevalent and not Recurrent Neoplasia: Meta-Analysis Presented at DDW 2018, Washington, DC. *Gastroenterology* 2018;154(6): S-2–S-3.
50. S Eluri, R Betancourt, C Randall, I Perjar, J Hollyfield, JT Woosley, **NJ Shaheen**, ES Dellon. Subepithelial Fibrosis Resolves after Topical Steroid Treatment in Adults with Eosinophilic Esophagitis, but Tissue Samples are Rarely Adequate to Make This Determination Presented at DDW 2018, Washington, DC. *Gastroenterology* 2018;154(6): S-251.
51. S Eluri, A Guthikonda, SE Moist, RM Beitia, ES Dellon, **NJ Shaheen**. Prevalence of Intestinal Metaplasia and Dysplasia in the Gastric Cardia in Patients with Barrett's Esophagus after

Endoscopic Eradication Therapy. Presented at DDW 2018, Washington, DC. *Gastrointestinal Endoscopy* 2018;87 (6): AB143–AB144.

52. SB Wani, JL Williams, S Komanduri, VR Muthusamy, **NJ Shaheen**. Regional variations and trends in quality indicator (QI) performance in Barrett's esophagus (BE): Results from a population-based study using a national benchmarking registry. Presented at DDW 2018, Washington, DC. *Gastrointestinal Endoscopy* 2018;87 (6): AB537.\*
53. MI Canto, **NJ Shaheen**, M Ford, J Alejandro, N Almario, L Voltaggio, E Montgomery, CJ Lightdale. Safety, efficacy, and durability of endoscopic nitrous oxide cryoballoon ablation for eradication of Barrett's neoplasia. Presented at DDW 2018, Washington, DC. *Gastrointestinal Endoscopy* 2018;87(6): AB277.\*
54. S Eluri, A Guthikonda, SE Moist, RM Beitia, ES Dellon, **NJ Shaheen**. Intestinal Metaplasia and Dysplasia in the Gastric Cardia Decreases after Successful Eradication Therapy in Patients with Barrett's Esophagus. Presented at DDW 2018, Washington, DC. *Gastrointestinal Endoscopy* 2018;87(6): AB273–AB274.\*
55. SB Wani, JL Williams, S Komanduri, VR Muthusamy, **NJ Shaheen**. Endoscopists biopsy the least those who need it the most: An analysis of Barrett's esophagus biopsy practices from a national quality benchmarking registry. Presented at DDW 2018, Washington, DC. *Gastrointestinal Endoscopy* 2018;87(6): AB114.
56. JD Machicado, S Han, VC Simon, BJ Qumseya, S Sultan, S Komanduri, A Rastogi, VR Muthusamy, VM Kushnir, R Haidry, R Singh, R Yadlapati, K Ragunath, HT Hammad, **NJ Shaheen**, SB Wani. Presented at DDW 2018, Washington, DC. Practice patterns and beliefs in the use of advanced imaging modalities (aims) in surveillance of Barrett's esophagus (BE): A survey of international experts. Presented at DDW 2018, Washington, DC. *Gastrointestinal Endoscopy* 2018;87 (6): AB87–AB88.
57. FH Ramay, V Kaul, **NJ Shaheen**, DK Pleskow, V Little, HC Fernando, NS Nishioka, J Nieto, and others. Liquid nitrogen spray cryotherapy is effective for Barrett's esophagus-associated intramucosal adenocarcinoma: Results from a multicenter US Registry. Presented at DDW 2018, Washington, DC. *Gastrointestinal Endoscopy* 2018;87 (6): AB284.\*
58. MI Canto, JA Abrams, CJ Lightdale, AJ Trindade, JA Dumot, PG Iyer, DL Diehl, HS Khara, **NJ Shaheen**. Post-procedural pain profile associated with the use of a novel contact cryoballoon focal ablation system for neoplastic Barrett's esophagus. Presented at DDW 2018, Washington, DC. *Gastrointestinal Endoscopy* 2018;87(6): AB284–AB285.\*
59. RE Pouw, T Beyna, K Belghazi, AD Koch, AW Gotink, EJ Schoon, R Haidry, BL Weusten, and others. A prospective study using a new device for endoscopic resection of early neoplasia in Barrett's esophagus. Presented at DDW 2018, Washington, DC. *Gastrointestinal Endoscopy* 2018;87(6): AB279.\*
60. AO Chang, CC Cotton, S Eluri, A Guthikonda, RD Madanick, R Beitia, SE Moist, ES Dellon, RC Fitzgerald, **NJ Shaheen**. Acceptability of tissue collection by Cytosponge in U.S. patients with Barrett's esophagus. Presented at DDW 2017, Chicago, IL. *Gastroenterology* 2017;152(5, Suppl 1):S457.
61. A Guthikonda, CC Cotton, AO Chang, S Eluri, RD Madanick, M Spacek, SE Moist, K Ferrell, ES Dellon, **NJ Shaheen**. Histologic progression during treatment with radiofrequency ablation is associated with poorer outcomes of endoscopic eradication therapy. Presented at DDW 2017, Chicago, IL. *Gastroenterology* 2017;152(5, Suppl 1):S458-459.
62. X Sun, AK Chandar, MI Canto, PN Thota, M Brock, **NJ Shaheen**, DG Beer, JS Wang, GW Falk, PG. Iyer, JA. Abrams, MV-Ramani, M Veigl, A Miron, J Willis, DT Patil, I Nalbantoglu, K Guda, SD Markowitz, X Zhu, R Elston, A Chak. Identification of genomic regions associated

with susceptibility to Barrett's esophagus and esophageal adenocarcinoma in African Americans: the Cross BERNET Admixture Study. Presented at DDW 2017, Chicago, IL. *Gastroenterology* 2017;152(5, Suppl 1):s233.

63. NT Koutlas, S Rusin, I Perjar, J Hollyfield, JT Woosley, **NJ Shaheen**, ES Dellon. Impact of smoking, alcohol consumption, and NSAID use on risk for and phenotypes of eosinophilic esophagitis. Presented at DDW 2017, Chicago, IL. *Gastroenterology* 2017;152(5, Suppl 1):s857.
64. S Eluri, CC Cotton, V Kaul, V Joshi, BJ Hoffman, **NJ Shaheen**. Liquid nitrogen spray cryotherapy effectively eradicates Barrett's esophagus irrespective of severity of baseline histology: Results of a U.S. multicenter registry. Presented at DDW 2017, Chicago, IL. *Gastrointestinal Endoscopy* 2017;85(5, Suppl):ab564-565.
65. CC Reed, C Fan, NT Koutlas, S Eluri, **NJ Shaheen**, ES Dellon. Long-term efficacy of a food elimination diet in adults with eosinophilic esophagitis. Presented at DDW 2017, Chicago, IL. *Gastroenterology* 2017;152(5, Suppl 1):s857-858.
66. AO Chang, DA Katzka, DM Geno, T Smyrk, R Beitia, JA Alexander, **NJ Shaheen**, RC Fitzgerald, ES Dellon. The Cytosponge is a safe and well-tolerated method of sampling esophageal tissue in patients with eosinophilic esophagitis. Presented at DDW 2017, Chicago, IL. *Gastroenterology* 2017;152(5, Suppl 1):s207-208.\*
67. S Eluri, I Perjar, J Hollyfield, S Rusin, JT Woosley, **NJ Shaheen**, ES Dellon. Treatment of eosinophilic esophagitis in adults improves heartburn severity but not dyspepsia: Results from a prospective study. Presented at DDW 2017, Chicago, IL. *Gastroenterology* 2017;152(5, Suppl 1):s857-858.
68. CC Reed, C Fan, NT Koutlas, Z Stefanidis, S Eluri, **NJ Shaheen**, ES Dellon. Treatment with compounded oral viscous budesonide is effective and provides a durable response in patients with eosinophilic esophagitis. Presented at DDW 2017, Chicago, IL. *Gastroenterology* 2017;152(5, Suppl 1):s864-865.
69. S Eluri, I Perjar, J Hollyfield, S Rusin, JT Woosley, **NJ Shaheen**, ES Dellon. A multivariable model predicts complete histologic response to topical corticosteroid treatment in eosinophilic esophagitis. Presented at DDW 2017, Chicago, IL. *Gastrointestinal Endoscopy* 2017;85(5, Suppl):ab121.\*
70. A Guthikonda, CC Cotton, RD Madanick, M Spacek, SE Moist, K Ferrell, E Dellon, **NJ Shaheen**. Clinical Outcomes Following Recurrence of Intestinal Metaplasia after Successful Treatment of Barrett's Esophagus with Radiofrequency Ablation. Presented at DDW 2016, San Diego, CA. *Gastrointestinal Endoscopy* 2016;83(5, Suppl):ab559-560.
71. X Sun, LE Onstad, R Elston, GW Falk, WM Grady, MI Canto, **NJ Shaheen**, J Wang, P Iyer, JA Abrams, T Vaughan, A Chak. Combining GWAS With Linkage Analysis Identifies a SNP Associated With Barrett's Esophagus And Esophageal Adenocarcinoma. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s178.\*
72. T Runge, S Eluri, JT Woosley, **NJ. Shaheen**, E Dellon. Control of Inflammation With Topical Steroids Decreases Need for Subsequent Esophageal Dilation in Patients With Eosinophilic Esophagitis. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s664.
73. S Wani, VR Muthusamy, **NJ Shaheen**, R Yadlapati, RH Wilson, J. Abrams, J Bergman, A Chak, KJ Chang, A Das, JA Dumot, S Edmundowicz, G Eisen, GW Falk, MB Fennerty, LB Gerson, GG Ginsberg, D Grande, M Hall, BD Harnke, J Inadomi, J Jankowski, CJ Lightdale, Ji Makker, RD Odze, O Pech, R Sampliner, SJ Spechler, G Triadafilopoulos, MB Wallace, KK Wang, I Waxman, S Komanduri. Development of Quality Indicators for Endoscopic

Eradication Therapies (EET) in Barrett's Esophagus: The TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Presented at DDW 2016, San Diego, CA. *Gastrointestinal Endoscopy* 2016;83(5, Suppl):ab129-130.\*

74. S Eluri, T Runge, J Hansen, B Kochar, CC Reed, B Robey, JT Woosley, **NJ Shaheen**, E Dellon. Diminishing Effectiveness of Maintenance Topical Steroid Therapy on Long-term Endoscopic and Histologic Outcomes in Eosinophilic Esophagitis. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s658.
75. E Dellon, WA Wolf, S Rusin, I Perjar, J Hollyfield, JT Woosley, **NJ Shaheen**. Esophageal Dilation Explains Discordance Between Histologic and Symptom Response in a Prospective Study of Eosinophilic Esophagitis. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s662.
76. WA Wolf, CC Cotton, S Rusin, I Perjar, J Hollyfield, JT Woosley, **NJ Shaheen**, E Dellon. Evaluation of an Optimal Histologic Threshold for Treatment Response in a Prospective Cohort of Eosinophilic Esophagitis Patients. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s661.
77. CC Cotton, R Haidry, S Eluri, E Dellon, L Lovat, **NJ Shaheen**. Evidence-based Surveillance Intervals Following Radiofrequency Ablation (RFA) of Barrett's Esophagus (BE): An Analysis of Recurrence in the US RFA Registry with Validation in the UK National Halo Registry. Presented at DDW 2016, San Diego, CA. *Gastrointestinal Endoscopy* 2016;83(5, Suppl):ab181.\*
78. A Blum, AK Chandar, GW Falk, MI Canto, J Wang, P Iyer, **NJ Shaheen**, WM Grady, JA Abrams, K Guda, W Brock, A Singh, A Chak. Exceptional Families With Barrett's Esophagus, Esophageal Adenocarcinoma, and Breast Cancer. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s857.
79. BJ Kendall, JH Rubenstein, MB Cook, T Vaughan, LA Anderson, LJ Murray, **NJ Shaheen**, D Corley, HB El-Serag, DC Whiteman, AP Thrift. Gluteofemoral Obesity Is Associated With a Reduced Risk of Barrett's Esophagus in Men: A Pooled Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s852.
80. P Vennalaganti, G Eisen, GW Falk, LB Gerson, JR Goldblum, SA Gross, N Gupta, GB Haber, A Infantolino, P Iyer, DA Johnson, V Kaul, S Kothari, CJ. Lightdale, F Schnoll-Sussman, **NJ Shaheen**, MS Smith, KK Wang, Y Zhang, P Sharma. Increased Detection of Barrett's Esophagus-Associated Neoplasia Using Wide Area Transepithelial Sampling in Conjunction With 4-Quadrant Forceps Biopsies: Final Results From a Multi-Center, Prospective, Randomized Trial. Presented at DDW 2016, San Diego, CA. *Gastrointestinal Endoscopy* 2016;83(5, Suppl):ab122-123.\*
81. WA Wolf, CC Cotton, M McKinley, V Kaul, S Kothari, BJ Hoffman, **NJ Shaheen**. Liquid Nitrogen Spray Cryotherapy Clinical Outcomes for Barrett's Esophagus Management: Results of a United States Multicenter Registry. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s264-265.
82. S Eluri, CC Cotton, BJ Hoffman, V Kaul, M McKinley, **NJ Shaheen**. Liquid Nitrogen Spray Cryotherapy is a Versatile Management Modality for Pre-Malignant and Malignant Lesions of the Esophagus: Results from a Multicenter U.S. Registry. Presented at DDW 2016, San Diego, CA. *Gastrointestinal Endoscopy* 2016;83(5, Suppl):ab160-161.\*
83. JA Abrams, S Komanduri, **NJ Shaheen**, Z Wang, RI Rothstein. Radiofrequency Ablation for the Treatment of Weight Regain After Roux-en-Y Gastric Bypass Surgery. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s824.

84. S Eluri, T Runge, J Hansen, B Kochar, CC Reed, B Robey, JT Woosley, **NJ Shaheen**, E Dellon. Risk of Relapse After Successful Steroid Treatment in Eosinophilic Esophagitis Depends on Initial Steroid Dose. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s658.
85. A Blum, V Varadan, S Venkitachalam, Y Guo, AM Kieber-Emmons, L Ravi, AK Chandar, P Iyer, MI Canto, J Wang, **NJ Shaheen**, J Barnholtz-Sloan, S Markowitz, J Willis, Y Shyr, A Chak, K Guda Transcriptome Sequencing Identifies Potentially Functional Gene Fusions in Esophageal Adenocarcinomas. Presented at DDW 2016, San Diego, CA. *Gastroenterology* 2016;150(4, Suppl 1):s153-154.\*
86. Li N., Cotton C.C., Wolf W.A., Pasricha S., Hathorn K.E., Eluri S., Runge T., Madanick R.D., Dellon E.S., Spacek M., Moist S.E., **Shaheen N.J.** Body mass index (BMI) is associated with efficacy and durability of radiofrequency ablation (RFA) in Barrett's esophagus. Presented at DDW 2015, Chicago, IL. *Gastrointestinal Endoscopy* 2015 81:5 SUPPL. 1 (AB506-AB507).
87. WA Wolf, CC Cotton, S Eluri, T Runge, S Komanduri, K Chang, B Overholt, R Pruitt, **N Shaheen**. Initial Treatment With Endoscopic Mucosal Resection Decreases the Incidence of Esophageal Adenocarcinoma in Patients With Barrett's, With High-Grade Dysplasia. Presented at ACG 2015, Honolulu, HI. *American Journal of Gastroenterology* 2015;110(10 Suppl).
88. CC Cotton, WA Wolf, S Eluri, T Runge, A Infantolino, R Muthusamy, C Lightdale, **N Shaheen**. Incidence of Adenocarcinoma of the Gastric Cardia Is Similar to That of Adenocarcinoma in the Esophagus After Successful Radiofrequency Ablation in Barrett's Esophagus. Presented at ACG 2015, Honolulu, HI. *American Journal of Gastroenterology* 2015;110(10 Suppl).
89. S Eluri, H Wolfsen, C Lightdale, J Abrams, J Dumot, B Hoffman, BD Greenwald, **N Shaheen**. Efficacy of Single-Dose Liquid Nitrogen Ablative Therapy: Greater Than Half Have Regression With a Single Dose. Presented at ACG 2015, Honolulu, HI. *American Journal of Gastroenterology* 2015;110(10 Suppl).
90. T Runge, S Eluri, CC Cotton, C Burk, J Woosley, **N Shaheen**, ES Dellon. Safety and Efficacy of Esophageal Dilatation in a Large Cohort of Patients With Eosinophilic Esophagitis. Presented at ACG 2015, Honolulu, HI. *American Journal of Gastroenterology* 2015;110(10 Suppl).
91. T Runge, S Eluri, CC Cotton, J Woosley, **N Shaheen**, ES Dellon. Characterization, Outcomes, and Predictors of Esophageal Perforation in Patients With Eosinophilic Esophagitis. Presented at ACG 2015, Honolulu, HI. *American Journal of Gastroenterology* 2015;110(10 Suppl).
92. Hussain Z.H., Fukami N., Smith M.S., Sreenarasimhaiah J., Kaul V., Kothari S., Greenwald B.D., **Shaheen N.J.**, Levenick J.M., Edmundowicz S.A., Kushnir V.M., Joshi V., Mashimo H., Hyder S.M., Gardner T.B., Rothstein R.I., Gordon S.R. Safety and efficacy of same session spray cryotherapy and endoscopic mucosal resection for Barrett's esophagus and early esophageal neoplasia: A multicenter experience. Presented at DDW 2015, Chicago, IL. *Gastrointestinal Endoscopy* 2015 81:5 SUPPL. 1 (AB508).
93. Eluri S., Li N., Overholt B.F., Pasricha S., Lightdale C.J., Runge T., Infantolino A., Wolf W.A., Muthusamy V.R., Cotton C.C., Pruitt R.E., **Shaheen N.J.** The effect of pre-treatment stricture on outcomes after radiofrequency ablation (RFA) for Barrett's esophagus: Results from the U.S. RFA registry. Presented at DDW 2015, Chicago, IL. *Gastrointestinal Endoscopy* 2015 81:5 SUPPL. 1 (AB509-).

94. Cotton C.C., Duits L.C., Wolf W.A., Peery A.F., Dellon E.S., Bergman J.J., **Shaheen N.J.** Is there a spatial predisposition to dysplasia in a Barrett's Esophagus segment? A combined analysis of the surf and AIM - dysplasia trials. Presented at DDW 2015, Chicago, IL. *Gastrointestinal Endoscopy* 2015 81:5 SUPPL. 1 (AB498-AB499).
95. Runge T., **Shaheen N.J.**, Orlando R.C. Defective barrier function in neosquamous epithelium: A risk factor for recurrent barrett's esophagus: A BETRNet pilot project. Presented at DDW 2015, Chicago, IL. *Gastrointestinal Endoscopy* 2015 81:5 SUPPL. 1 (AB504-).
96. Wolf W.A., Gebhart J.H., Rusin S., Covey S., Higgins L.L., Beitia R.M., Speck O., Woodward K., Cotton C.C., Runge T., Eluri S., Woosley J.T., **Shaheen N.J.**, Dellon E.S. Impact of clinical and endoscopic features on BMI in patients with eosinophilic esophagitis. Presented at DDW 2015, Chicago, IL. *Gastroenterology* 2015 148:4 SUPPL. 1 (S796-).
97. Runge T., Eluri S., Cotton C.C., Burk C.M., Wolf W.A., Woosley J.T., **Shaheen N.J.**, Dellon E.S. Persistence of the fibrostenotic phenotype of eosinophilic esophagitis over time: Once dilated, frequently dilated. Presented at DDW 2015, Chicago, IL. *Gastroenterology* 2015 148:4 SUPPL. 1 (S797-).
98. Eluri S., Runge T., Cotton C.C., Burk C.M., Wolf W.A., Woosley J.T., **Shaheen N.J.**, Dellon E.S. The extreme narrow-caliber esophagus: Characterization of a novel phenotype in eosinophilic esophagitis. Presented at DDW 2015, Chicago, IL. *Gastroenterology* 2015 148:4 SUPPL. 1 (S798-).
99. Blum A., Varadan V., Guo Y., Kieber-Emmons A.M., Ravi L., Chandar A.K., Canto M.I., Wang J.S., **Shaheen N.J.**, Barnholtz- Sloan J., Willis J., Markowitz S., Shyr Y., Chak A., Guda K. Discovery of novel gene-fusions in esophageal adenocarcinoma using next-gen RNA sequencing. Presented at DDW 2015, Chicago, IL. *Gastroenterology* 2015 148:4 SUPPL. 1 (S78-).
100. Wolf W.A., Cotton C.C., Eluri S., Triadafilopoulos G., Runge T., Wolfsen H.C., Li N., Komanduri S., Chmielewski G.W., Ertan A., Dellon E.S., **Shaheen N.J.** Rates of recurrence and achievement of a second complete eradication of intestinal metaplasia in patients treated with radiofrequency ablation for barrett's esophagus. Presented at DDW 2015, Chicago, IL. *Gastroenterology* 2015 148:4 SUPPL. 1 (S139-)\*
101. Duits L.C., Cotton C.C., Phoa K.Y.N., Ten Kate F.T., Seldenrijk C.A., Offerhaus J., Visser M., Meijer S.L., Mallant-Hent R.C., Krishnadath K.K., Pouw R.E., Tijssen J., **Shaheen N.J.**, Bergman J.J. The surf-trial pre-assessment cohort: A multivariable model accurately predicts neoplastic progression in barrett's esophagus patients with low-grade dysplasia. Presented at DDW 2015, Chicago, IL. *Gastroenterology* 2015 148:4 SUPPL. 1 (S159-)\*
102. Vennalaganti P., Eisen G., Falk G.W., Gerson L.B., Gross S.A., Goldblum J.R., Gupta N., Haber G.B., Infantolino A., Iyer P.G., Johnson D.A., Kaul V., Kothari S., Lightdale C.J., **Shaheen N.J.**, Smith M.S., Schnoll-Sussman F., Wang K.K., Zhang Y., Sharma P. Increased detection of barrett's esophagus (BE)-associated Neoplasia using wide-area trans-epithelial sampling in conjunction with 4-quadrant biopsies: Interim results from a multi-center, prospective, randomized trial. Presented at DDW 2015, Chicago, IL. *Gastroenterology* 2015 148:4 SUPPL. 1 (S348-).
103. Eluri S., Brugge W.R., Daglilar E.S., Jackson S.A., Styn M.A., Callenberg K.M., Welch D.C., Barr T.M., Duits L.C., Bergman J.J., **Shaheen N.J.** Genetic mutations at key loci predict progression to high-grade dysplasia or esophageal adenocarcinoma in barrett's esophagus. Presented at DDW 2015, Chicago, IL. *Gastroenterology* 2015 148:4 SUPPL. 1 (S356-).
104. Cotton C.C., Hiller S., Green D.J., Wolf W.A., Wheeler S.B., **Shaheen N.J.**, Dellon E.S. Six-food elimination diet or topical steroids for first-line treatment of eosinophilic esophagitis: A



cost-utility analysis. Presented at DDW 2015, Chicago, IL. Gastroenterology 2015 148:4 SUPPL. 1 (S2-).\*

105. Varadan V., Blum A., Guo Y., Kieber-Emmons A.M., Ravi L., Kresak A., Chandar A.K., Canto M.I., Wang J.S., **Shaheen N.J.**, Barnholtz-Sloan J., Willis J., Markowitz S., Shyr Y., Chak A., Guda K. Large-scale transcriptome sequencing identifies two signaling sub-networks as critical mediators of barrett's carcinogenesis. Presented at DDW 2015, Chicago, IL. Gastroenterology 2015 148:4 SUPPL. 1 (S562).
106. Li N., Pasricha S., Chmielewski G.W., Ertan A., Wolf W.A., Corbett F.S., Cotton C.C., Camara D.S., Eluri S., Rothstein R.I., Runge T., Triadafilopoulos G., **Shaheen N.J.** Impact of barrett's esophagus and treatment with radiofrequency ablation on patient quality of life: Results from the U.S. RFA registry. Presented at DDW 2015, Chicago, IL. Gastroenterology 2015 148:4 SUPPL. 1 (S216-).\*
107. Wolf W.A., Cotton C.C., Muthusamy V.R., Eluri S., Pruitt R.E., Runge T., Wolfsen H.C., Li N., Pasricha S., Komanduri S., **Shaheen N.J.** Choice of initial radiofrequency ablation treatment device in barrett's esophagus is associated with different rates of recurrence and complications. Presented at DDW 2015, Chicago, IL. Gastroenterology 2015 148:4 SUPPL. 1 (S216-S217).
108. Dellon E.S., Rusin S., Gebhart J.H., Covey S., Speck O., Woodward K., Higgins L.L., Beitia R.M., Madanick R.D., Levinson S.E., Woosley J.T., **Shaheen N.J.** A set of clinical and endoscopic features predicts the presence of eosinophilic esophagitis with high accuracy, allowing omission of low-yield biopsies: Results from a prospective study. Presented at DDW 2015, Chicago, IL. Gastroenterology 2015 148:4 SUPPL. 1 (S411-).
109. Dellon E.S., Rusin S., Gebhart J.H., Covey S., Higgins L.L., Beitia R.M., Speck O., Woodward K., Woosley J.T., **Shaheen N.J.** In search of a non-invasive blood test for diagnosis and monitoring of EOE: A prospective study of a serum biomarker panel. Presented at DDW 2015, Chicago, IL. Gastroenterology 2015 148:4 SUPPL. 1 (S411-S412).
110. Cotton C.C., Duits L.C., Wolf W.A., Muthusamy V.R., Eluri S., Pruitt R.E., Runge T., Wolfsen H.C., Li N., Pasricha S., Komanduri S., **Shaheen N.J.** Barrett's esophagus advanced neoplasia calculator (BANC): A personalized, web-based predictive model of high grade dysplasia and adenocarcinoma following successful eradication of barrett's esophagus with radiofrequency ablation. Presented at DDW 2015, Chicago, IL. Gastroenterology 2015 148:4 SUPPL. 1 (S53-).\*
111. Cotton C., Wolf W.A., Komanduri S., Lightdale C., Infantolino A., Wolfsen H., **Shaheen N.** Site volume is inversely associated with recurrence rate after successful radiofrequency ablation (RFA): An analysis of the U.S. RFA registry. Presented at the 2015 ACG Annual Meeting, Washington, DC. American Journal of Gastroenterology 2014 109 SUPPL. 2 (S657-S658).
112. Cotton C., Wolf W.A., Komanduri S., Lightdale C., Infantolino A., Wolfsen H., **Shaheen N.** Site volume is associated with achievement of complete eradication of intestinal metaplasia (CEIM) in radiofrequency ablation (RFA). Presented at the 2015 ACG Annual Meeting, Washington, DC. American Journal of Gastroenterology 2014 109 SUPPL. 2 (S658-S659).
113. Cottrell ML, Yang KH, Heather M.A. Prince, Craig Syke, Nicole White, Stephanie Malone, Evan S Dellon, Ryan D Madanick, **NJ Shaheen**, Julie A Nelson, Ronald Swanstrom, Kristine B Patterson, Angela D.M. Kashuba. Predicting Effective Truvada® PrEP Dosing Strategies With a Novel PK-PD Model Incorporating Tissue Active Metabolites and Endogenous Nucleotides (EN). HIV Research for Prevention 2014: AIDS Vaccine, Microbicide and ARV-based Prevention Science (HIV R4P) in Cape Town South Africa, October 28<sup>th</sup>-31<sup>st</sup>. AIDS Research and Human Retroviruses 2014;30(Suppl 1):A60.

114. Pasricha S, Triadafilopoulos G, Li N, Muthasamy VR, Wolf WA, Chmielewski GW, Cotton CC, Corbett FS, Camara DS, **Shaheen NJ**. All-Cause Mortality in Patients with Barrett's Esophagus Undergoing Radiofrequency Ablation: Results from the U.S. RFA Registry. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s130.\*
115. Cotton CC, Wolf WA, Pasricha S, Li N; Hathorn KE, Madanick RD, Dellon, ES, Spacek M, Moist SE, **Shaheen NJ**. Random Biopsies in Endoscopically Normal Esophagus Improve Yield of Recurrent Intestinal Metaplasia after Successful Radiofrequency Ablation. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s29.\*
116. Cotton CC, Wolf WA, Pasricha S, Li N, Hathorn KE, Madanick RD, Dellon ES, Spacek M, Moist SE, **Shaheen NJ**. The Incidence of Neoplastic Gastric Cardia Nodules following Radiofrequency Ablation of Neoplastic Barrett Esophagus. Presentation at DDW 2014, Chicago, IL. *Gastrointestinal Endoscopy* 2014;79(4, Suppl):ab496-497.
117. Cotton CC, Wolf WA, Li N, Pasricha S, Hathorn KE, Spacek M, Moist SE, Madanick RD, Dellon ES, **Shaheen NJ**. Development of Erosive Esophagitis during Radiofrequency Ablation for Barrett's Esophagus is Associated with an Increased Number of Sessions for Successful Treatment. Presentation at DDW 2014, Chicago, IL. *Gastrointestinal Endoscopy* 2014;79(4, Suppl):ab219-220.
118. Sun X, Chak A, Falk GW, Grady WM, Kinnard MF, Mittal SK, Canto MI, **Shaheen NJ**, Wang JS, Iyer PG, Abrams JA, Willis J, Markowitz S, Barnholtz-Sloan J, Brock W, Elston R. Predicting Barrett's esophagus in Families of Patients with Barrett's esophagus: A BETRNet Model Fitting Clinical Data to a Genetic Paradigm. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s305.
119. KK Walp, SP Hallquist, A Bults N Fukami, DG Forcione, **NJ Shaheen**, MS Smith. Liquid Nitrogen Spray Cryotherapy Can Be Used Safely In Retroflexion For Treatment Of Lesions At The Esophagogastric Junction And Gastric Cardia. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s662.
120. Li N, Pasricha S, Cotton CC, Wolf WA, Spacek MB, Moist SB, **Shaheen NJ**. Dysplasia in the gastric cardia is not uncommon among patients who are successful treated by radiofrequency ablation for dysplastic Barrett's esophagus – A prospective study. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s661.
121. Wolf WA, Lao-Sirieix P, Duits LC, Chak A, **Shaheen NJ**, Fitzgerald R, Bergman JJ. Utility of a Biomarker Panel to Predict Progression to Esophageal Adenocarcinoma in Barrett's Esophagus. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s330.
122. Wolf WA, Overholt BF, Li N, Lightdale CJ, Cotton CC, Wolfsen HC, Pasricha S, Wang Kenneth K, **Shaheen NJ**. Durability of Radiofrequency Ablation (RFA) in Barrett's Esophagus with Dysplasia: The AIM Dysplasia Trial at Five Years. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s131.\*
123. Wolf WA, Lightdale CJ, Li N, Wolfsen HC, Cotton CC, Chang KJ, Pasricha S, Overholt BF, **Shaheen NJ**. Incidence of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus Undergoing Radiofrequency Ablation (RFA). Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s301.
124. Wolf WA, Pruitt RE, Ertan A, Cotton CC, Komanduri S, Pasricha S, Infantolino A, Li N, Rothstein RI, **Shaheen NJ**. Predictors of Esophageal Adenocarcinoma in Patients with Prior Radiofrequency Ablation (RFA) for Treatment of Barrett's Esophagus: Results from the U.S. RFA Registry. Presentation at DDW 2014, Chicago, IL. *Gastrointestinal Endoscopy* 2014;79(4, Suppl):ab217.

125. Wolf WA, Cotton CC, Li N, Pasricha S, Hathorn KE, Spacek M, Moist SE, Madanick RD, Dellon ES, **Shaheen NJ**. Modifiable Risk Factors Predict Recurrence of Barrett's Esophagus After Successful Radiofrequency Ablation. Presentation at DDW 2014, Chicago, IL. *Gastrointestinal Endoscopy* 2014;79(4, Suppl):ab115.\*
126. Hathorn KE, Lightdale CJ, Wolf WA, Corbett FS, Pasricha S, Rothstein RI, Cotton CC, Camara DS, Muthusamy VR, **Shaheen NJ**. Predictors of Complications from Radiofrequency Ablation (RFA) During Treatment of Barrett's Esophagus: Results from the U.S. RFA Registry. Presentation at DDW 2014, Chicago, IL. *Gastrointestinal Endoscopy* 2014;79(4, Suppl):ab 152-153.\*
127. Dellon ES, Covey S, Speck O, Woodward K, Rusin S, Gebhart JH, Woosley JT, **Shaheen NJ**. Immunohistochemical evidence of inflammation is similar in patients with eosinophilic esophagitis and PPI-responsive esophageal eosinophilia: A prospective cohort study. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s17.\*
128. Dellon ES, Speck O, Woodward K, Covey S, Rusin S, Gebhart JH, Woosley JT, **Shaheen NJ**. Major basic protein, eotaxin-3, and mast cell tryptase staining for diagnosis of eosinophilic esophagitis: A prospective study. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s664.
129. Dellon ES, Erichsen R, Baron JA, **Shaheen NJ**, Vyberg M, Sorensen HT, Pedersen L. The increasing incidence and prevalence of eosinophilic esophagitis outpaces changes in endoscopic and biopsy practice: National population-based estimates from Denmark. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s664-665.
130. Wolf WA, Green DJ, Hughes JT, Cotton CC, Woosley JT, **Shaheen NJ**, Dellon ES. Dilation of strictures prior to therapy predicts histologic non-response to topical steroids in eosinophilic esophagitis. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s666.
131. Green DJ, Wolf WA, Hughes JT, Cotton CC, Woosley JT, **Shaheen NJ**, Dellon ES. Most patients demonstrate correlation between symptoms, endoscopic findings, and histology in response to topical steroid treatment in eosinophilic esophagitis. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s668.
132. Cotton CC, Green DJ, Hughes JT, Wolf WA, Woosley JT, **Shaheen NJ**, Dellon ES. When eosinophilic esophagitis is refractory to topical steroids: Treatment options and clinical outcomes. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):673-674.
133. Wolf WA, Green DJ, Hughes JT, Cotton CC, Woosley JT, **Shaheen NJ**, Dellon ES. What cut-point should be used to define a histologic response to topical steroid use in eosinophilic esophagitis? A data-driven approach using symptoms and endoscopic findings. Presentation at DDW 2014, Chicago, IL. *Gastroenterology* 2014;146(5, Suppl 1):s665-666.
134. Dellon ES, Jensen ET, Martin CF, **Shaheen NJ**, Kappelman MD. The prevalence of eosinophilic esophagitis in the United States: Estimates from a large administrative database. Presentation at DDW 2013, Orlando, FL. *Gastroenterology* 2013;144(5, Suppl 1):489.
135. Pasricha S, Hathorn KE, Bulsiewicz WJ, Li N, Rogers AJ, Madanick RD, Dellon ES, **Shaheen NJ**. Esophageal Endoscopic Mucosal Resection: Efficacy and Safety at a Tertiary Care Center. Presentation at DDW 2013, Orlando, FL. *Gastrointestinal Endoscopy* 2013;77(5, Suppl):ab346.
136. Pasricha S, Bulsiewicz WJ, Rothstein RI, Infantolino A, Ertan A, Camara DS, Dellon ES, Triadafilopoulos F, **Shaheen NJ**. Gender differences and response to radiofrequency

ablation for Barrett's esophagus: Results from the U.S. RFA Registry. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s376-77.

137. Hathorn KE, Bulsiewicz WJ, Pruitt RE, Chmielewski GW, Madanick RD, Corbett FS, Rothstein RI, Lightdale CJ, Triadafilopoulos G, **Shaheen NJ**. What is the histology of subsquamous intestinal metaplasia (SSIM) in patients with prior radiofrequency ablation (RFA) for treatment of Barrett's esophagus (BE)? Results from the U.S. RFA Registry. Poster presentation. Digestive Disease Week. Orlando FL. May 2013. Gastroenterology 2013;144(5, Suppl 1):s377.
138. Pasricha S, Bulsiewicz WJ, Infantolino A, Madanick R, Corbett SF, Pruitt RE, Chmielewski GW, Overholt BF, **Shaheen NJ**. National practice patterns in the timing of radiofrequency ablation (RFA) for Barrett's esophagus: Results from the U.S. RFA Registry. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s580.
139. Li N, Bulsiewicz WJ, Lightdale CJ, Madanick RD, Triadafilopoulos G, Lyday WD, Muthusamy VR, Infantolino A, Overholt BF, **Shaheen NJ**. Racial differences in the characteristics of Barrett's esophagus (BE) and response to radiofrequency ablation (RFA) treatment: Results from the U.S. RFA Registry. Digestive Disease Week. Orlando FL. May 2013. Gastroenterology 2013;144(5, Suppl 1):s75.\*
140. Pasricha S, Bulsiewicz WJ, Triadafilopoulos G, Wolfsen HC, Lightdale CJ, Ertan A, Camara DS, Komanduri S, Corbett FS, **Shaheen NJ**. Initiation of radiofrequency ablation with circumferential versus focal therapy does not alter efficacy or safety in Barrett's esophagus: Results from the U.S. RFA Registry. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s514.
141. Ghorbani S, Tsai F, Jang S, Dumot JA, Greenwald BD, McKinley M, Habr F, **Shaheen NJ**, Coyle W. Safety and Efficacy of Endoscopic Spray Cryotherapy for Esophageal Cancer: Results of The National Cryospray Registry. Digestive Disease Week. Orlando FL. May 2013. Gastrointestinal Endoscopy 2013;77(5, Suppl):ab348.
142. Ghorbani S, Tsai F, Greenwald BD, Jang S, Dumot JA, McKinley M, **Shaheen NJ**, Habr F, Coyle W. Safety and Efficacy of Endoscopic Spray Cryotherapy for Barrett's Dysplasia: Results of The National Cryospray Registry. Digestive Disease Week. Orlando FL. May 2013. Gastrointestinal Endoscopy 2013;77(5, Suppl):ab338.
143. Sun X, Elston R, Guda K, Falk GW, Grady WM, Kinnard MF, Mittal SK, Canto MI, **Shaheen NJ**, Iyer PG, Wang JS, Abrams JA, Barnholtz-Sloan J, Willis J, Markowitz S, Chak A. Genetic linkage predisposing to Familial Barrett's Esophagus (FBE). Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s675.
144. Erickson K, **Shaheen NJ**, Donovan T, Dellon ES, Madanick RD. The Risk of Dental Erosion in GERD Patients as Measured by the Basic Erosive Wear Examination. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s842.
145. Bulsiewicz WJ, Dellon ES, Lyday WD, Ertan A, Camara DS, Komanduri S, Chmielewski GW, Muthusamy VR, Shaheen NJ. Predictors of recurrent Barrett's esophagus after successful radiofrequency ablation in a nationwide, multicenter cohort: Results from the U.S. RFA Registry. Oral presentation (presidential plenary). Digestive Disease Week. Orlando, FL. May, 2013. Gastroenterology 2013;144(5, Suppl 1):s1.\*
146. Li N, Bulsiewicz WJ, Chmielewski GW, Corbett FS, Infantolino A, Dellon ES, Pruitt RE, Camara DS, Lyday WD, **Shaheen NJ**. Surveillance practices in community and academic settings in patients who achieve complete eradication of intestinal metaplasia (CEIM) after radiofrequency ablation (RFA): Results from the U.S. RFA Registry. Digestive Disease Week. Orlando FL. May 2013. Gastrointestinal Endoscopy 2013;77(5, Suppl):ab139.\*

147. Hathorn KE, Bulsiewicz WJ, Ertan A, Overholt BF, Pruitt RE, Lyday WD, Infantolino A, Wolfsen HC, **Shaheen NJ**. Predictors of subsquamous intestinal metaplasia (SSIM) in patients with prior radiofrequency ablation (RFA) for treatment of Barrett's esophagus: Results from the U.S. RFA Registry. Digestive Disease Week. Orlando FL. May 2013. Gastrointestinal Endoscopy 2013;77(5, Suppl):ab138-139.\*
148. Pasricha S, Bulsiewicz WJ, Muthusamy VR, Komanduri S, Wolfsen HC, Pruitt RE, Ertan A, Chmielewski GW, **Shaheen NJ**. Effect of site volume on eradication of Barrett's esophagus (BE): Results from the U.S. RFA Registry. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s697.
149. Dellon ES, Kim HP, Sperry SLW, Rybnicek DA, Woosley JT, **Shaheen NJ**. Eosinophilic esophagitis is a progressive fibrostenotic disease: Insights from a phenotypic analysis. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s485-486.
150. Hathorn KE, Bulsiewicz WJ, Dellon ES, Rothstein RI, Corbett FS, Muthusamy VR, Overholt BF, Komanduri S, **Shaheen NJ**. The efficacy and safety of radiofrequency ablation (RFA) for treatment of Barrett's esophagus containing intramucosal carcinoma (IMC): Results from the U.S. RFA Registry. Oral presentation. Digestive Disease Week. Orlando FL. May 2013. Gastroenterology 2013;144(5, Suppl 1):186-187.\*
151. Madanick RD, Bulsiewicz WJ, Wolfsen HC, Lightdale CJ, Lyday WD, Triadafilopoulos G, Dellon ES, Rothstein RI, **Shaheen NJ**. Compliance with high-dose acid suppression does not appreciably alter the efficacy or safety of radiofrequency ablation (RFA) in Barrett's esophagus (BE): Results from the U.S. RFA Registry. Poster presentation. Digestive Disease Week. Orlando FL. May 2013. Gastrointestinal Endoscopy 2013;77(5, Suppl):ab335.
152. Dellon ES, Kim HP, Sperry SLW, Rybnicek DA, Woosley JT, **Shaheen NJ**. Decreasing frequency of the fibrostenotic phenotype of eosinophilic esophagitis: Time trends over the past decade. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s490.
153. Jensen ET, Martin CF, **Shaheen NJ**, Kappelman MD, Dellon ES. High prevalence of co-existing autoimmune conditions among patients with eosinophilic esophagitis. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s491.
154. Kim HP, Sperry SLW, Rybnicek DA, Woosley JT, **Shaheen NJ**, Dellon ES. Differences in presentation of eosinophilic esophagitis by atopic status, eosinophilia, and age of symptom onset: An analysis of non-endoscopic phenotypes. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s490.
155. Gebhart JH, Hathorn KE, **Shaheen NJ**, Dellon ES. The esophageal biopsy "pull" sign: A novel and highly specific endoscopic finding in eosinophilic esophagitis. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s486.
156. Hathorn KE, Gebhart JH, **Shaheen NJ**, Dellon ES. Is low body mass index a risk factor for eosinophilic esophagitis? Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s490.
157. Wolf WA, Jerath MA, Sperry SLW, **Shaheen NJ**, Dellon ES. Dietary elimination therapy is an effective option for adults with eosinophilic esophagitis. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s488.
158. Speck O, Woodward K, Covey, S, Woosley JT, **Shaheen NJ**, Dellon ES. A training curriculum for pathologists yields highly reproducible esophageal eosinophil counts. Presentation at DDW 2013, Orlando, FL. Gastroenterology 2013;144(5, Suppl 1):s488.

159. Pasricha S, Gupta A, Speck O, Woosley JT, Bulsiewicz WJ, **Shaheen NJ**, Dellon ES. Characterization of patients with Lymphocytic Esophagitis, an emerging clinicopathologic disease. Presentation at DDW 2013, Orlando, FL. *Gastroenterology* 2013;144(5, Suppl 1):s499.
160. Bulsiewicz WJ, Pasricha S, Komanduri S, Muthusamy VR, Rothstein RI, Wolfsen HC, Lightdale CJ, Overholt BF, Camara DS, **Shaheen NJ**. Durability of reversion to squamous mucosa after successful eradication of Barrett's esophagus (BE) with radiofrequency ablation (RFA): Results from the U.S. RFA Registry. *Digestive Disease Week. Orlando FL. May 2013. Gastrointestinal Endoscopy* 2013;77(5, Suppl):ab26.\*
161. Madanick RD, Sigmon L, Ferrell K, **Shaheen NJ**, Dellon ES. Gabapentin for the treatment of chronic cough: A novel approach to treating a challenging clinical problem. Presented at ACG, 2012, Las Vegas, NV. *American Journal of Gastroenterology* 2012;107(10 SUPPL.).
162. Dellon ES, Speck O, Woodward K, Hores JM, Williams CG, Woosley JT, **Shaheen NJ**. Diagnostic utility of peripheral eosinophil counts and IgE levels for diagnosis of eosinophilic esophagitis. Presented at ACG, 2012, Las Vegas, NV. *American Journal of Gastroenterology* 2012;107(10 SUPPL.).
163. Rybnicek DA, Pfaff ER, Bulsiewicz WJ, **Shaheen NJ**, Dellon ES. Can eosinophilic esophagitis be reliably identified in administrative databases? Presented at ACG, 2012, Las Vegas, NV. *American Journal of Gastroenterology* 2012;107(10 SUPPL.).
164. Dellon ES, Sheik A, Speck O, Woodward K, Whitlow AB, Hores J, Ivanovic M, Chau A, Woosley JT, Madanick RD, Orlando RC, **Shaheen NJ**. Nebulized/swallowed vs viscous/swallowed budesonide for treatment of eosinophilic esophagitis: Results from a randomized, open-label, clinical trial. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s180.\*
165. Bulsiewicz WJ, Lightdale CJ, Pruitt RE, Triadafilopoulos G, Lyday WD, **Shaheen NJ**. Predictors of complete eradication of Barrett's esophagus by radiofrequency ablation (RFA) in a nationwide, multicenter cohort: Results from the U.S. RFA Registry. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s3-4.\*
166. Dellon ES, Carroll CF, Allen JK, Cook S, Peery AF, **Shaheen NJ**, Kappelman M. A decade of increased gastrointestinal endoscopy utilization and costs in the United States, 2000-2009. Presented at DDW, 2012, San Diego, CA. *Gastrointestinal Endoscopy* 2012;75(4, Suppl):ab120.\*
167. Bulsiewicz WJ, Infantolino A, Ertan A, Komanduri S, Rothstein RI, Wolfsen HC, Chmielewski GW, Corbett FS, Camara DS, **Shaheen NJ**. Length of Barrett's esophagus predicts likelihood of complete eradication of intestinal metaplasia and number of treatment sessions of radiofrequency ablation (RFA): Results from the U.S. RFA Registry. Presented at DDW, 2012, San Diego, CA. *Gastrointestinal Endoscopy* 2012;75(4, Suppl):ab121.\*
168. **Shaheen NJ**, Bulsiewicz WJ, Lyday WD, Triadafilopoulos G, Wolfsen HC, Komanduri S, Chmielewski G, Ertan A, Corbett FS, Camara DS, Rothstein RI, Overholt BF. Prior fundoplication does not improve subsequent safety or efficacy outcomes of radiofrequency ablation (RFA): Results from the U.S. RFA Registry. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s1040-1041.\*
169. Bulsiewicz WJ, Infantolino A, Lightdale CJ, Ertan A, Pruitt RE, Muthusamy R, Overholt BF, **Shaheen NJ**. The safety and efficacy of endoscopic mucosal resection prior to radiofrequency ablation for dysplastic Barrett's esophagus: Results from the U.S. RFA Registry. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):427.\*

170. Kim HP, Bulsiewicz WJ, Cotton CC, Dellon ES, Madanick RD, **Shaheen NJ**. Durability of Radiofrequency Ablation (RFA) for Eradication of Dysplasia in Barrett's Esophagus (BE) and Risk Factors for Recurrent Disease. Presented at DDW, 2012, San Diego, CA. *Gastrointestinal Endoscopy* 2012;75(4, Suppl):ab289.
171. Bulsiewicz WJ, Kim HP, Cotton CC, Dellon ES, Pasricha S, Madanick RD, Spacek M, Chen XL, Orlando RC, **Shaheen NJ**. The safety of radiofrequency ablation (RFA) for treatment of neoplastic Barrett's esophagus (BE): A study of 244 patients with dysplasia or early cancer. Presented at DDW, 2012, San Diego, CA. *Gastrointestinal Endoscopy* 2012;75(4, Suppl):ab289-290.
172. Paul N, Kurzbard N, **Shaheen NJ**, Karsan SS, Spiegel BM. Development of a Nomogram for Expected Allocation in Randomized Controlled Trials: Case Study of Treatment for Hepatic Encephalopathy. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s580.
173. Bulsiewicz WJ, Kim HP, Cotton CC, Dellon ES, Pasricha S, Madanick RD, Spacek M, Chen XL, Orlando RC, **Shaheen NJ**. Eradication of Barrett's esophagus (BE) with neoplasia using radiofrequency ablation (RFA): A study of 244 patients with dysplasia or early cancer. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s751.
174. **Shaheen NJ**, Bulsiewicz WJ, Rothstein RI, Komandun S, Wolfsen HC, Triadafilopoulos G, Lyday WD, Ertan A, Pruitt RE, Infantolino A, Chmielewski GW, Muthusamy VR, Corbett FS, Camara DS, Lightdale CJ, Overholt BF. Radiofrequency ablation (RFA) safely treats Barrett's esophagus in a nationwide, multicenter cohort: Results from the U.S. RFA Registry. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):752.
175. Bulsiewicz WJ, Kim HP, Cotton CC, Dellon ES, Pasricha S, Madanick RD, **Shaheen NJ**. Predictors of "Difficult to Ablate" Barrett's esophagus among 244 patients with dysplasia or early cancer. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s752.
176. Bulsiewicz WJ, **Shaheen NJ**, Hansen MB, Pruitt AP, Orlando RC. Effect of Amiloride on Acid-Induced Heartburn in Non-Erosive Reflux Disease. Presented at DDW 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s753.
177. **Shaheen NJ**, Bulsiewicz WJ, Rothstein RI, Komanduri S, Wolfsen HC, Muthusamy R, Triadafilopoulos G, Lyday WD, Ertan A, Pruitt RE, Infantolino A, Chmielewski GW, Corbett FS, Camara DS, Lightdale CJ, Overholt BF. Eradication rates of Barrett's esophagus using radiofrequency ablation (RFA): Results from the U.S. RFA Registry. Presented at DDW, 2012, San Diego, CA. *Gastrointestinal Endoscopy* 2012;75(4, Suppl):ab460.
178. Kim HP, Bulsiewicz WJ, Cotton CC, Dellon ES, Madanick RD, Pasricha S, **Shaheen NJ**. Endoscopic mucosal resection (EMR) prior to radiofrequency ablation (RFA) is equally effective and safe compared to RFA alone for the eradication of Barrett's esophagus (BE). Presented at DDW, 2012, San Diego, CA. *Gastrointestinal Endoscopy* 2012;75(4, Suppl):ab461-462.
179. Dellon ES, Sheik A, Whitlow AB, Ivanovic M, Chau A, Woodward K, Speck O, Hores J, Woosley JT, Madanick RD, Orlando RC, **Shaheen NJ**. Mucosal contact time determines histologic effectiveness of oral budesonide preparations in eosinophilic esophagitis: A randomized trial using scintigraphy. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):180.\*
180. Dellon ES, Speck O, Woodward K, Woosley JT, **Shaheen NJ**. The patchy nature of esophageal eosinophilia in eosinophilic esophagitis: Insights from pathology samples from a clinical trial. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s432.

181. Dellon ES, Woodward K, Speck O, Hores J, Woosley JT, **Shaheen NJ**. Symptoms do not correlate with histologic response in eosinophilic esophagitis. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s432.
182. Dellon ES, Erichsen R, Pedersen L, **Shaheen NJ**, Baron JA, Sorensen HT, Vyberg M. Development and validation of a registry-based case definition of eosinophilic esophagitis in the linked health registries in Denmark. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s432.
183. Dellon ES, Carroll CF, Allen JK, Cook SF, Peery AF, **Shaheen NJ**, Kappelman MD. A decade of increased gastrointestinal endoscopy utilization and costs in the United States, 2000-2009. Presented at DDW, 2012, San Diego, CA. *Gastrointestinal Endoscopy* 2012;75(4, Suppl):ab64.
184. Kim HP, Vance RB, **Shaheen NJ**, Dellon ES. Prevalence of endoscopic findings in eosinophilic esophagitis: A meta-analysis. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s432-33.
185. Kim HP, Vance RB, **Shaheen NJ**, Dellon ES. A meta-analysis of the diagnostic utility of the endoscopic features of eosinophilic esophagitis. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s433.
186. Rybnicek DA, Bulsiewicz WJ, **Shaheen NJ**, Dellon ES. ICD-9 codes do not reliably identify cases of eosinophilic esophagitis: A cautionary tale. Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s436.
187. Rybnicek DA, Dorn SD, Shaheen NJ, Dellon ES. Can an internet search tool provide clues into the evolving epidemiology of eosinophilic esophagitis? Presented at DDW, 2012, San Diego, CA. *Gastroenterology* 2012;142(5, Suppl 1):s436.
188. Bulsiewicz WJ, Pasricha S, Dellon ES, Madanick RD, Spacek MB, Orlando RC, **Shaheen NJ**. Efficacy and predictors of stricture development following radiofrequency ablation for Barrett's esophagus at a tertiary referral center. Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s217.
189. Bulsiewicz WJ, Pasricha S, Dellon ES, Madanick RD, **Shaheen NJ**. Predictors of Difficulty Eradicating Barrett's Esophagus with Radiofrequency Ablation. 1033100 Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s216.
190. Jovov B, Tobey N, **Shaheen NJ**, Djukic Z, Orlando GS, Orlando RC. Sub-Optimal Barrier Function in Neosquamous Epithelium following Ablative Therapy 1019605 Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s218.
191. Garman KS, Anderson B, Zhang X, Huo X, Diehl AM, Souza RF, **Shaheen NJ**. An In Vitro and In Vivo Analysis of MicroRNA in the Pathogenesis of Barrett's Esophagus . 1036358 Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s309.
192. Madanick RD, Kass S, **Shaheen NJ**. On-therapy Versus Off-therapy Testing in Patients with Symptoms of Refractory Gastroesophageal Reflux Disease: a Cost-Utility Analysis. 1036358 Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s200.
193. Dellon ES, Bower JJ, Keku TO, Chen XL, Miller CR, Woosley JT, Orlando RC, **Shaheen NJ**. Constitutively active tyrosine kinase due to the FIP1L1-PDGFR $\alpha$  fusion protein: A potential non-allergic pathogenic mechanism in eosinophilic esophagitis? 1034253 Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s236-237.



194. Sperry SL, **Shaheen NJ**, Dellon ES. Effect of guidelines for eosinophilic esophagitis on variability of diagnostic criteria in the medical literature. Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s240.
195. Sperry SL, Crockett SD, Miller CB, **Shaheen NJ**, Dellon ES. Time trends in foreign body impactions in the esophagus: What is the impact of the increasing prevalence of eosinophilic esophagitis? 1033095 Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s241.
196. Peery AF, Cao H, Dominik R, **Shaheen NJ**, Dellon ES. Reliability of endoscopic findings in eosinophilic esophagitis with white light and narrow band imaging 1030271 Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s236.
197. Bulsiewicz WJ, Rogers AJ, Dellon ES, Pasricha S, Madanick RD, Grimm IS, **Shaheen NJ**. The Clinical Utility of Endoscopic Ultrasound Before Ablation in Patients with Barrett's Esophagus and High-grade Dysplasia or Intramucosal Carcinoma Presented at DDW, 2011, Chicago, IL. *Gastrointestinal Endoscopy* 2011;73(4, Suppl):ab209.
198. Murphy TJ, Nason KS, **Shaheen NJ**, Schindler JS, Schipper PH, Hoppo T, Diggs BS, Sauer DA, Morris C, Luketich JD, Jobe BA. A Cross-sectional Analysis of the Prevalence of Barrett's Esophagus in Otolaryngology Patients with Laryngeal Symptoms Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s211-212.
199. Bulsiewicz WJ, Pasricha S, Dellon ES, Madanick RD, **Shaheen NJ**. The effect of operator experience on treatment of dysplastic Barrett's esophagus with radiofrequency ablation. 1032942 Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s211.
200. Garman KS, Peery AF, Daugherty N, Hoppo T, Bream S, Sanz AF, Spacek MB, Connors D, Faulx AL, Chak A, Luketich JD, Jobe BA, **Shaheen NJ**. Yield of Transnasal Endoscopy in an Unselected General Medical Population. Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s211.
201. Sperry SL, Seth D, Crockett, C. B. Miller, **Shaheen NJ**, Dellon ES. Esophageal foreign body impaction presenting to the emergency department: Time trends, utilization and treatment modalities. 1033121 Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s732-733.
202. Peery AF, Garman KS, Daugherty N, Hoppo T, Bream S, Sanz AF, Spacek MB, Connors D, Faulx AL, Chak A, Luketich JD, **Shaheen NJ**, Jobe BA. Feasibility, Safety and Acceptability of Office-based, Screening Transnasal Endoscopy. 1032542 Presented at DDW, 2011, Chicago, IL. *Gastrointestinal Endoscopy* 2011;73(4, Suppl):ab157.\*
203. Jankowski JA, Vakil NB, Ferguson MK, Bennett C, Moayyedi P, Bergman JJ, Harrison RF, Barr H, deCaestecker J., Inadomi JM, **Shaheen NJ**, Meltzer SJ, Fennerty MB, Waxman I, Rangunath K, Kahrilas PJ, Attwood SE, Vieth M, Gay LJ, Krishnadath KK, Longcroft-Wheaton GR, Singh R, Armstrong D, Wang KK, Bhandari P, Poller D, Yerian L, Hongo M, Kay E, Sanders S. BARrett's Dysplasia CANcer Task force - BAD CAT: A global, multidisciplinary, consensus on the management of high grade dysplasia and early mucosal cancer in Barrett's esophagus. Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s178.\*
204. Dorn SD, David Wei, Nilay D. Shah, Joel F. Farley, **Shaheen NJ**, Robert S. Sandler, Michael Kappelman.<sup>1</sup> Impact of the 2008-2009 Economic Recession on Colonoscopy Utilization Among the Insured. Presented at DDW, 2011, Chicago, IL. *Gastroenterology* 2011;140(5, Suppl 1):s51.\*

205. Dellon ES, Jacquelyn J. Bower, Temitope O. Keku, Xiaoxin L. Chen, C. Ryan Miller, John T. Woosley, Orlando RC, **Shaheen NJ**. Markers of tyrosine kinase activity for diagnosis and treatment response in eosinophilic esophagitis: A pilot study of pERK 1/2 and pSTAT5. Presented at DDW, 2011, Chicago, IL. Gastroenterology 2011;140(5, Suppl 1):s187.\*
206. Hoppo T, Sanz AF, Nason KS, Carroll T, Rosen C, Normolle DP, **Shaheen NJ**, Luketich JD, Jobe BA. How Much Pharyngeal Acid is "Normal?": Normative Data for Laryngopharyngeal Reflux Events Using Hypopharyngeal Multichannel Intraluminal Impedance (HMII). Presented at DDW, 2011, Chicago, IL. Gastroenterology 2011;140(5, Suppl 1):s992.\*
207. **Shaheen NJ**, Denison H, Björck K, Silberg DG. Prevalence of esophageal mucosal breaks in patients with gastroesophageal reflux disease who have a partial response to proton pump inhibitor therapy. Presented at DDW, 2011, Chicago, IL. Gastrointestinal Endoscopy 2011;73(4, Suppl):ab281.
208. **Shaheen NJ**, Denison H, Björck K, Karlsson M, Silberg DG. Efficacy of a novel  $\gamma$ -aminobutyric acid type B receptor (GABA<sub>B</sub>) agonist, lesogaberan, as an add-on to proton pump inhibitor (PPI) therapy in the treatment of gastroesophageal reflux disease in patients who have a partial response to PPI therapy. Presented at DDW, 2011, Chicago, IL. Gastroenterology 2011;140(5, Suppl 1):s580.
209. **Shaheen NJ**, Denison H, Björck K, Silberg DG. Safety profile of a novel  $\gamma$ -aminobutyric acid type B receptor (GABA<sub>B</sub>) agonist, lesogaberan, as an add-on to proton pump inhibitor (PPI) therapy in the treatment of gastroesophageal reflux disease in patients who have a partial response to PPI therapy. Presented at DDW, 2011, Chicago, IL. Gastroenterology 2011;140(5, Suppl 1):s577.
210. **Shaheen NJ**, Wang KK, Wolfsen HC, Fleischer DE, Overholt BF, Galanko JA, Lightdale CJ. Durability of Reversion to Neosquamous Epithelium follow Radiofrequency Ablation for Dysplastic BE: Longterm Follow-up of the AIM Dysplasia Trial. Presented at DDW, 2011, Chicago, IL. Gastroenterology 2011;140(5, Suppl 1):s179.\*
211. **Shaheen NJ**, Fleischer DE, Eisen GM, Wang KK, Peery AF, Infantolino A, Chak A, Wolfsen HC, Falk GW, Muthasamy VR, Lightdale CJ. Durability of Epithelial reversion after radiofrequency ablation: Follow-up of the AIM Dysplasia trial. Presented at DDW, 2010, New Orleans, LA. Gastroenterology 2010;138(5, Suppl 1).\*
212. Terry NG, Zhu Y, Gebhart SC, Brown WJ, Bright SD, Zieffle C, Woosley JT, **Shaheen NJ**, Wax A. Detection of dysplasia in Barrett's esophagus with angle-resolved low coherence interferometry. Presented at DDW, 2010, New Orleans, LA. Gastroenterology 2010;138(5, Suppl 1) 511c.\*
213. Crockett SD, Lipcus I, Bright SD, Campbell M, Sampliner RE, Wang KK, Boolchand V, Lutzke LS, Carr C, Fowler B, Walsh J, **Shaheen NJ**. Do numeracy skills impact cancer risk perception in Barrett's esophagus? Presented at DDW, 2010, New Orleans, LA. Gastroenterology 2010;138(5, Suppl 1) M1099.\*
214. Dellon ES, Chen X, Miller CR, Fritchie KF, Rubinas TC, Woosley JT, **Shaheen NJ**. Presence of tryptase positive mast cells in the esophageal epithelium differentiates eosinophilic esophagitis from gastroesophageal reflux disease. Presented at DDW, 2010, New Orleans, LA. Gastroenterology 2010;138(5, Suppl 1) 875.\*
215. Dellon ES, Madanick RD, Fritchie KF, Rubinas TC, Woosley JT, **Shaheen NJ**. Eosinophilic esophagitis in patients with an endoscopically normal esophagus: Clinicopathologic features and time trends. Presented at DDW, 2010, New Orleans, LA. Gastroenterology 2010;138(5, Suppl 1) S1078.

216. Halsey KD, Heath J, Petruzzo B, Madanick RD, Dellon ES, **Shaheen NJ**, Greenwald BD. Eosinophilic infiltration of the distal esophagus following endoscopic ablation of Barrett's esophagus. Presented at DDW, 2010, New Orleans, LA. *Gastroenterology* 2010;138(5, Suppl 1) M1110.\*
217. Dellon ES, Fritchie KF, Rubinas TC, Woosley JT, **Shaheen NJ**. Are there racial differences in the clinical, endoscopic, and histologic features of eosinophilic esophagitis? Presented at DDW, 2010, New Orleans, LA. *Gastroenterology* 2010;138(5, Suppl 1) S1077.
218. Dellon ES, Gibbs W, Fritchie K, Rubinas T, Wilson L, Woosley JT, **Shaheen NJ**. Can eosinophilic esophagitis be differentiated from gastroesophageal reflux disease? A clinicopathologic case-control study. Presented at the Annual Meeting of the American College of Gastroenterology, 2009, San Diego, CA. *American Journal of Gastroenterology* 2009;104(10 Suppl).
219. Dellon ES, Gibbs W, Fritchie K, Rubinas T, Wilson L, Woosley JT, **Shaheen NJ**. Progression of symptoms and endoscopic findings with age: Clues of the natural history of eosinophilic esophagitis? Presented at the Annual Meeting of the American College of Gastroenterology, 2009, San Diego, CA. *American Journal of Gastroenterology* 2009;104(10 SUPPL.).
220. Dellon ES, Madanick RD, **Shaheen NJ**. Narrow band imaging highlights endoscopic findings in eosinophilic esophagitis. Presented at the Annual Meeting of the American College of Gastroenterology, 2009, San Diego, CA. *American Journal of Gastroenterology* 2009;104(10 SUPPL.).
221. Madanick RD, Ezzedine S, Dellon ES, Patel S, Morgan DR, **Shaheen NJ**. Results of esophageal pH-Impedance testing at a tertiary care center demonstrate high rates of persistently abnormal esophageal acid exposures on acid suppressive therapy. Presented at the Annual Meeting of the American College of Gastroenterology, 2009, San Diego, CA. *American Journal of Gastroenterology* 2009;104(10 SUPPL.).
222. Madanick RD, Ezzedine S, Dellon ES, Patel S, Morgan DR, **Shaheen NJ**. Management based upon pH Impedance results varies significantly between patients and across age groups. Presented at the Annual Meeting of the American College of Gastroenterology, 2009, San Diego, CA. *American Journal of Gastroenterology* 2009;104(10 SUPPL.).
223. Garmin KS, Acharya CR, Madanick RD, Provenzale D, Potti A, **Shaheen NJ**. Distinguishing biologically relevant phenotypes in Barrett's esophagus: a microarray analysis. Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;136 (Suppl 1): T1914.
224. Jovov B, **Shaheen NJ**, Djukic Z, Orlando RC. E-cadherin cleavage in gastroesophageal reflux disease. Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;136 (Suppl 1): M1834.
225. Dellon ES, Fritchie KJ, Rubinas TC, Woosley JT, **Shaheen NJ**. Inter- and intra-observer reliability for determination of eosinophil counts in patients with esophageal eosinophilia. Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;136 (Suppl 1): S1865.
226. Dellon ES, Fritchie KJ, Rubinas TC, Woosley JT, **Shaheen NJ**. Validity of a novel method for assessing eosinophil counts in esophageal biopsies using virtual microscopy. Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;136 (Suppl 1): S1865.
227. Dellon ES, Gibbs WB, Rubinas TC, Fritchie KJ, Woosley JT, **Shaheen NJ**. Esophageal dilation in eosinophilic esophagitis: safety and predictors of clinical response and complications. Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;136 (Suppl 1): S1863.

228. Jin Z, Cheng Y, Gu J, Zheng Y, Mori Y, Olaru A, Bogdan CP, Kan T, Hamilton JP, Selaru FM, David S, Wolfsen HC, Wallace MB, **Shaheen NJ**, Washington MK, Wang JS, Canto MI, Bhattacharyya AK, Nelson MA, Wagner PD, Romero Y, Wang KK, Feng Z, Sampliner RE, Meltzer SJ. A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;136 (Suppl 1): 197.\*
229. Greenwald BD, Dumont JA, Abrams JA, Lightdale CJ, Mallat DB, David DS, Nishioka NS, Burdick SJ, Johnston MH, **Shaheen NJ**, Wolfsen HC. Endoscopic spray cryotherapy for esophageal cancer: safety and efficacy. Presented at DDW, 2009, Chicago, IL. *Gastrointestinal Endoscopy* 2009; 69(5): AB349.
230. **Shaheen NJ**, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, Bronner MP, Goldblum JR, et al. How durable is the reversion to neosquamous epithelium in subjects undergoing radiofrequency ablation for dysplastic Barrett's esophagus? Two year follow-up of the AIM-Dysplasia randomized, sham-controlled trial. Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;1069 (Suppl 1): W1822.\*
231. **Shaheen NJ**, Bright SD, Madanick RD, Buckmire RA, Couch ME, Dellon ES, Galanko J, Sharpless V, Morgan D, Carretta EE, Spacek M, Heidt P, Henke DC. What is the efficacy of acid suppression in chronic cough? Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;136 (Suppl 1): 491.\*
232. **Shaheen NJ**, Greenwald BD, Dumot JA, Wolfsen HC, Abrams JA, Burdick SJ, Barthel JS, Wang KK, Johnston MH, Nishioka NS, Mallat DB, Zfass AM, Smith JO, Lightdale CJ. Safety and efficacy of spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Presented at DDW, 2009, Chicago, IL. *Gastrointestinal Endoscopy* 2009; 69(5): AB357.
233. Wang KK, Fritcher EB, Halling KC, Nelson MA, Bhattacharyya AK, Zheng Y, Gu J, **Shaheen NJ**, Canto MI, Wang JS, Wolfsen HC, Lutzke LS, Romero Y, Meltzer SJ, Ding IY, Sampliner RE. The use of FISH in a multi-center blinded study to predict the development of neoplasia in Barrett's esophagus. Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;136 (Suppl 1): 1035.\*
234. Wax A, Terry NG, Zhu Y, Gebhart SC, Brown WJ, Bright SD, Carretta EE, Woosley JT, **Shaheen NJ**. Detection of dysplasia in Barrett's esophagus with angle-resolved low coherence interferometry. Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;136 (Suppl 1): T1881.
235. Peery AF, Madanick RD, Dellon ES, Galanko J, **Shaheen NJ**. What is the effect of anti-reflux surgery on pulmonary function testing and mortality in lung transplant recipients with acid reflux? Presented at DDW, 2009, Chicago, IL. *Gastroenterology* 2009;136 (Suppl 1): W1822.
236. Mody R, Meissner B, **Shaheen NJ**. Examination of proton pump inhibitor (ppi) utilization among gastroesophageal reflux (gerd) patients using electronic medical records (EMR). Accepted by International Society for Pharmacoeconomics and Outcomes Research 2009, Barcelona, Spain.
237. **Shaheen NJ**, Peura D, Perez MC et al. Impact of baseline LA grade on healing of erosive esophagitis (EE) following treatment with TAK-390MR, a proton pump inhibitor (PPI) with a novel dual delayed release formulation, compared to lansoprazole. *American Journal of Gastroenterology*. Presented at the Annual Meeting of the American College of Gastroenterology, 2008, Orlando, FL. *Gastroenterology* 2008; 103: S10-11.
238. Dellon ES, Gibbs W, Rubinas T, Fritchie K, Woosley J, **Shaheen NJ**. Seasonal variation in the diagnosis of eosinophilic esophagitis: A case-control analysis. *American Journal of*

Presented at the Annual Meeting of the American College of Gastroenterology, 2008, Orlando, FL Gastroenterology 2008; 103: S20.\*

239. Dellon ES, Farrell T, Bozyski E, **Shaheen NJ**. Diagnosis of eosinophilic esophagitis after prior Nissen fundoplication for presumed “refractory GERD”: Implications for pre-operative evaluation. Presented at the Annual Meeting of the American College of Gastroenterology, 2008, Orlando, FL. American Journal of Gastroenterology 2008; 103: S20.
240. Moody R, Meissner B, **Shaheen NJ**. Utilization and costs of medical services among gastroesophageal reflux patients using “real world” data. American Journal of Presented at the Annual Meeting of the American College of Gastroenterology, 2008, Orlando, FL. Gastroenterology 2008; 103: S398.
241. Muthusamy VR, Rastogi A, Edmundowicz SA, **Shaheen NJ**, Sharma P, Chang KJ. The utility of endoscopic ultrasound (eus) in patients with Barrett’s esophagus (BE) and high grade dysplasia (HGD): Analysis of the Aim Dysplasia trial experience. Presented at DDW, 2008, San Diego, CA. Gastrointest Endosc 2008; 67: AB99.\*
242. Sharma P, **Shaheen NJ**, Perez MC, Pilmer B, Lee M, Peura DA. TAK-390MR, a proton pump inhibitor (PPI) with a novel dual delayed release (DDR) formulation, is highly effective in the healing of erosive esophagitis (EE): Data from two randomized controlled trials. Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1): S1073.
243. Dellon ES, Gibbs WB, Woosley JT, Rubinas TC, **Shaheen NJ**. Increasing incidence of eosinophilic esophagitis: a persistent trend after accounting for procedure indication and biopsy rate. Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1):S1972.
244. Sharma P, Sampliner RE, Hoffman B, Jobe BA, Hunter JG, **Shaheen NJ**. Clinical and endoscopic characteristics of a large cohort of Barrett’s esophagus (BE) patients with low and high-grade dysplasia. Presented at DDW, 2008, San Diego, CA. Gastrointest Endosc 2008; 67: AB174.
245. Dellon ES, Madanick RD, Edmundowicz SA, Hawes RH, Jobe BA, **Shaheen NJ**. Biopsy yield of dysplastic Barrett’s esophagus based on location within the barrett’s segment. Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1): M1933.
246. Bumgarner JM, Panjehpour M, Long M, Dellon ES, Overholt BF, **Shaheen NJ**. Comparison of catheter-based radiofrequency ablation and photodynamic therapy for Barrett’s esophagus. Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1): M1942.
247. Rubenstein JH, Kao JY, Madanick RD, Zhang M, Wang M, Spacek M, Donovan J, Bright SD, **Shaheen NJ**. The association of circulating adiponectin multimers with Barrett’s esophagus. Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1): M1950.
248. Chen XL, Ma Y, Qin R, Madanick RD, Orlando RC, **Shaheen NJ**. Differential expression of tight junction proteins in Barrett’s metaplasia, dysplasia and (esophageal) adenocarcinoma. Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1): M1967.
249. Lippmann QK, Madanick RD, Spacek M, Heidt P, Morgan DR, Bright SD, Zimmer C, **Shaheen NJ**. Psychological well-being and quality of life (QoL) in Barrett’s esophagus (BE) compared to gastroesophageal reflux disease (GERD). Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1): M1027.
250. **Shaheen NJ**, Sharma P, Overholt BF, Lightdale CJ, Wolfsen HC et al. A randomized, multicenter, sham-controlled trial of radiofrequency ablation (RFA) for subjects with Barrett’s

esophagus (BE) containing Dysplasia: Interim results of the AIM Dysplasia Trial. Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1): 213.\*

251. **Shaheen NJ**, Wolfsen HC, Hawes RH, Rothstein RI, Spechler SJ, Galanko J, Bright SD, Infantolino A, Siddiqui A. Impact of Barrett's esophagus containing dysplasia on patient quality of life: Interim results of a randomized, sham-controlled trial of radiofrequency ablation (AIM Dysplasia trial). Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1): M1030.
252. **Shaheen NJ**, Bronner MP, Fleischer DE, Rothstein RI, Sharma VK, Lightdale CJ, Overholt BF, Eisen GM, Sampliner RE, Sharma P, Bennett AE. subsquamous intestinal metaplasia is a common finding in ablation-naive patients with dysplastic Barrett's esophagus, and significantly decreases in prevalence after radiofrequency ablation. Presented at DDW, 2008, San Diego, CA. Gastrointest Endosc 2008; 67: AB176.
253. Lightdale CJ, Overholt BF, Wang KK, Mashimo H, Sharma VK, Fleischer DE, Galanko J, **Shaheen NJ**, Sharma P. Predictors and quantitative assessment of incomplete response after radiofrequency ablation for dysplastic Barrett's esophagus: analysis of randomized sham-controlled clinical trial (the AIM Dysplasia Trial). Presented at DDW, 2008, San Diego, CA. Gastrointest Endosc 2008; 67: AB182.
254. Sampliner RE, Wang KK, **Shaheen NJ**, Wolfsen HC, Wang JS, Meltzer SJ, Washington K, Gu J, Zheng Y. Interspire/EDRN Barrett's esophagus (BE) Study: Interim report of a multicenter case-control study of progressors to high-grade dysplasia/adenocarcinoma vs. nonprogressors. Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1): M1995.
255. **Shaheen NJ**, Goldblum JR, Sampliner RE, Chak A, Wang KK, Fennerty MB, Hawes RH, Hunter JG. Are biopsies after ablation for dysplastic Barrett's esophagus of adequate depth to detect glandular mucosa beneath the neosquamous epithelium? Comparative histopathological outcomes from a randomized, sham-controlled trial (AIM Dysplasia Trial). Presented at DDW, 2008, San Diego, CA. Gastroenterology 2008; 134 (Suppl 1): W1876.
256. Dellon ES, Lippman QK, Galanko J, **Shaheen NJ**. Nurse experience: A strong and previously unidentified predictor of screening colonoscopy complications. Presented at DDW, 2007, Washington, D.C. Gastroenterology 2007; 132 (Suppl 2):A129.\*
257. Dellon ES, Lippman QK, Galanko J, **Shaheen NJ**. Endoscopy nurse experience predicts screening colonoscopy procedure times and cecal intubation rates. Presented at DDW, 2007, Washington, D.C. Gastroenterology 2007; 132 (Suppl 2):A128.\*
258. Jovov B, Van Itallie CM, Carson JL, **Shaheen NJ**, Anderson JM, Orlando RC. Does claudin expression play a role in the acid resistance of Barrett's esophagus? Presented at DDW, 2007, Washington, D.C. Gastroenterology 2007; 132: A261.
259. Inadomi JM, Madanick RD, Somsouk MA, **Shaheen NJ**. Radiofrequency ablation is more cost-effective than endoscopic surveillance or esophagectomy among patients with Barrett's esophagus and low-grade dysplasia. Presented at DDW, 2007, Washington, D.C. Gastroenterology 2007; 132: A53.\*
260. **Shaheen NJ**, Wolfsen HC, Hawes RH et al. Impact of a diagnosis of dysplastic Barrett esophagus on quality of life parameters and willingness to enroll in a randomized sham-controlled trial of ablation (U.S. AIM Dysplasia Trial). Presented at DDW, 2007, Washington, D.C. Gastroenterology 2008; 134: A323.
261. Rothstein RI, Chang K, Overholt BF, Bergman JJ, **Shaheen NJ**. Focal ablation for treatment of dysplastic Barrett esophagus: Safety profile and initial experience with the Halo

90 device in 508 cases. Presented at DDW, 2007, Washington, D.C. Gastrointestinal Endoscopy 2007; 65: AB147.

262. Ganz RA, Overholt BF, Sharma VK, Panjepour M, DeMeester SR, Bohorfoush A, Freeman SR, Eysselein VE, Gress FG, Branch MS, Chang K, Muthusamy VR, Pace SC, Pruitt RE, Fleischer DE, **Shaheen NJ**, Triadafilopoulos G. Halo 360 Circumferential ablation is safe and effective for the treatment of Barrett esophagus and high-grade dysplasia: A US Multi-Center Registry. Presented at DDW, 2007, Washington, D.C. Gastroenterology 2007; 132 (suppl 2): S1336.
263. Glenn DL, Madanick RD, Galanko J, Sharpless G, **Shaheen NJ**. Is NSAID use associated with a lower risk of Barrett's esophagus in patients with GERD symptoms? A case-control study. Presented at DDW, 2007, Washington, D.C. Gastroenterology 2007; 132 (Suppl 2): A262.
264. Vaughn B, Madanick R, Heidt-Davis P, **Shaheen NJ**. Gastroesophageal reflux in chronic sleep maintenance insomnia. Presented at the Annual Meeting of the Association of Professional Sleep Societies, Minneapolis, MN. Sleep 2007; 30: A313.
265. Dellon ES, Sandler RS, **Shaheen NJ**. GI endoscopy nurse experience predicts polyp detection during screening colonoscopy. Presented at American College of Gastroenterology National Meeting, Philadelphia, PA. Am J Gastroenterol 2007; 102 (S2): S433 (A855).
266. Madanick R, Cheng N, Crawford S, **Shaheen NJ**. Esophageal Impedance detection of cycling, a specific finding in GERD. Presented at American College of Gastroenterology National Meeting, Philadelphia, PA. Am J Gastroenterol 2007; 102 (S2): S154.
267. Peery AF, Madanick RD, Galanko JA, **Shaheen NJ**. What is the incidence of acidic and non-acidic gastroesophageal reflux in lung transplant recipients? Presented at American College of Gastroenterology National Meeting, Philadelphia, PA. Am J Gastroenterol 2007; 102 (S2): S156.
268. Puli SR, Westhoff B, **Shaheen NJ**, Wei J, Slehria S, Bansal A, Rastogi A, Sharma P. Incidence of esophageal adenocarcinoma after endoscopic ablative therapy for Barrett's esophagus: a systematic review and meta analysis. Presented at DDW, 2006, Los Angeles, CA. Gastroenterology 2006; 130 (Suppl 2): T1011.
269. Fisher DA, Galanko J, Dudley TK, **Shaheen NJ**. Comorbidity and colorectal cancer screening utilization in a national sample of Veterans Health Administration patients. Presented at DDW, 2006, Los Angeles, CA. Gastroenterology 2006; 130: A37.\*
270. **Shaheen NJ**, Berenson K, Doyle J, Brown K. How do consumers take "over-the-counter" omeprazole? Presented at DDW, 2006, Los Angeles, CA. Gastroenterology 2006; 130: A172.
271. Fisher DA, Johnson MR, **Shaheen NJ**. Mail return of fecal occult blood testing is low in a VA population and strongly related to race: a retrospective study. Presented at DDW, 2006, Los Angeles, CA. Gastroenterology 2006; 130: A617.
272. **Shaheen NJ**, Spacek MB, Galanko JA, Heidt-Davis P. Cigarette smoking and Barrett's esophagus: A case-control study. Presented at DDW, 2006, Los Angeles, CA. Gastroenterology 2006; 130: A565.
273. **Shaheen NJ**, Monyak JT, Brown KA. Does treatment satisfaction correlate with absence of esophageal mucosal pathology (EMP) in users of prilosec OTC? Presented at American College of Gastroenterology, 2006, Las Vegas, NV. Am J Gastroenterol 2006; 101: S49.

274. **Shaheen NJ**, Monyak JT, Brown KA. Prevalence of clinically relevant esophageal mucosal pathology in subjects who self-initiate use of prilosec OTC. Presented at American College of Gastroenterology, 2006, Las Vegas, NV. *Am J Gastroenterol* 2006; 101: S49.
275. Ringel Y, Shah R, Hu Y, Morris CB, Bangdiwala SI, **Shaheen NJ**, Whitehead WE, Drossman DA. Esophageal symptoms in patients with Functional Esophageal Disorders (FED) are predicted by psychological but not physiological factors. Presented at DDW 2005, Chicago, IL. *Gastroenterology* 2005; 128: A66.\*
276. **Shaheen NJ**, Walzer N. Abnormal distal esophageal acid exposures do not predict response to acid suppressive therapy in subjects with heartburn symptoms and normal upper endoscopy. Presented at DDW 2005, Chicago, IL. *Gastroenterology* 2005; 128: A-396.
277. Brown A, Behrns K, Grimm IS, Morton J, **Shaheen NJ**. Mortality and Incidence associated with pancreatic cancer are significantly decreasing in African Americans (AA) compared to other racial groups: A comparison of national population and hospital based trends from 1992-2002. Presented at DDW 2005, Chicago, IL. *Gastroenterology* 2005; 128: A-558.
278. Mitchell KL, Heidt P, Galanko JA, Choi S, **Shaheen NJ**. A negative upper endoscopy leads to a decrease in patient anxiety: a prospective, longitudinal study. Presented at DDW 2005, Chicago, IL. *Gastroenterology* 2005; 128: A-538.
279. **Shaheen NJ**, Mitchell KL, Spacek M, Davis P, Galanko JA, Sandler RS. Body fat distribution predicts the presence of Barrett's esophagus: a case-control study. Presented at DDW 2005, Chicago, IL. *Gastroenterology* 2005; 128: A-231.
280. Hansen RA, Schommer JC, **Shaheen NJ**. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising. Presented at DDW 2005, Chicago, IL. *Gastroenterology* 2005; 128: A-336.
281. Johnson TG, **Shaheen NJ**. The etiology of diarrheal illness in a Sub-Saharan African Country. Presented at American College of Gastroenterology National Meeting, 2005, Honolulu, HI. *Am J Gastroenterol* 2005; 100: S377.
282. **Shaheen NJ**, Hocutt BL, Schmitz SM, Lawrence KR. What is the Positive Predictive Value of Endoscopy for BE? Presented at DDW, 2004, New Orleans, LA. *Gastroenterology* 2004; 126:A179.
283. **Shaheen NJ**, Hocutt BL, Schmitz SM, Lawrence KR. Referral source is associated with outcome in Barrett's esophagus. Presented at DDW 2004, New Orleans, LA. *Gastroenterology* 2004; 126: A180.
284. Wei JT, Green B, Schmitz SM, Noble M, Provenzale D, **Shaheen NJ**. Internet users with Barrett's esophagus overestimate their cancer risk. Presented at DDW 2004, New Orleans, LA. *Gastroenterology* 2004; 126: A113.\*
285. Slehria S, Wei JT, Hall M, **Shaheen NJ**, Sharma P. Endoscopic ablation therapies for Barrett's esophagus: A meta-analysis of incidence of adenocarcinoma in patients with Barrett's esophagus undergoing ablation. Presented at DDW 2004, New Orleans, LA. *Gastroenterology* 2004;126:A50.\*
286. Ringel Y, Drossman DA, Dyson T, **Shaheen NJ**, Morris C, Hu Y, Bangdiwala SI, Whitehead WE. Characterization of physiological and psychological factors in functional esophageal disorders (FED). Presented at DDW 2004, New Orleans, LA. *Gastroenterology* 2004; 126:A28.\*



287. Shaheen AW, Palker T, Walter EB, Galanko JA, **Shaheen NJ**, Dolor RJ. Prescription medication sharing in primary care. Presented at the Society of General Internal Medicine's Annual National Meeting, May 17, 2004, Chicago, IL. *JGIM* 2004; 19 (Suppl 1): 197.\*
288. **Shaheen NJ**, Stuart S, Schmitz SM, Mitchell KL, Fried MW, Zacks S, Russo MW, Galanko J, Shrestha R. Pantoprazole reduces the size of post-banding ulcers after elective endoscopic variceal band ligation: a randomized, controlled trial. Presented at American College of Gastroenterology National Meeting, 2004, Orlando, FL. *Am J Gastroenterol* 2004; 99: S72.\*
289. Sultan S, Badreddine R, **Shaheen NJ**, Provenzale D. Validity of self-reported endoscopic surveillance history in patients with Barrett's esophagus. Presented at American College of Gastroenterology National Meeting, 2004, Orlando, FL. *Am J Gastroenterol* 2004; 99: S237.
290. Lawrence KR, Schmitz SM, Levinson S, Malkin M, Brody M, Galanko J, **Shaheen NJ**. The effect of a negative screening upper endoscopy on quality of life and health-related anxiety in patients with GERD. Presented at American College of Gastroenterology National Meeting, 2004, Orlando, FL. *Am J Gastroenterol* 2004; 99: S25.
291. **Shaheen NJ**, Ali S, Schmitz S. Should subjects with symptoms of extra-esophageal reflux undergo endoscopy for Barrett's screening? Presented at Digestive Diseases Week, 2003, Orlando, FL. *Gastroenterology* 2003; 124: A640.
292. **Shaheen NJ**, Inadomi JM, Sharma P, Overholt BF. What is the best management strategy for high grade dysplasia in Barrett's esophagus? A cost-effectiveness analysis. Presented at Digestive Diseases Week, 2003, Orlando, FL. *Gastroenterology* 2003; 124: A33-34.\*
293. **Shaheen NJ**, Provenzale D, Schmitz SM, Green B, Wei J. Patients with Barrett's esophagus greatly over-estimate their risk of esophageal adenocarcinoma. Presented at the American College of Gastroenterology National Meeting, 2003, Baltimore, MD. *Am J Gastroenterol* 2003; 98: S20.
294. **Shaheen NJ**, Ascher B, Schmitz SM. How much does a diagnosis of Barrett's esophagus raise life insurance premiums? Presented at the American College of Gastroenterology National Meeting, 2003, Baltimore, MD. *Am J Gastroenterol* 2003; 98: S222.\*
295. Green B, **Shaheen NJ**, Noble M, Schmitz SM, Wei JT, Provenzale D. Information sources and cancer risk in subjects with Barrett's esophagus. Presented at the American College of Gastroenterology National Meeting, 2003, Baltimore, MD. *Am J Gastroenterol* 2003; 98: S228.\*
296. Brown A, Schmitz SM, Kraft D, Martin C, Sharpless G, **Shaheen NJ**. Who pays for clinical GI research? Presented at the American College of Gastroenterology National Meeting, 2003, Baltimore, MD. *Am J Gastroenterol* 2003; 98: S230.\*
297. Brown A, Schmitz SM, Kraft D, Martin C, Sharpless G, **Shaheen NJ**. The study funding source is associated with study quality in GI research. Presented at the American College of Gastroenterology National Meeting, 2003, Baltimore, MD. *Am J Gastroenterol* 2003; 98: S235.
298. Brown A, Schmitz SM, Kraft D, Martin C, Sharpless G, **Shaheen NJ**. Where are the negative clinical studies? An assessment of reported outcomes in the GI literature. Presented at the American College of Gastroenterology National Meeting, 2003, Baltimore, MD. *Am J Gastroenterol* 2003; 98: S230.
299. Chand N, Miller C, Cassara J, Ruffin K, Cattau EL, **Shaheen N**, Stanley S, Johnson D. Barrett's surveillance per the ACG guidelines. Do we really do what they say? Presented at

the American College of Gastroenterology National Meeting, 2003, Baltimore, MD. Am J Gastroenterol 2003; 98: S20.

300. Wei JT, Sharma P, **Shaheen NJ**. Endoscopic ablation therapies for Barrett's esophagus: A systematic review and meta-analysis of stricture complications. Presented at the American College of Gastroenterology National Meeting, 2003, Baltimore, MD. Am J Gastroenterol 2003; 98: S33.
301. Wang DL, Schindler BA, Yager J, Cohen D, Novak D, Wilkerson L, **Shaheen N**. Taking the Pulse of academic faculty: Are there gender differences? Psychosomatics 2003; 44: 149A.
302. Corey KE, Schmitz SM, **Shaheen NJ**. Does a surgical anti-reflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A Meta-Analysis. Presented at Digestive Diseases Week, 2002, San Francisco, CA. Gastroenterology 2002; 122: A292.
303. Goodgame B, El-Serag HB, **Shaheen NJ**, Galanko JA. The risk of cirrhosis and hepatocellular carcinoma among HCV-infected patients: A systematic review. Presented at Digestive Diseases Week, 2002, San Francisco, CA. Gastroenterology 2002; 123: 50.
304. Heider TR, Behrns KE, Koruda MJ, **Shaheen NJ**, Lucktong TA, Bradshaw B, Farrell TM. Fundoplication improves disordered esophageal motility. Presented at Digestive Diseases Week, 2002, San Francisco, CA. Gastroenterology 2002; 123: 30.
305. **Shaheen NJ**, Silverman LM, Lawrence LB, Rohlfis EM, Buse JB, Sandler RS. Are hemochromatosis gene mutations a risk factor for type 2 diabetes? Presented at Digestive Diseases Week, 2001. Gastroenterology 2001; 120: A227.
306. Ringel Y, Drossman DA, **Shaheen NJ**, Keeter LE, Jones KR, Burnett CK, Whitehead WE. esophageal muscle tone predicts esophageal sensation in patients with functional esophageal disorders and healthy controls. Presented at Digestive Diseases Week, 2001. Gastroenterology 2001; 120: A 220.
307. Lucktong TA, **Shaheen NJ**, Farrell TM. Resection of benign esophageal stricture through a minimally invasive endoscopic and transgastric approach. Presented at the Southern Surgical Society, 2001. American Surgeon 2002; 68: 720-23.\*
308. Ringel Y, Jones KR, **Shaheen NJ**, Burnett CK, Bradshaw B, Whitehead WE, Drossman DA. Esophageal motility and sensory response to non-painful and painful intraluminal esophageal balloon distensions by barostat in healthy subjects. Presented at Digestive Diseases Week, 2000. Gastroenterology 2000; 118: A386.
309. **Shaheen NJ**, Sandler RS, Silverman LM, et al. Are hemochromatosis gene mutations a risk factor for colon cancer? Presented at Digestive Diseases Week, 2000. Gastroenterology 2000; 118: A703.\*
310. **Shaheen NJ**, Lawrence LB, richrich DJ, Sandler RS. Quality of colonoscopy reporting: a process of care study. Presented at Digestive Diseases Week, 2000. Gastroenterology 2000; 118: A465.
311. Robertson DJ, **Shaheen NJ**, Sandler RS. 6-MP is the most cost-effective therapy after surgical resection in Crohn's disease? Presented at Digestive Diseases Week, 2000. Gastroenterology 2000; 118: A891.
312. Ringel Y, Jones KR, **Shaheen NJ**, Burnett CK, Bradshaw B, Drossman DA, Whitehead WE. Comparison of different methods for measurement of esophageal sensation by barostat. Presented at American College of Gastroenterology Meeting, 2000. American Journal of Gastroenterology 2000; 95: A70.

313. Sachdeva N, Ryan J, **Shaheen NJ**, Bozymski EM. Pneumopericardium secondary to esophagopericardial fistula. Presented at American College of Gastroenterology Meeting, 2000. American Journal of Gastroenterology 2000; 95: A660.
314. **Shaheen NJ**, Lawrence LB, Bacon BR, Barton JC, Barton N, Galanko JA, Martin CF, Sandler RS. The incidence of self-reported genetic discrimination in hemochromatosis. Presented at American College of Gastroenterology Meeting, 2000. American Journal of Gastroenterology 2000; 95: A788.
315. **Shaheen NJ**, Crosby MA, Bozymski EM. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Presented at Digestive Diseases Week, 1999. Gastroenterology 1999; 116: G0404.
316. **Shaheen NJ**, Crosby MA, O'Malley MS, Ransohoff DF, Sandler RS, Murray SC, Galanko JA. Clinician's attitudes toward the performance of colorectal cancer screening measures by non-physician clinicians. Presented at Digestive Diseases Week, 1999. Gastroenterology 1999; 116: G2200.
317. Ofman JJ, **Shaheen NJ**, Desai AA, Moody B, Bozymski EM, Weinstein WM. Assessing process of care in Barrett's esophagus. Presented at Digestive Diseases Week, 1999. Gastroenterology 1999; 116: G0368.
318. **Shaheen NJ**, Robertson DJ, Crosby MA, Furs S, May D, Harlan W, Grimm IS, Isaacs KL, Bozymski EM. Does premedication with either intravenous or oral hyoscyamine facilitate colonoscopy? Presented at Digestive Diseases Week, May, 1998. Gastrointestinal Endoscopy 1998; 47: A46.
319. **Shaheen NJ**, Braun M, Grimm IS, Bacon BR, Sandler RS, Downs S. Liver biopsy vs. genetic analysis for the diagnosis of hereditary hemochromatosis: A decision analysis. Presented at Digestive Diseases Week, May, 1998. Gastroenterology 1998; 114: L0580.
320. Crosby MA, **Shaheen NJ**, O'Malley MS, Murray SC, Klenzak JS, Ransohoff DF, Sandler RS, Mulherin S. Factors associated with colorectal cancer screening: the North Carolina primary care physician screening survey. Presented at the 1998 American College of Gastroenterology Meeting, October 1998. American Journal of Gastroenterology 1998; 93: 1686.
321. **Shaheen NJ**, Crosby MA, O'Malley MS, Murray SC, Klenzak JS, Ransohoff DF, Sandler RS, Galanko JA, Cummings M, Holliday J, Lengerich E, White M. Practices and attitudes of nurse practitioners and physician assistants with respect to colorectal cancer screening: The North Carolina NP and PA CRC Screening Survey. Presented at the 1998 American College of Gastroenterology Meeting, October 1998. American Journal of Gastroenterology 1998; 93: 1699.\*
322. **Shaheen NJ**, Klenzak JS, Furs S, Grimm IS, Russo M, Isaacs KL, Bozymski EM. Elective esophageal variceal band ligation: is overnight observation necessary? Abstract presented at Digestive Diseases Week, May, 1997. Gastrointestinal Endoscopy 1997; 45: 230.
323. Furs S, Isaacs KL, Bozymski EM, **Shaheen NJ**, Grimm IS, Harlan W, Scarlett Y. Endoluminal formalin therapy for refractory radiation-induced hemorrhagic proctitis. Abstract presented at Digestive Diseases Week, May, 1997. Gastrointestinal Endoscopy 1997; 45: 330.
324. **Shaheen NJ**, Bacon BR, Grimm IS. Clinical characteristics of patients diagnosed with hereditary hemochromatosis who lack the Cys282Tyr mutation. Abstract presented at Digestive Diseases Week, May, 1997. Gastroenterology 1997; 112: A1381.

325. Klenzak JS, Bozymski EM, Sears V, Harlan W, **Shaheen NJ**. Esophagitis: Clinical correlates with disease and symptom reporting. Abstract presented at 1997 National ACG Meeting, October 1997. *American Journal of Gastroenterology* 1997; 92: 1595.\*
326. Robertson DJ, **Shaheen NJ**, Klenzak JS, Grimm IS. An unusual case of persistent fevers. Abstract presented at 1997 National ACG Meeting, October 1997. *American Journal of Gastroenterology* 1997; 92: 1649.
327. Klenzak JS, **Shaheen NJ**, Grimm IS, Furs S. The Baylor score does not predict rebleeding following endoscopic therapy for acute upper gastrointestinal hemorrhage. Abstract presented at Digestive Diseases Week, May, 1996. *Gastrointestinal Endoscopy* 1996; 43: 247.
328. **Shaheen NJ**, Grimm IS. Comparison of the Caldwell Needle with the Angiocath Needle for large volume paracentesis. Abstract presented at American Society of Liver Diseases Annual Meeting, November, 1995. *Hepatology* 1995; 22: 162A.

(\* = Oral Presentation)

### Electronic Resources Created (7)

1. **Shaheen NJ**. Burn All Barrett's Esophagus. ACG Education Universe 2011; C238: <http://universe.gi.org/citation.asp?c=238>.
2. **Shaheen NJ**. Barrett's Esophagus: What to Do for No Dysplasia, LGD and HGD?. ACG Education Universe 2011; C206: <http://universe.gi.org/citation.asp?c=206>
3. Dellon ES, **Shaheen NJ**. Cryoablation for Barrett's esophagus with high grade dysplasia. *The DAVE Project*. Posted April 15, 2010. [http://daveproject.org/ViewFilms.cfm?film\\_id=919](http://daveproject.org/ViewFilms.cfm?film_id=919).
4. Dellon ES, **Shaheen NJ**. Treating Dysplastic Barrett's Epithelium with the BARRX Device. *The DAVE Project*.
5. Madanick RD, **Shaheen NJ**. Early Gastric Cancer. Up-to-Date, 2008. [http://www.utdol.com/online/content/topic.do?topicKey=gicancer/6577&selectedTitle=2~131&source=search\\_result](http://www.utdol.com/online/content/topic.do?topicKey=gicancer/6577&selectedTitle=2~131&source=search_result).
6. **Shaheen NJ**. Diagnosis of Digestive Disorders. Merck On-Line Medical Library. <http://www.merck.com/mmhe/sec09/ch119/ch119c.html>. May, 2007.
7. **Shaheen NJ**. Symptoms of Digestive Disorders. Merck On-Line Medical Library. <http://www.merck.com/mmhe/sec09/ch119/ch119b.html>. May, 2007.

### National/International Invited Lectures (289)

1. "Approach to the patient with dysphagia in 2022," International Society for Diseases of the Esophagus Annual Meeting, Virtual, September 28, 2022.
2. "Modern management of the post-endoscopic eradication therapy patient," Digestive Diseases Week, San Diego, CA, May 22, 2022.
3. "Maximizing outcomes with endoscopic eradication therapy, Digestive Diseases Week, San Diego, CA, May 22, 2022.

4. "Dilemmas in Barrett's Esophagus," Spring Post-Graduate Course, American Gastroenterological Association, San Diego, CA, May 21, 2022.
5. "Mucosal Ablation," American College of Gastroenterology Annual Meeting, Las Vegas, NV, Oct. 25, 2021.
6. "Barrett's Esophagus - Burn, Freeze, or Observe? Dysplasia Update," American College of Gastroenterology Annual Post-Graduate Course, Las Vegas, NV, Oct 23, 2021.
7. "Barrett's Esophagus Update," Mexican Society of Gastroenterology, Virtual, August 21, 2021.
8. "Should we biopsy a normal Z line?", American Foregut Society Annual Meeting, Virtual, September 26, 2020.
9. The Alvin Zfass State of the Art Lecture, "What we are doing now for Barrett's doesn't work. How can we change it?" Virginia Medical College GI and Liver CME Course, given virtually on August 1, 2020.
10. The Basil Hirschowitz Lecture, "The Evolution of screening, surveillance, and treatment of Barrett's esophagus." ASGE Postgraduate Course, given virtually on July 18, 2020.
11. "New Endoscopic Methods for Treatment of Patients with Barrett's Esophagus," 4th Annual Methodist Digestive Institute Symposium, Irving, TX, February 8, 2020.
12. "Endoscopic Therapy of Barrett's Esophagus," Visiting Professorship, Mount Sinai Hospital, New York City, NY, January 17, 2020.
13. "Controversies in Treating Barrett's Esophagus," New York Society of Gastrointestinal Endoscopy Annual Meeting, New York City, NY, December 20, 2019.
14. "Keynote Address: Why What We Are Doing For Barrett's Doesn't Matter (And What We Can Do to Change It)," New York Society of Gastrointestinal Endoscopy Annual Meeting, New York City, NY, December 19, 2019.
15. "Screening for Barrett's Esophagus," Amsterdam Medical Center, Amsterdam, Netherlands, November 29, 2019.
16. "Endoscopic and Surgical Management of Achalasia," The ACG Annual Post-Graduate Course, San Antonio, TX, October 26, 2019.
17. "Endoscopic Detection of Esophageal Neoplasia." State of the Art Screening and Surveillance for Gastrointestinal Cancers. Rush University Medical Center, Chicago, IL, June 15, 2019.
18. "The Donald O. Castell, MD, Lecture: Controversies in Esophageal Disorders." DDW Clinical Symposium, San Diego, CA, May 19, 2019.
19. "Outcomes in Barrett's Esophagus: Can We Do Better?" ASGE Plenary Session, DDW, San Diego, CA, May 18, 2019.
20. "Role of Ablation in the Management of Barrett's Esophagus." DDW Clinical Symposium, San Diego, CA, May 18, 2019.
21. "Bedside and Didactic Teaching: The Unfunded Mandate in an RVU World!" AGA Division Chiefs Symposium at DDW, San Diego, CA, May 17, 2019.

22. "The David Bull Memorial Lecture: Misplaced Priorities and Barrett's Esophagus." Medical Grand Rounds at Wayne State University. Detroit, MI, May 10, 2019.
23. "Endoscopic Therapy for Barrett's Esophagus." Edgar Achkar ACG Visiting Professorship, Michigan State GI Society, Detroit, MI, May 9, 2019.
24. "Endoscopic Treatment of Esophageal Neoplasia." Visiting Professor, Saint Louis University, St. Louis, MO, April 18, 2019.
25. "Misplaced Priorities and Barrett's Esophagus." Visiting Professor, Washington University, St. Louis, MO, April 17, 2019.
26. "Barrett's Esophagus: An Update on Diagnosis and Treatment." Baylor College of Medicine 19th Annual GI and Liver Course, Houston, TX, March 30, 2019.
27. "Why What We Are Doing for Barrett's Doesn't Much Matter." Gastroenterology & Hepatology Grand Rounds, University of Wisconsin, Madison, WI, February 12, 2019.
28. "Update on Treatment of Barrett's Esophagus." Gastroenterology & Hepatology Grand Rounds, Wake Forest University, Winston-Salem, NC, January 31, 2019.
29. "Endoscopic Management of Esophageal Neoplasia." San Diego GI Society, San Diego, CA, October 18, 2018.
30. "Predicting Progression to Cancer – the Holy Grail." ACG Annual National Meeting, Philadelphia, PA, October 9, 2018
31. "Premalignant Lesions of the Esophagus." ACG Annual Postgraduate Course, Philadelphia, PA, October 7, 2018.
32. "Screening for Barrett's esophagus: Are We There Yet?" Chicago Live Endoscopy Course, Chicago, IL, September 28, 2018.
33. "Barrett's esophagus Controversies." Texas Society for Gastroenterology and Endoscopy Annual Meeting, Austin, TX, September 22, 2018.
34. "Proton Pump Inhibitors: Risks and Realities." Texas Society for Gastroenterology and Endoscopy Annual Meeting, Austin, TX, September 22, 2018.
35. "Eosinophilic Esophagitis: Medical and Endoscopic Management." ACG Midwest Regional Course, Indianapolis, IN, August 26, 2018.
36. "Screening of Barrett's Neoplasia." DDW Clinical Symposium, Washington, DC, June 5, 2018.
37. "Wrap or no wrap after Barrett's ablation?" SSAT Symposium, Washington, DC, June 4, 2018.
38. "The Art of Contract Negotiations." DDW Committee sponsored symposium, Washington, DC, June 3, 2018.
39. "Misplaced Priorities and Barrett's Esophagus." Medical Grand Rounds, Cleveland Clinic, Cleveland, OH, April 19, 2018.
40. "Barrett's esophagus: From Surveillance to Ablation." ACG Eastern Regional Course, Boston, MA, April 14, 2018.

41. "Barrett's Esophagus and Esophageal Cancer." NCI Cancer Prevention Fellowship Program Seminar Series, Washington, DC, April 3, 2018.
42. "Barrett's Esophagus: Shifting Sands." Norton Medical-Surgical Esophageal Conference, Scottsdale, AZ, March 3, 2018.
43. "Surgical Failure: Bad Surgery, Bad Surgeon, Bad Patient or Just Bad Luck?" Norton Medical-Surgical Esophageal Conference, Scottsdale, AZ, March 3, 2018.
44. "Misplaced Priorities and Barrett's Esophagus." GI Grand Rounds, University of Minnesota, Minneapolis, MN, February 1, 2018.
45. "Barrett's esophagus: Diagnosis, Management and Treatment." ACG Governor's Course, Las Vegas, NV, January 26, 2018.
46. "Evaluation and Management of Barrett's Esophagus." ACG Southern Regional Course, Nashville, TN, December 2, 2017.
47. "A cut, A burn, A freeze: What is the best weapon for dysplastic BE?" ACG Annual Meeting Symposium, Orlando, FL, October 17, 2017.
48. "Barrett's: Natural History, When to Ablate, and How?" ACG Annual Postgraduate Course, Orlando, FL, October 14, 2017.
49. "Barrett's esophagus: Diagnosis, Management and Treatment." ASGE Annual Postgraduate Course, Orlando, FL, October 13, 2017.
50. "Oesophageal Neoplasia Masterclass." University College London, London, UK, September 18, 2017.
51. "Treatment of Esophageal Neoplasia," California Pacific Medical Center, San Francisco, CA, September 13, 2017.
52. "Endoscopic therapy of Barrett's Esophagus." 2017 Update in Gastroenterology, University of Alabama-Birmingham, Birmingham, AL, September 9, 2017.
53. "Barrett's Esophagus and HGD: Endoscopic Treatment." World Congress of Surgery, Basel, Switzerland, August 16, 2017.
54. "Evaluation and Treatment of GISTs." World Congress of Surgery, Basel, Switzerland, August 15, 2017.
55. "How to build and maintain a clinical research database." Career Advancement Course, Association for Academic Surgery, Basel, Switzerland, August 13, 2017.
56. "Misplaced Priorities and Barrett's Esophagus." Alberta Society of Gastroenterology Annual Meeting, Lake Louise, Alberta, Canada, May 27, 2017.
57. "Screening for BE: Which Test in Which Patient?" DDW Combined Clinical Symposium, DDW 2017, Chicago, IL, May 6, 2017.
58. "The Size of the Problem: Endoscopic Diagnosis of Esophageal Neoplasia." Cancer Research UK International Symposium on Oesophageal Cancer, Cambridge, UK, April 27, 2017.
59. "Endoscopic Therapy for Esophageal Neoplasia." Medical Grand Rounds, Drexel University School of Medicine, Philadelphia, PA, March 29, 2017.

60. "Misplaced Priorities and Barrett's Esophagus." GI Grand Rounds, University of Michigan, Ann Arbor, MI, March 21, 2017.
61. "Endoscopic Treatment of Early Esophageal Cancer." American Society of Clinical Oncology Annual GI Cancers Symposium 2017, San Francisco, CA, January 19, 2017.
62. "An Evening with the Expert." Mercy Medical Center, Baltimore, Maryland, November 3, 2016.
63. "Misplaced Priorities and Barrett's Esophagus." Medical Grand Rounds, Penn State University School of Medicine, Hershey, PA, November 2, 2016.
64. "Endoscopic Therapy of Barrett's Esophagus." Central Pennsylvania Society of Gastrointestinal Endoscopy, Hershey PA, November 2, 2016.
65. "Trial Design and Clinical Endpoints in GERD." AGA Symposium on Drug Discovery in Gastroenterology & Hepatology, Washington, DC, October 27, 2016.
66. "Personalized Barrett's Management." American College of Gastroenterology National Meeting, Las Vegas, NV, October 18, 2016.
67. "Barrett's Esophagus: Ablate Everyone?" American College of Gastroenterology Annual Post-Graduate Course, Las Vegas, NV, October 16, 2016.
68. "Barrett's Esophagus with Low-Grade Dysplasia." Virginia Gastroenterology Society Annual Meeting, Williamsburg, VA, September 10, 2016.
69. "What is the Risk of Cancer for Cardiac Mucosa?" AGA Freston Conference, Chicago, IL, August 20, 2016.
70. "Endoscopic Eradication Therapy for Barrett's Neoplasia: 10 years later." Chicago Live Endoscopy Course, Chicago, IL, August 14, 2016.
71. "Who Needs Radiofrequency Ablation and When?" University of Manitoba "Diagnostics in Gastroenterology" Forum, Winnipeg, Canada, June 10, 2016.
72. "State of the Art Presentation: What Decides Outcomes After Ablation for Barrett's Esophagus?" AGA Research Forum, DDW 2016, May 24, 2016.
73. "Barrett's Surveillance: Making Sense of the Different Recommendations." SSAT Symposium, DDW 2016, San Diego, CA, May 24, 2016.
74. "How to Use Successful Time Management to Enhance Your Career." AGA Research Symposium. DDW 2016, San Diego, CA, May 23, 2016.
75. "Cut, Burn or Freeze for Barrett's Esophagus?" DDW Combined Clinical Symposium. San Diego, CA, May 21, 2016.
76. "Endoscopic Diagnosis of Esophageal Cancer," Cancer Research UK International Symposium on Esophageal Cancer, Oxford, UK, June 6, 2015.
77. "Misplaced Priorities and Barrett's Esophagus," Medical Grand Rounds and the 20<sup>th</sup> Annual James Respass Distinguished Lecture, University of Virginia, Charlottesville, VA, June 4, 2015.
78. "Management of Barrett's Esophagus," The Underwood Symposium, Houston Methodist Hospital, Houston, TX, May 29, 2015.



79. "Buried Barrett's Metaplasia after Endoluminal Ablation - A Ticking Time Bomb or Much Ado About Nothing?" SSAT Session at DDW, Washington, DC, May 18, 2015.
80. "Barrett's Esophagus: You Mean You Still Screen for That?" ASGE Spring Postgraduate Course, Washington, DC, May 18, 2015.
81. "Barrett's Dysplasia: What To Do, When And How? AGA Spring Post-Graduate Course, Washington, DC, May 16, 2015.
82. "Cough, Wheeze, Sore Throat And More: What Is Related To GERD And How To Approach?" AGA Spring Post-Graduate Course, Washington, DC, May 16, 2015.
83. "Managing non-dysplastic and dysplastic Barrett's esophagus: the old and the new," Kansas City Live Endoscopy Course, Kansas City, MO, April 25, 2015.
84. "Preventing Esophageal Adenocarcinoma," Medical Grand Rounds, Walter Reed Hospital, Washington, DC, March 27, 2015.
85. "Barrett's Esophagus: Detection, Surveillance, Treatment." 15<sup>th</sup> Annual Educational Meeting in Gastroenterology, Cedars Sinai Medical Center, Los Angeles, CA, March 6, 2015.
86. "Barrett's related early cancer - endoscopic eradication therapies," 12<sup>th</sup> Annual Rocky Mountain Interventional Endoscopy Course, Denver, CO, February 13, 2015.
87. "Ablate All Barrett's – A Pro/Con Debate," AGA Winter Congress, Miami, FL, January 23, 2015.
88. "Treatment of Barrett's Esophagus," New York Society for Gastrointestinal Endoscopy Annual Course, New York, NY, December 17, 2014.
89. "Barrett's Esophagus and Management of Dysplasia," University of South Florida CME conference, December 6, 2014, Tampa, FL.
90. "Barrett's Esophagus and Esophageal Cancer," AGA/JUCC Combined Conference, Tokyo, Japan, November 21, 2014.
91. "Misplaced Priorities and Barrett's Esophagus," the Berk/Bockus Honorary Lecture, Jefferson Medical College, Philadelphia, PA, October 22, 2014.
92. "Barrett's Esophagus: Detection, Surveillance, Treatment." ACG Annual Postgraduate Course, Philadelphia, PA, October 18, 2014.
93. "Defeating Barrett's esophagus: Cut, burn or freeze?" ASGE Annual Course at ACG Meeting, Philadelphia, PA, October 17, 2014.
94. "Does RFA Alter the Molecular Features of the Squamous Mucosa?" International Society for Diseases and the Esophagus Biannual Meeting, Vancouver, BC, Canada, September 22, 2014.
95. "Longterm Outcomes of RFA" International Society for Diseases and the Esophagus Biannual Meeting, Vancouver, BC, Canada, September 23, 2014.
96. "Barrett's Esophagus Guidelines," ASGE Endofest Endoscopy Course, Las Vegas, NV, September 19, 2014.

97. "Eosinophilic Esophagitis," ASGE Endofest Endoscopy Course, Las Vegas, NV, September 21, 2014.
98. Functional Heartburn and Dyspepsia," 2014 ACG Midwestern Regional Postgraduate Course, Indianapolis, IN, August 23, 2014.
99. "Barrett's Esophagus: State of the Art," 2014 ACG Midwestern Regional Postgraduate Course, Indianapolis, IN, August 23, 2014.
100. "How Not to Manage Barrett's Esophagus: What Have We Learned?" Chicago Live CME Course, Northwestern University SOM, Chicago, IL, August 7, 2014.
101. "Misplaced Priorities and Barrett's Esophagus," Visiting Professor, Louisiana State University School of Medicine, Shreveport, LA, July 17, 2014.
102. "Misplaced Priorities and Barrett's Esophagus," Visiting Professor, Massachusetts General Hospital, Boston, MA, July 15, 2014.
103. "Biomarkers to predict Barrett's progression," NIH BETRNet Annual Meeting, Bethesda, MD, July 1, 2014.
104. "Why what we are doing now for Barrett's doesn't much matter," Irish Society of Gastroenterology National Meeting, Naas, Ireland, June 13, 2014.
105. "Hold the Wrap, There's So Much More That Can Be Done for GERD," ACG Eastern Regional Postgraduate course, Washington, DC, June 7, 2014.
106. "Medical and Endoscopic Treatment of Barrett's Esophagus," DDW Combined Clinical Symposium, Chicago, IL, May 6, 2014.
107. "Resection and Ablation: Achieving the Best Results," ASGE Symposium at DDW, Chicago, IL, May 5, 2014.
108. "Risk factors for and management of recurrent IM/Dysplasia or cancer." 2014 Medical and Surgical Aspects of Esophageal Disorders: Pathophysiology and Treatment CME Course by University of Southern California, Kona, Hawaii, February 3, 2014.
109. "Worldwide studies of the long term safety and efficacy of RFA." 2014 Medical and Surgical Aspects of Esophageal Disorders: Pathophysiology and Treatment CME Course by University of Southern California, Kona, Hawaii, February 3, 2014.
110. "Eosinophilic Esophagitis: Are We There Yet?" ACG Board of Governors/ASGE Best Practices Course, Las Vegas, NV, January 24, 2014.
111. "Current Controversies in Barrett's Esophagus," Case-Western Reserve University CME, Cleveland, OH, December 6, 2013.
112. "Misplaced Priorities and Barrett's Esophagus," The 2013 Klein Family Foundation Lecture, Yale Bridgeport Hospital, Bridgeport, CT, October 24, 2013.
113. "Can We Prevent Cancer in Barrett's Esophagus?" The 2013 Emily Couric Lecture at the ACG National Meeting, San Diego, CA, October 15, 2013.
114. "Eosinophilic Esophagitis: Diagnosis and Treatment," ACG Learning Lunch, San Diego, CA, October 13, 2013.
115. "How to Treat Eosinophilic Esophagitis," ASGE Postgraduate Course at the Annual ACG Meeting, San Diego, CA, October 11, 2013.

116. "Burn and Freeze Barrett's Esophagus," ASGE Postgraduate Course at the Annual ACG Meeting, San Diego, CA, October 11, 2013.
117. Lumenitis," ASGE Endofest Conference, Las Vegas, NV, September 20, 2013.
118. "Occurrence of Barrett's esophagus in the Population," AGA Freston Conference, Chicago, IL, August 17, 2013.
119. "Clinical Research in Barrett's Esophagus," Visiting Professorship at University of Chicago, Chicago, IL, August 9, 2013.
120. "Advances in Risk Stratification and Screening," Chicago Live CME Course, Chicago, IL, August 2, 2013.
121. "Initial Work Up & Determining Who Should be Referred for Anti-Reflux Surgery," University of Pittsburgh's Benign Esophageal Disorders CME Course, Pittsburgh, PA, June 6, 2013.
122. "Endoscopic Therapy for Barrett's Esophagus," GI Grand Rounds and Visiting Professor, Indiana University, Indianapolis, IN, June 3, 2013.
123. The role of endoscopic therapy in the management of high-grade dysplasia and mucosal carcinoma at the GE junction," Digestive Diseases Week Combined Clinical Symposium, Orlando, FL, May 19, 2013.
124. "Hands-On Course: Ablative Therapy," American Society for Gastrointestinal Endoscopy's Spring Postgraduate Course, Orlando, FL, May 19, 2013.
125. "Hands-On Course: Ablative Therapy," American College of Gastroenterology Eastern Regional Postgraduate Course, Washington, DC, April 13, 2013.
126. "Barrett's Ablative Therapies: Patient Selection, Technical Issues, & Post-Procedure Surveillance," American College of Gastroenterology Eastern Regional Postgraduate Course, April 13, 2013.
127. "Endoscopic Therapy for Barrett's Esophagus," Tufts University GI Grand Rounds, Boston, MA, April 11, 2013.
128. "Evolving Concepts in Barrett's Esophagus," Emory University Department of Medicine Grand Rounds, Atlanta, GA, February 12, 2013.
129. "Endoscopic Therapy for Barrett's Esophagus," Emory University GI Grand Rounds, Atlanta, GA, February 11, 2013.
130. "Eosinophilic Esophagitis: Treat with Diet? Treat with Drugs?," American College of Gastroenterology Western Regional Post-Graduate Course, Los Angeles, CA, January 25, 2013.
131. "Endoscopic Approaches to Esophageal Cancer," American Society of Clinical Oncology's 10<sup>th</sup> Annual GI Symposium, San Francisco, CA, January 24, 2013.
132. "Dealing with Dysplasia," American Gastroenterological Association's 2013 Clinical Congress, San Diego, CA, January 18, 2013.
133. "Radiofrequency Ablation for Barrett's Esophagus." American Society for Gastrointestinal Endoscopy Hands-On Course, San Diego, CA, January 17, 2013.

134. "Ablative Therapy for Barrett's Esophagus," Visiting Professor, Florida Hospital, Orlando, FL, November 29, 2012.
135. "Evolving Concepts in Barrett's Esophagus," Mount Sinai Medical School GI Grand Rounds and Visiting Professor, New York, NY, November 16, 2012.
136. "What is the Role of Endoscopic Management of Early Esophageal Cancer?" University of Pittsburgh Department of Thoracic Surgery, Visiting Professor and CME lecture, Pittsburgh, PA, November 1, 2012.
137. "Have the Odds Changed?: Do New Results Influence Old Algorithms in Treatment of Non-Dysplastic Barrett's Esophagus?" American College of Gastroenterology Annual Meeting Symposium, Las Vegas, NV, October 22, 2012.
138. "Barrett's Ablative Therapies - Patient Selection, Technical Issues, Complications, and Post-Procedure Surveillance," American College of Gastroenterology Annual Postgraduate Course, Las Vegas, NV, October 21, 2012.
139. "Optimizing Follow-up after Ablation Therapy: How Long and at Which Interval?" 13<sup>th</sup> World Congress of the International Society of Diseases of the Esophagus, Venice, Italy, October 17, 2012.
140. "RFA for Barrett's Esophagus with and without Dysplasia," 13<sup>th</sup> World Congress of the International Society of Diseases of the Esophagus, Venice, Italy, October 15, 2012.
141. "GERD and Barrett's Esophagus: What the PCP Needs to Know," Mountain AHEC CME, Asheville, NC, September 28, 2012.
142. "New Directions in Eosinophilic Esophagitis," Ohio State Gastroenterology Society Annual Meeting, Columbus, OH, September 22, 2012.
143. "Barrett's Esophagus: Is Surveillance Necessary?" Mercy Hospital CME, Baltimore, MD, September 13, 2012.
144. "The Epidemiology of Barrett's Esophagus," "Chicago Live," Northwestern U. CME Course, Chicago, IL, August 24, 2012.
145. "Endoscopic Management of Barrett's Esophagus," American College of Gastroenterology Midwest Region CME Course, Indianapolis, IN, August 25, 2012.
146. "Evolving Concepts in Barrett's Esophagus," Visiting Professor and GI Grand Rounds, Case Western University, Cleveland, OH, June 7, 2012.
147. "Endoscopic Cryotherapy," American Society for Gastrointestinal Endoscopy Hands-On Workshop, San Diego, CA, May 22, 2012.
148. "Proton Pump Inhibitors: Are They Living Up to the Promise?" DDW Combined Symposium Invited Lecture, San Diego, CA, May 22, 2012.
149. "Which Journal to Pick and How to Address Decision Letters," American Gastroenterological Association sponsored symposium at DDW, San Diego, CA, May 21, 2012.
150. "Non-Variceal Upper GI Bleeding: Burn, Inject, Clip or Do Them All?" American Gastroenterological Association's National Spring Postgraduate Course, San Diego, CA, May 19, 2012.

151. "News from the Ablation Front," NCI's Barrett's Esophagus and Adenocarcinoma Consortium (BEACON) National Meeting, Washington, DC, May 17, 2012.
152. "Ablative Therapy for Barrett's Esophagus," Society for Gastrointestinal Endoscopy of India (SGEI) India EndoCon 2012, Calcutta, India, April 28, 2012.
153. "Endoscopic Treatment of Barrett's Esophagus," The Alvin Zfass Lecture, Virginia Commonwealth University's Annual CME Course, Richmond, VA, March 24, 2012.
154. "Update in Barrett's Esophagus," North Carolina Society of Gastroenterology Annual Meeting, Pinehurst, NC, March 3, 2012.
155. "Screening and Surveillance for Barrett's Esophagus," ACG/ASGE Best Practices Course, Huntington Beach, CA, January 29, 2012.
156. "Eosinophilic Esophagitis: Update," ACG/ASGE Best Practices Course, Huntington Beach, CA, January 27, 2012.
157. "Ablative Therapies in Barrett's Esophagus," American Gastroenterological Association's Clinical Congress, Miami, FL, January 20, 2012.
158. "Novel Therapies for Early Stage Esophageal Cancer," MD Anderson's 10<sup>th</sup> Annual Oncology Update: Advances and Controversies," Steamboat Springs, CO, January 14, 2012.
159. "Evolving Concepts in Barrett's Esophagus," Internal Medicine Grand Rounds, University of Alabama, Birmingham," Birmingham, AL, November 30, 2011.
160. "An Endoscopic Approach to Barrett's Esophagus," Birmingham Gut Club, Birmingham, AL, November 30, 2011.
161. "Burn All Barrett's?" American College of Gastroenterology Annual Meeting Symposium, Washington, DC, November 1, 2011.
162. "Barrett's Esophagus: What to do for No Dysplasia, Low-Grade Dysplasia, and High-Grade Dysplasia," American College of Gastroenterology Annual Post-Graduate Course, Washington, DC, October 29, 2011.
163. "Minimally Invasive Treatment of Esophageal Cancer," the Jasjit Bindra Memorial Lecture in Esophageal Cancer, Yale University Cancer Center Grand Rounds, New Haven, CT, October 11, 2011.
164. "Evolving Concepts in Barrett's Esophagus," Medical Grand Rounds, Newcastle University School of Medicine, Newcastle, Australia, July 13, 2011.
165. "An Endoscopic Approach to Barrett's Esophagus," Gastroenterology Research Conference, Newcastle University School of Medicine, Newcastle, Australia, July 13, 2011.
166. "An Endoscopic Approach to Barrett's Esophagus," Sydney Gut Club, Sydney, Australia, July 12, 2011.
167. "Evolving Concepts in Barrett's Esophagus," Visiting Professor for GI Research Day, University of Toronto, Toronto, Canada, June 22, 2011.
168. "Pre-cancerous Lesions of the Esophagus," University of Manitoba Cancer Conference, Winnipeg, Canada, June 17, 2011.

169. "Meet the Expert: Barrett's Esophagus," Sociedad Espanola Pathologica Digestiva Annual Meeting, Seville, Spain, June 14, 2011.
170. "Which Barrett's Dysplasias Should be Treated and How?," AGA- Sociedad Espanola Pathologica Digestiva Post-Graduate Course, SEPD Annual Meeting, Seville, Spain, June 12, 2011.
171. "Evolving Concepts in Barrett's Esophagus," Medical Grand Rounds and Scholarly Day, Cleveland Clinic, Cleveland, OH, June 1, 2011.
172. "Decision Analysis Models of GERD and Barrett's Esophagus," NIH CISNet Annual Meeting, Boston, MA, May 13, 2011.
173. "Burying Barrett's: Situations and Solutions," ASGE Symposium, Chicago, IL, May 8, 2011.
174. "Epidemiology and Risk Factors for Eosinophilic Esophagitis," DDW Combined Symposium, Chicago, IL, May 8, 2011.
175. "Endoluminal Therapies for Barrett's Esophagus," American Society for Gastrointestinal Endoscopy's National Spring Post-Graduate Course, Chicago, IL, May 8, 2011.
176. "Update in GERD," International Foundation for Functional Gastrointestinal Disorders, Milwaukee, WI, April 9, 2011.
177. "Challenging Problems in Gastrointestinal Upper Endoscopy," 3<sup>rd</sup> Annual Foregut Surgery Conference, Methodist Institute for Technology, Innovation, and Education, Houston, TX, March 10, 2011.
178. "Radiofrequency Ablation," American Gastroenterological Association's Clinical Congress, Miami Beach, FL, January 16, 2011.
179. "Hands-On Faculty – Radiofrequency Ablation," American Gastroenterological Association's Clinical Congress, Miami Beach, FL, January 16, 2011.
180. "Screening and Surveillance for Barrett's Esophagus," American Gastroenterological Association's Clinical Congress, Miami Beach, FL, January 15, 2011.
181. "The Irregular Z Line: Biopsy? Burn? Ignore?," Johns Hopkins University School of Medicine Annual Update in Gastroenterology, Baltimore, MD, November 11, 2010.
182. "Update on the Management of Barrett's Esophagus," American College of Gastroenterology's Annual Post-Graduate Course, October 16, 2010.
183. "Gastrointestinal Bleeding in the Foregut: Scoping the Evidence," American Society of Gastrointestinal Endoscopy's Post-Graduate Course at the ACG Annual Meeting, San Antonio, TX, October 15, 2010.
184. "Endoscopic Therapy of Barrett's Esophagus," American Society of Gastrointestinal Endoscopy's Post-Graduate Course at the ACG Annual Meeting, San Antonio, TX, October 15, 2010.
185. "Ablation for Barrett's Esophagus," St Mark's International Course for Gastrointestinal Endoscopy, Toronto, ON, October 14, 2010.
186. "Screening and Surveillance for Barrett's Esophagus," Creighton University Esophageal Diseases Conference, Omaha, NE, September 30, 2010.

187. "Endoscopic Interventions for Inoperable Esophageal Cancer," Creighton University Esophageal Diseases Conference, Omaha, NE, September 29, 2010.
188. "The Future of Endoscopic Therapy: Will We Stop the Cancer Epidemic?" Northwestern Multidisciplinary Course on Esophageal Diseases, September 25, 2010.
189. "Epidemiology of Barrett's Esophagus and Esophageal Adenocarcinoma," Northwestern Multidisciplinary Course on Esophageal Diseases, September 24, 2010.
190. "Endoscopic Therapy of Barrett's Esophagus," St. Louis University Annual Gastrointestinal Cancers Symposium, September 11, 2010.
191. "The Clinical Trialists' Workshop: Ablative Therapy for Barrett's Esophagus," International Society of Diseases of the Esophagus Meeting, Kagoshima, Japan, September 3, 2010.
192. "Economic Analyses of Cost-Effectiveness of Ablative Therapy for Barrett's Esophagus," OESO (World Organization for Study of Diseases of the Esophagus) Meeting, Boston, MA, August 31, 2010.
193. "Radiofrequency Ablation for Dysplastic Barrett's Esophagus," OESO (World Organization for Study of Diseases of the Esophagus) Meeting, Boston, MA, August 29, 2010.
194. "How I Do It: Eradicate BE," American Society for Gastrointestinal Endoscopy's National Spring Postgraduate Course, New Orleans, LA, May 5, 2010.
195. "Why Screen for BE?" American Society for Gastrointestinal Endoscopy's National Spring Postgraduate Course, New Orleans, LA, May 5, 2010.
196. "What Needs Burned, What Needs Watched," DDW Combined Clinical Symposium, New Orleans, LA, May 4, 2010.
197. "Meet the Professor: Ablation of BE: Tips and Tricks," AGA Meet the Professor Series at DDW, New Orleans, LA, May 3, 2010.
198. "Ablation of Barrett's Esophagus with LGD or No Dysplasia: The Pro Position," American Society for Gastrointestinal Endoscopy Symposium at DDW, New Orleans, LA, May 3, 2010.
199. "Getting Things Done: The Nitty-Gritty," American Society for Gastrointestinal Endoscopy's Grant-Writing Skills Workshop, New Orleans, LA, May 2, 2010.
200. "Difficult Cases in Esophageal Diseases," American Gastroenterological Association's National Spring Postgraduate Course, New Orleans, LA, May 1-2, 2010.
201. "Building Your Research Team," American Gastroenterological Association's Academic Skills Workshop, Houston, TX, March 19, 2010.
202. "Improving Care in Barrett's Esophagus," Visiting Professor and Gut Club Meeting, University of Pittsburgh, Pittsburgh, PA, March 11, 2010.
203. "Barrett's Esophagus," Visiting Professor and Medical Grand Rounds, Northwestern University, Chicago, IL, February 16, 2010.
204. "Where Should I Go? – Academic Practice!" American Gastroenterological Association's Practice Skills Workshop, Las Vegas, NV, January 17, 2010.

205. "Can We Impact the Rising Incidence of Esophageal Adenocarcinoma?" American Gastroenterological Association's Clinical Congress, Las Vegas, NV, January 16, 2010.
206. "The Best of DDW – Esophageal Diseases," United European Gastroenterology Federation Annual Meeting (UEGW), London, UK, November 24, 2009.
207. "Improving Care in Barrett's Esophagus," Visiting Professor and GI Grand Rounds, Mt. Sinai Hospital, New York, NY, November 13, 2009.
208. "Is the Only Good Barrett's a Burned Barrett's?" American College of Gastroenterology Annual National Meeting, San Diego, CA, October 27, 2009.
209. "It's Dysplastic – Now What?," ASGE Postgraduate Course at the American College of Gastroenterology Annual National Meeting, San Diego, CA, October 23, 2009.
210. "Upper GI Bleeding – What Have We Learned?," ASGE Postgraduate Course at the American College of Gastroenterology Annual National Meeting, San Diego, CA, October 23, 2009.
211. "Improving Care in Barrett's Esophagus," Georgia Society of Gastroenterology Annual Meeting, Atlanta, GA, September 26, 2009.
212. "Endoscopic Therapy for Barrett's Esophagus," "Esophageal Madness" CME Course sponsored by Northwestern University, Las Vegas, NV, August 7, 2009.
213. "Ablative Therapy in Barrett's Esophagus," Visiting Professor & GI Grand Rounds, Ohio State University, Columbus, OH, July 17, 2009.
214. "Improving Care in Barrett's Esophagus," Visiting Professor, National Cancer Institute, Division of Cancer Prevention, Washington, DC, June 5, 2009.
215. "Endoscopic Intervention in Barrett's Esophagus," AGA Symposium, DDW, Chicago, IL, June 2, 2009.
216. "Burning Barrett's Mucosa: What Can Be Achieved?," DDW Combined Symposium, Chicago, IL, June 1, 2009.
217. "Endoscopic Ablative Therapy: Who Needs It, and What Methods?," Presidential Plenary, American Gastroenterological Association, Chicago, IL, June 1, 2009.
218. "Endoscopic Prevention of Adenocarcinoma," AGA "Meet the Professor" Luncheon, Chicago, IL, June 1, 2009.
219. "Ablative Therapy in Barrett's Esophagus: Which Methods, Which Patients?," Spring Post-Graduate Course, American Gastroenterological Association, Chicago, IL, May 30, 2009.
220. "Improving Care in Barrett's Esophagus," Visiting Professor and GI Grand Rounds, University of Washington, Seattle, WA, May 8, 2009.
221. "Non-Erosive Reflux Disease," Visiting Professor & GI Grand Rounds, St. Louis University, St. Louis, MO, March 12, 2009.
222. "Endoscopic Treatment of Barrett's Esophagus," Mayo Clinic Winter CME Course, Scottsdale, AZ, February 27, 2009.
223. "Endoscopic Ablation for Barrett's Esophagus," Annual Wake Forest University Gastroenterology CME Course, Winston-Salem, NC, October 18, 2008.



224. "Endoscopic Screening and Surveillance for Barrett's Esophagus: Anything New?" American College of Gastroenterology Annual Meeting, Orlando, FL, October 8, 2008.
225. "The New Barrett's Esophagus Guidelines: Ask the Experts What They Mean," American College of Gastroenterology Annual Meeting, Orlando, FL, October 7, 2008.
226. "Endoscopic Screening, Surveillance and Ablation of Barrett's Esophagus," American College of Gastroenterology Annual Post-Graduate Course, Orlando, FL, October 4, 2008.
227. "Outcomes in Endoscopy: How Can Research Inform the Quality of Care?" American Society of Gastrointestinal Endoscopy Post-Graduate Course, Orlando, FL, October 3, 2008.
228. "The Costs of Barrett's Esophagus," Medical Grand Rounds, University of Louisville, Louisville, KY, September 18, 2008.
229. "Ablative Therapy for Barrett's Esophagus," Kentucky Medical Association Annual Meeting, Louisville, KY, September 17, 2008.
230. "Diagnostic and Therapeutic Approach to NERD," American Gastroenterological Association Symposium, DDW 2008, San Diego, CA, May 21, 2008.
231. "Barrett's Esophagus – Meet the Professor," American Society of Gastrointestinal Endoscopy, DDW 2008, San Diego, CA, May 20, 2008.
232. "Benign Esophageal Strictures – Non-Operative Interventions," Society of Surgeons of the Alimentary Tract Spring Post-Graduate Course, San Diego, CA, May 18, 2008.
233. "The Rising Incidence of Esophageal Cancer – Is It Genes or Fat?" American Gastroenterological Association Spring Post-Graduate Course, San Diego, CA, May 18, 2008.
234. "The Costs of Barrett's Esophagus," GI Grand Rounds, Vanderbilt University, Nashville, TN, April 17, 2008.
235. "EMR in the Management of HGD and Early Cancer," Medical and Surgical Aspects of Esophageal and Foregut Disorders: Pathophysiology and Treatment, University of Southern California, Kauai, Hawaii, February 25, 2008.
236. "Radiofrequency Ablation – Has the Ablation Problem been Solved?," Medical and Surgical Aspects of Esophageal and Foregut Disorders: Pathophysiology and Treatment, University of Southern California, Kauai, Hawaii, February 23, 2008.
237. "Screening and Surveillance for Barrett's Esophagus," Medical and Surgical Aspects of Esophageal and Foregut Disorders: Pathophysiology and Treatment, University of Southern California, Kauai, Hawaii, February 21, 2008.
238. "Planning Your Next Five Years," AGA Academic Skills Workshop, San Antonio, TX, January 27, 2008.
239. "Radiofrequency Ablation for Barrett's Esophagus with Dysplasia," Barrett's Esophagus Translational Research Workshop, National Cancer Institute, Washington, D.C., January 24, 2008.

240. "The Hidden Costs of Diagnosing Barrett's Esophagus," Barrett's Esophagus Translational Research Workshop, National Cancer Institute, Washington, D.C., January 23, 2008.
241. "The Costs of Barrett's Esophagus," GI Grand Rounds, University of Arizona, January 16, 2008.
242. "The Costs of Barrett's Esophagus," Medical Grand Rounds, Duke University, October 5, 2007.
243. "Management of High-Grade Dysplasia," GI Grand Rounds, Visiting Professor, University of Pennsylvania, September 19, 2007.
244. "Oropharyngeal Dysphagia," American College of Gastroenterology/Virginia Gastroenterological Society Regional Course, September 8, 2007.
245. "Update in Gastrointestinal Disorders: DDW, 2007," Visiting Professor, Kansas University Medical Center, Kansas City, KS, June 26, 2007.
246. "Oropharyngeal Dysphagia, Achalasia and Other Esophageal Motility Problems: Clinical Relevance and Management," FALK Symposium 160, Portoroz, Slovenia, June 15, 2007.
247. "Barrett's Esophagus," Meet-the-Professor Lunch, DDW, Washington, DC, May 21, 2007.
248. "What's New in Screening and Surveillance," DDW Symposium, Washington, DC, May 20, 2007.
249. "How Evidence-Based Medicine has helped the Gastroenterologist," SSAT National Post-Graduate Course, DDW, 2007, Washington, DC, May 20, 2007.
250. "Mucosal Ablation for Dysplasia: Yes, No," Walter Reed Gastroenterology Symposium, Washington, DC, March 23-24, 2007.
251. "The Costs of Barrett's Esophagus," GI Grand Rounds, Emory University, Atlanta, GA, March 12, 2007.
252. "Planning Your Next Five Years," AGA Academic Skills Workshop, Miami, FL. February 9-11, 2007.
253. "The Costs of Barrett's Esophagus," GI Grand Rounds, UCLA School of Medicine, Los Angeles, CA, January 11-12, 2007.
254. "Controversies of the Esophagus," Southern California Society of Gastroenterology Annual CME Conference, Los Angeles, CA, July 23, 2006.
255. "Barrett's Esophagus," Southern California Society of Gastroenterology Annual CME Conference, Los Angeles, CA, July 23, 2006.
256. "Advances at the Top and Within: Therapeutic Endoscopy and Upper GI," University of Kentucky Visiting Professor and CME Course, Lexington, KY, June 22, 2006.
257. "GERD and Barrett's Esophagus: The Mountain and the Molehill," Medical Grand Rounds, The Ohio State University School of Medicine, Columbus, OH, May 31, 2006.
258. "Endoscopic Evaluation of Barrett's Esophagus and Dysplasia," American Gastroenterological Association Symposium, Los Angeles, CA, May 24, 2006.

259. "Barrett's Esophagus," American Society of Gastrointestinal Endoscopy's Meet-the-Professor Series, Los Angeles, CA, May 24, 2006.
260. "Barrett's Esophagus: Who should We Diagnose and How Should We Screen?" DDW Combined Clinical Symposium, Los Angeles, CA, May 23, 2006.
261. "Focused Clinical Update in Gastroesophageal Reflux Disease," American Gastroenterological Association's DDW program, Los Angeles, CA, May 22, 2006.
262. "Risks of Wasting Money – Screening for and Surveillance of Barrett's Esophagus," American Gastroenterological Association's National Postgraduate Course, Los Angeles, CA, May 21, 2006
263. "Endoscopic Surveillance Does Not Save Dollars or Lives," American Society of Gastrointestinal Endoscopy Symposium at DDW, Los Angeles, CA, May 21, 2006.
264. "Stratifying Risk in Barrett's Esophagus," GI Grand Rounds, Northwestern University, Chicago, IL, April 6, 2006.
265. "Stratifying Risk in Barrett's Esophagus," American Gastroenterological Association's Weekly Web Conference National Lecture Series, April 7, 2006, Durham, NC.
266. "Barrett's Esophagus and GERD: the Mountain and the Molehill," North Carolina Academy of Family Practice Winter Meeting, Asheville, NC, December 18, 2005.
267. "Biostatistics and Evidence-Based Medicine: A Primer." American College of Gastroenterology Post-Graduate Course, Honolulu, HI, October 29, 2005.
268. "Does Medical Therapy Prevent Progression of Barrett's Esophagus to Cancer?" American Gastroenterological Association's Barrett's Working Group, Chicago, IL, May 15, 2005.
269. "Barrett's Esophagus: Disease or Distraction?" Digestive Diseases Week, Chicago, IL, May 14, 2005.
270. "AGA/GRG Young Investigator Clinical Award Lecture – Patient-Centered Ramifications of Barrett's Esophagus." AGA Award Symposium, Digestive Diseases Week, Chicago, IL, May 14, 2005.
271. "Barrett's Esophagus and GERD: the Mountain and the Molehill," Medicine Grand Rounds, Eastern Virginia Medical School, Norfolk VA, March 15, 2005.
272. "Supra-Esophageal GERD." Department of Medicine Grand Rounds, Kansas University, March 15, 2005.
273. "Critical Review of Outcomes and Cost-Effectiveness in Management of Reflux Disease and it's Supra-Esophageal Complications." 5<sup>th</sup> Annual Symposium on Supra-Esophageal GERD, Miami, FL, February 26, 2005.
274. "Endoscopic Screening is Effective in GERD: The Con Position." American Society of Clinical Oncology National Meeting, January 27, 2005.
275. "Reducing Acid-Related Complications of GERD: Caring for the Patient with Barrett's Esophagus." Digestive Diseases Week, New Orleans, LA, May 17, 2004.
276. "Focused Clinical Update: Barrett's Esophagus." Digestive Diseases Week, New Orleans, LA, May 16, 2004.

277. "The Literature on Atypical Manifestations of GERD: Why are there No Definitive Studies?" Digestive Diseases Week, New Orleans, LA, May 16, 2004.
278. "Is all GERD Created Equal?, or, FED Up with NERDs." Update in Esophageal Diseases, a CME program by the University of Kentucky, Lexington, KY, April 17, 2004.
279. "Mentoring Clinical GI Research." American Gastroenterological Association's Academic Skills & Fellows Workshop, Washington D.C., March 19, 2004.
280. "A Critical View of Treatment Studies in Extra-Esophageal Manifestations of GERD." New Frontiers in GERD and Dyspepsia, a CME program by the University of Arizona, Tempe, AZ, January 24, 2004.
281. "Screening for Gastrointestinal Malignancy: Barrett's Esophagus." American College of Gastroenterology National Meeting, Baltimore, MD, October 11, 2003.
282. "Management of Barrett's Esophagus." American College of Gastroenterology National Meeting Postgraduate Course, Baltimore, MD, October 10, 2003.
283. "What is the Most Cost-Effective Approach to the Work-up of Patients with Reflux Symptoms?" Organisation Mondiale D'Etudes Specialisees sur les Maladies de l'Oesophage (International Organization for Esophageal Studies) Bi-Annual Meeting, Paris, France, September 3, 2003.
284. "Will Endoscopy Decrease Death from Cancer in Barrett's Esophagus?" American Gastroenterological Association's Barrett's Working Group, Orlando, FL, May 20, 2003.
285. "Endoscopic Surveillance in Barrett's Esophagus- Does it Help?" American Gastroenterological Association National Meeting Digestive Diseases Week, Orlando, FL, May 19, 2003.
286. "Screening and Surveillance in Barrett's Esophagus." American Gastroenterological Association International Consensus Conference on Barrett's Esophagus, Chicago, IL, Jan. 31, 2003.
287. "Barrett's Esophagus: Who Should Have Endoscopic Surveillance?" American Gastroenterological Association National Meeting, Digestive Diseases Week, New Orleans, LA, May 21, 2001.
288. "Ablating Non-Dysplastic Barrett's Esophagus is a Bad Idea!" American Gastroenterological Association National Meeting Digestive Diseases Week, San Francisco, CA, May 20, 2002.
289. "The Myths of Acid-Peptic Disease," American Academy of Family Practice Meeting, Charleston, SC, October 7, 2000.

## Teaching Responsibility

### I. Student Teaching

- a. Director, Carolina Medical Student Research Program, 2005-2020

Annually, I organize all research opportunities on campus for medical students. This includes collecting all funding opportunities and available research positions on campus, and matching students to funding opportunities.

- b. Course Director, Gastrointestinal Mechanisms of Disease, 2<sup>nd</sup> Year MedE 207, 1998-2007, Block Member 2007-2014

This approximately month-long course introduces students to the basic pathophysiology of gastrointestinal diseases. As part of my role, I gave 8 lectures in this course, and also perform as section leader for 8 two-hour blocks of small group sessions. I also design and coordinate the syllabus.

- c. Course Director, 4<sup>th</sup> year elective in Gastroenterology, MedI 407, 1997-2014

This month-long elective exposes 4<sup>th</sup> year students to the workings of the GI consult service. My role is to arrange the student assignments, coordinate student activities, and teach on the consult service.

- d. Inpatient Attending, GI Ward Service, 1996-2003

For 1-2 two week blocks per year, I performed the teaching duties of the GI inpatient service. These include daily didactic lectures to the 3<sup>rd</sup> year students, impromptu bedside teaching and the assessment of physical diagnosis skills of the 3<sup>rd</sup> year clerks.

- e. Inpatient GI Consult Service Attending, 1997-2016

For 1-2 two week blocks per year, I performed the teaching duties of the GI Consult Service. These include teaching students and residents assigned to the service, with both set didactic lectures as well as case-based and bedside teaching.

- f. Distinguished Scholars Program, 2000-2015

Every Year, I participated in a session of the Distinguished Medical Scholars program. This program, run by Dr. Steve Kizer, is designed to teach critical evaluation of the literature to students who have opted to take an extra year of education between their 3<sup>rd</sup> and 4<sup>th</sup> year of medical school. Teaching a session requires one or more meetings with the students to review pertinent literature regarding the clinical question to be discussed, and then attending the 2 hour session where the material is critically appraised.

- g. Faculty Advisor, UNC Student Chapter, American Medical Association, 2002-2016

Main responsibilities are meeting with student-elected officers, planning events, and assuring adherence to the guidelines for student chapters of the AMA.

## II. Resident Teaching

- a. Housestaff Lectures and Morning Reports, 1997-present

I participate episodically in the Housestaff Board Review, morning report, their CPC series, and Interns' Lecture series. This amounts to 2-3 one hour lectures per year.

- b. Inpatient Service Attending (See Above)
- c. Consult Service Attending (See Above)

## III. Fellow Teaching

a. Fellow's GI Pathophysiology Conference, 1997-present

I speak at our fellows' main educational conference 2-3 times/year, and mentor fellow's lectures another 2-3 times/year.

b. GI Grand Rounds, 1997-present

This weekly case conference centers on patient issues. I present cases in this conference frequently, and attend on a weekly basis to help with the teaching.

c. Attending on Endoscopy and Biliary Service, 1998-2007

Approximately 4 months/year, I attended on the Biliary or Endoscopy Service in GI procedures. A main function of this role is to supervise the learning of endoscopic techniques of the Fellows.

d. Fellowship Program Director, 2004-2009

Help design, implement and troubleshoot the curriculum for our 10-15 fellows per year. Control all administrative aspects of the fellowship program.

VI. Student Career Advisees - Career advisor for medical students interested in pursuing internal medicine. Advisees include:

- a. Class of 2012
  - i. A.J. Rogers
- b. Class of 2010
  - i. Megan Diehl
  - ii. Joseph Bumgarner
- c. Class of 2007
  - i. Lakshmi Murty
  - ii. Anne Finefrock
- d. Class of 2006
  - i. Peter Addler
  - ii. Colin Freccia
  - iii. Jason Pritchett
- e. Class of 2005
  - i. Norman Gray
  - ii. Holly Shaffer
  - iii. Kate Mitchell
- f. Class of 2004
  - i. Kristen Browske
  - ii. David Harding
  - iii. Tom Whitlock
  - iv. Nauzima Allaudeen
  - v. Molly Blackley
- g. Class of 2003
  - i. Elizabeth Davis
  - ii. Phuong Doan
  - iii. Heather Holden
  - iv. Allison Coble
  - v. Shannon Vish
- h. Class of 2002
  - i. Jay Manning

IV. Student Research Preceptees (year-long)

- a. Class of 2022 – Angela Xue (UNC MD)
- b. Class of 2021 – Shweta Bhatia (UNC MD)
- c. Class of 2020 – William King (UNC MD)
- d. Class of 2019 - Audrey Chang (UNC MD)
- e. Class of 2018 – Athidi Gonikonda (UNC MD)
- f. Class of 2015 – Kelly Hathorn (Duke U MD)
- g. Class of 2014 – Hannah Kim (Dartmouth U. MD, Doris Duke Fellowship winner)
- h. Class of 2013 – Cary Cotton (UNC MD)
- i. Class of 2012 – A.J. Rogers (UNC MD)
- j. Class of 2011 – Brian Petullo (UNC MD)
- k. Class of 2008 - Joseph Bumgarner (UNC MD)
- l. Class of 2007 - David Locke Glenn (UNC MD)
- m. Class of 2005 - Kate Lawrence (UNC MD, Doris Duke Fellowship winner)
- n. Class of 2003 - Kathleen Corey (Duke U. MD, UNC MPH)
- o. Class of 2002 - Brooke Lawrence (Duke U. MD, UNC MPH)
- p. Class of 2000 - Melissa Crosby (UNC MD, Holderness Fellowship winner)
- q. Class of 1999 - Jennifer Klenzak (UNC MD)

V. Resident Research Preceptees

- a. Anne Peery, Class of 2009
- b. Natasha Von-Roenn, Class of 2005
- c. Joseph Cassara, Class of 2003

VI. Fellow Research Preceptees

- a. Sidney Greenberg, Class of 2024
- b. Cary Cotton, Class of 2022
- c. Craig Reed, Class of 2019
- d. Swathi Eluri, Class of 2018
- e. Thomas Runge, Class of 2018
- f. Asher Wolf, Class of 2017
- g. Sarina Pasricha, Class of 2016
- h. Will Bulseiwicz, Class of 2014
- i. Anne Peery, Class of 2013
- j. David Frantz, Class of 2012
- k. Seth Crockett, Class of 2012
- l. Millie Long, Class of 2010
- m. Sid Barritt, Class of 2010
- n. Shannon Vish, Class of 2008
- o. Evan Dellon, Class of 2008
- p. Joseph Cassara, Class of 2008
- q. Greg Austin, Class of 2007
- r. Jeffery Wei, Class of 2005
- s. Michelle Thiny, Class of 2005
- t. Ofer Feder, Class of 2003
- u. Neeraj Sachdeva, Class of 2002
- v. Doug Robertson, Class of 2000

VII. Graduate Supervision, Committees – I have served as the Master’s thesis advisor, reader or PhD dissertation committee member to the following individuals:

1. Haoran Zhang, PhD candidate, Duke U Biomechanical Engineering Class of 2023
2. Sanne van Muenster, PhD candidate, University of Amsterdam, Amsterdam, Netherlands, Class of 2022.

3. Charles Gaber, PhD candidate, University of North Carolina, Department of Epidemiology, UNC Gillings School of Global Public Health, 2022.
4. Zach Steelman, PhD candidate, Duke U Biomechanical Engineering, Class of 2020
5. Lucas Duits, PhD candidate, University of Amsterdam, Amsterdam, Netherlands, Class of 2019.
6. Nan, Li, PhD Candidate, University of North Carolina, Department of Epidemiology, UNC Gillings School of Global Public Health, Class of 2016.
7. Roos Pouw, MD, PhD candidate, University of Amsterdam, Amsterdam, Netherlands, Class of 2012.
8. Neil Terry, PhD candidate, Duke U Biomechanical Engineering Class of 2012.
9. Evan Dellon, MD, MPH candidate, UNC Gillings School of Global Public Health, Class of 2008
10. Quinn Lippmann, MPH candidate, UNC Gillings School of Global Public Health, Class of 2008
11. Greg Austin, MD, MPH candidate, UNC Gillings School of Global Public Health, Class of 2007
12. Raj Medapalli, MD, MPH candidate, UNC Gillings School of Global Public Health, Class of 2006
13. Jeffrey Wei, MD, MPH candidate, UNC Gillings School of Global Public Health, Class of 2005
14. Douglas Robertson, MD, MPH candidate, UNC Gillings School of Global Public Health, Class of 2005



## Grants Funded (Yearly Total Direct Costs)

### *Current Funding*

- 2018-23 North Carolina Translational and Clinical Science Institute (NC TRACS). This award funds all personnel and activities of NC TraCS, UNC's CTSA award. Co-Principal Investigator (Shaheen/Buse PIs), National Institutes of Health, NCATS, UL1TR002489 (50% effort), \$9,279,679.
- 2021-26 Short-term Research Training Grant. Principal Investigator, National Institutes of Health, NIDDK, T35DK007386 (1% effort), \$172,350.
- 2022-27 Multicenter randomized controlled trial of surveillance versus endoscopic therapy for Barrett's esophagus with low-grade dysplasia: the SURVENT Trial. Multi-PI (Shaheen, Wani, Souza, Durkalski), National Institutes of Health, NIDDK, U01 DK129191 (5% effort), \$2,200,000.
- 2022-27 Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation. Multi-PI (Shaheen, Markowitz, Bettegowda, Chak, Wani, Willis), National Institutes of Health, NCI, U01 CA271867 (10% effort), \$781,052.

### *Past Funding*

- 2017-22 Advanced a/LCI Systems for Improved Clinical Utility in Barrett's Esophagus. Co-Principal Investigator (Shaheen/A. Wax PIs), National Institutes of Health, NCI, R01CA210544 (10% effort), \$501,101.
- 2020-21 Multicenter randomized controlled trial of surveillance versus endoscopic therapy for Barrett's esophagus with low-grade dysplasia: the SURVENT Trial. Multi-PI (Shaheen, Wani, Souza, Durkalski), National Institutes of Health, NIDDK, U34DK124174-01 (5% effort), \$299,248.
- 2011-21 Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma – The BETRNet Consortium. PI's Berger/Chak/Elston/Grady/Markowitz, Shaheen Site PI, National Cancer Institutes, U54CA163060 (5% effort), \$1,026,058.
- 2014-19 Budesonide versus fluticasone for treatment of eosinophilic esophagitis. Co-Investigator (E Dellon PI), National Institutes of Health, NIDDK, R01 DK101856, (5% effort), \$1,249,529.
- 2012-19 U.S. Registry of Liquid Nitrogen Spray Cryotherapy for Barrett's Esophagus. Principal Investigator. CSA Medical (5% effort), \$760,400.
- 2013-18 Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy. Principal Investigator, National Institutes of Health, NIDDK. K24DK100548 (50% effort), \$164,060.
- 2014-16 Can quercetin increase claudin-4 and improve esophageal barrier function? Principal Investigator, National Institutes of Health, NIDDK. R21DK097529 (5% effort), \$143,888.
- 2011-16 Racial Disparities in Barrett's Esophagus. Richardson/Earp Grant PIs, Shaheen/Chen Project PIs. National Cancer Institutes. U54CA156733 (3% effort), \$898,285.

- 2012-15 Stratifying Risk in Barrett's Esophagus: Towards Biomarker-Based Patient Management. Principal Investigator. American Society of Gastrointestinal Endoscopy. (5% effort), \$155,000.
- 2011-15 Preventing HIV Infection in Women: Targeting Antiretrovirals to Mucosal Tissues. PI A. Kashuba, Shaheen Co-Investigator. National Institutes of Allergy and Infectious Diseases. U01 AI095031 (2% effort), \$1,479,082
- 2009-14 United States Radiofrequency Ablation Registry. PI Shaheen. Covidien Medical, Inc. (2% effort) \$2,430,000.
- 2006-14 Ablation of Intestinal Metaplasia with Dysplasia with a Novel Device – AIM Dysplasia. PI Shaheen, Covidien Medical, Inc., 2% effort) \$842,000.
- 2011-14 Phase I AND II Clinical Trials of Cancer Prevention Agents. PI S. Chow, Shaheen Co-Investigator. National Cancer Institutes. N01 CN35158 (procurement contract) (2% effort).
- 2013-15 Building a Better Neosquamous Barrier. PI's Shaheen/Orlando. National Cancer Institutes. 5U54CA163060 (substudy). (2% effort), \$75,000.
- 2010-13 Barrett's and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS). Vaughan, PI, Shaheen Co-Investigator/Site PI, National Cancer Institutes R01CA136725 (5% effort), \$1,230,812.
- 2011-13 Center for HIV/AIDS Vaccine Immunology (CHAVI). Haynes, PI, Shaheen Co-Investigator. U01 AI067854 (substudy) (3% effort) \$46,623,214.
- 2011-13 Is the Squamous Epithelium "Normal" Following Endoscopic Ablation of Dysplastic Barrett's Esophagus? PI Shaheen/Orlando. American Society for Gastrointestinal Endoscopy, (5% effort), \$75,000.
- 2011-13 A Phase 2b, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate Efficacy of a Novel Selective 5-HT4 Receptor Agonist, SSP-002358 Taken in Addition to a Proton Pump Inhibitor in Subjects with Gastroesophageal Reflux Disease with Persistent Regurgitation with or without Heartburn while on Proton Pump Inhibitor Therapy. Shaheen, PI. Shire Pharmaceuticals. (3% effort). \$4,678,000.
- 2005-12 Familial Barrett's Esophagus Co-Investigator/Site PI, National Institutes of Health R01DK070863 (Chak, PI) (5% effort) \$387,664.
- 2008-11 Clinical Risk Factors for Barrett's Esophagus in a Primary Care Setting Co-Investigator, National Institutes of Health, R21DK081161 (Jobe, PI), (10% effort) \$133,250.
- 2009-11 Effect of a Low Carbohydrate Diet on Gastroesophageal Reflux Disease Principal Investigator, Takeda Pharmaceuticals, (10% effort) \$136,000.
- 2008-10 Barrett's Esophagus: Risk Factors in Women Co-Investigator, National Institutes of Health, R21 DK077742 (Corley, PI), (10% effort) \$88,250.
- 2007-10 Risk Perception in Barrett's Esophagus. Principal Investigator, National Institutes of Health, R03 DK075842, (15% effort, no cost extension) \$87,618.

- 2006-10 Immunology of the Gastrointestinal Tract in Acute HIV Infection. A CHAVI Study. Co-Investigator, National Institutes of Health U01 AI067854 (5% effort) (Haynes, PI), \$32,000.
- 2007-09 Biomarkers in Adenocarcinoma of the Esophagus  
Principal Investigator, National Institutes of Health, SPORE Developmental Grant, \$45,000.
- 2006-08 Predictive Biomarkers for Esophageal Adenocarcinoma in Subjects with Barrett's Esophagus. Co-Investigator, Site PI, National Institutes of Health CA095060 (Gerner, PI), \$56,000.
- 2006-08 A Phase 3 Study to Evaluate the Efficacy and Safety of a Novel Proton Pump Inhibitor to an Active Comparator on Healing of Erosive Esophagitis. T-EE04085 Co-Investigator (Site PI), TAP Pharmaceuticals, \$52,000.
- 2006-07 Modulation of Biomarkers of Barrett's Esophagus by Aspirin: A Pilot Study.  
Co-Principal Investigator, Triangle Community Foundation, \$60,000.
- 2005 A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intra-gastric Acid Control and Healing Status of Erosive Esophagitis After Treatment with Esomeprazole 10 mg and 40 mg Once Daily, D9612L00062.  
Co-Investigator (Site PI), AstraZeneca, \$56,000.
- 2005-06 An Investigation of the Prevalence of Clinically Relevant Esophageal Mucosal Pathology (EMP) in Prilosec OTC Users, D9612L00084.  
Principal Investigator, AstraZeneca, \$60,000.
- 2004-05 GERD as an Etiology of Sleep Disturbances,  
Principal Investigator, Eisai-Janssen Co., \$125,000.
- 2004-05 A Randomized, Double Blinded, Placebo-Controlled Trial of Tegaserod alone or in Combination with Omeprazole in Patients with Non-Erosive GERD,  
Co-Investigator (Site PI), Novartis Inc., \$140,000.
- 2004-06 Chronic Cough and Reflux Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial, IRUSE SOM0313  
Principal Investigator, AstraZeneca, \$196,000.
- 2003 Decision Analysis Model of the Management of High Grade Dysplasia in Barrett's,  
Principal Investigator, Eisai-Janssen Co., \$30,000.
- 2001-03 Proton Pump Inhibition as an Adjunct to Elective Esophageal Banding,  
Principal Investigator, Wyeth Ayerst Co., \$56,000 yearly.
- 2001-06 Epidemiologic Case-Control Study of Barrett's Esophagus, 1K23DK59311-01  
Principal Investigator, National Institutes of Health K 23 Career Development Award, \$100,000.
- 2000-01 Barrett's Esophagus Surveillance Trial (BEST), 1R03DK056748-01  
Co-investigator (R. Sandler), National Institutes of Health, \$50,000 yearly.
- 2000-02 Role of HFE Mutations in Cystic Fibrosis,  
Co-investigator (L. Silverman), Cystic Fibrosis Foundation, \$75,000 yearly.
- 1999-01 Clinical Utility of the C282Y Mutation

- Principal Investigator, American College of Gastroenterology Junior Faculty Development Award, \$40,000 yearly.
- 1999-02 Lanreotide as a Pharmacologic Adjunct in Variceal Bleeding, Co-Investigator (N. Grace), Henri Beaufour Industries, \$100,000 yearly.
- 1998 Prevalence of Genetic Discrimination in Hereditary Hemochromatosis, Principal Investigator, American Digestive Health Foundation Outcomes Research Award, \$50,000.
- 1998 Incidence of Hemochromatosis in Type 2 Diabetes, 5MO1 RR000046, Principal Investigator, National Institutes of Health, \$20,000.
- 1997 Barriers to Implementation of Colorectal Cancer Screening by Flexible Sigmoidoscopy, Principal Investigator, State of North Carolina Department of Health and Human Services, \$100,000.
- 1995 Comparison of Paracentesis Needles for Large Volume Paracentesis, Principal Investigator, Tri-Med Industries, \$5,600.

### **Professional Service**

#### **National Committees**

- 2022 President-Elect, International Society for Diseases of the Esophagus
- 2021 Vice-President, International Society for Diseases of the Esophagus
- 2020 Ad Hoc Member, NIH Special Emphasis Panel, (ZCA1 SRB-T (M3) R, NCI
- 2014-2020 Director, ACG Institute for Research and Education
- 2014 Ad Hoc Member, NIH Special Emphasis Panel, (ZDK1 GRB-2 (M3)), NIDDK
- 2013 Ad Hoc Member, NIH Special Emphasis Panel,( ZRG1 DKUS-D), NIDDK
- 2012 Ad Hoc Member, NIH Special Emphasis Panel,( ZDK1-GRB6-J2), NIDDK
- 2012 Appointed to Medicare Evidence Development & Coverage Advisory Committee (MEDCAC)
- 2012 Ad Hoc Member, NIH Special Emphasis Panel,( ZDK1-GRZ6-J1), NIDDK
- 2010-present Board of Trustees, American College of Gastroenterology
- 2009-2020 Board of Directors, American College of Gastroenterology Institute
- 2009-2011 Chair, Practice Parameters Committee, American College of Gastroenterology
- 2009 Course Director, 2009 American Gastroenterological Association Spring Post-Graduate Course
- 2008 Course Director, 2009 American Gastroenterological Association Clinical Congress
- 2007-2010 Chair, Research Committee, American College of Gastroenterology
- 2007 Ad Hoc member, NIDDK DDK-C Special Review Study Section
- 2007 Course Director, 2007 Annual National Postgraduate Course, American Society of Gastrointestinal Endoscopy
- 2007 Course Director, 2007 Annual National Postgraduate Course, American College of Gastroenterology
- 2006 Co-Chair, National Quality Measures Task Force, American College of Gastroenterology
- 2006 NIH National Commission on Digestive Diseases (NCDD), Diseases of the Oropharynx and Esophagus Working Group
- 2006 International Advisory Committee of the International Working Group for the Classification of Oesophagitis (IWGCO)
- 2006 Ad Hoc Member, NIH Special Emphasis Panel (ZDK1-GRB8-O2), NIDDK
- 2006-present Member, AMA Consortium/AGA Institute/NCQA GERD Working Group

2006	Ad Hoc Member, NIH Special Emphasis Panel (ZRG1 SBIB-A 50), Small Business Grants
2006-2008	Public Relations Committee, American Society for Gastrointestinal Endoscopy
2006-2010	Annual Scientific Program Committee, American Society for Gastrointestinal Endoscopy
2005	Member, NIH Special Emphasis Panel (ZDK1-GRB8-J1), NIDDK
2003-present	Abstract Selection Committee, American College of Gastroenterology, Outcomes Section, Chairman 2004, 2005
2002-present	U.S. Food and Drug Administration Gastroenterology and Urology Devices Panel, consultant
2002-2009	American College of Gastroenterology National Research Grants Committee Chairman, 2006-2009
2002	National Institutes of Health Ad Hoc Study Section for Barrett's Esophagus

### Memberships and Organizations

American College of Gastroenterology  
 American Gastroenterological Association  
 American Society of Gastrointestinal Endoscopy  
 American College of Physicians  
 American Medical Association  
 North Carolina Society of Gastroenterology  
 North Carolina Medical Society

### Editorial Appointments

2013-2016	Senior Associate Editor, <i>American Journal of Gastroenterology</i>
2009-2013	Associate Editor, <i>American Journal of Gastroenterology</i>
2009-2013	Associate Editor, <i>Clinical and Translational Gastroenterology</i>
2007-2013	Editorial Board, <i>Clinical and Translational Science</i>
2007-present	Editorial Board, <i>Clinical Gastroenterology and Hepatology</i>
2005-present	Editorial Board, <i>World Journal of Gastroenterology</i>
2005-present	Reviewer, <i>New England Journal of Medicine</i>
2002-2007	Editorial Board, <i>Gastroenterology</i>
2002-present	Reviewer, <i>Gut</i>
2002-present	Reviewer, <i>American Family Physician</i>
2002-present	Reviewer, <i>Inflammatory Bowel Disease</i>
2001-2006	Contributor, <u>Selected Summaries</u> , <i>Gastroenterology</i>
2000-2008	Editorial Board, <i>Evidence-Based Gastroenterology</i>
2000-present	Reviewer, <i>Alimentary Pharmacology and Therapeutics</i>
1999-present	Reviewer, <i>Gastroenterology and Hepatology</i>
1999-present	Reviewer, <i>Gastroenterology</i>
1998-present	Reviewer, <i>American Journal of Medicine</i>
1998-present	Reviewer, <i>JAMA</i>
1998-present	Reviewer, <i>Digestive Diseases and Sciences</i>
1997-present	Reviewer, <i>American Journal of Gastroenterology</i>

### School of Medicine Committees

2018	Member, Search Committee, Chair of Family Medicine
2011-2013	Steering Committee, Strategic Plan, UNC SOM
2009-2013	UNC Curriculum Committee
2005-2012	Program on Translational Research Steering Committee
2005	Dean's Task Force on Strategic Planning, Chair, Faculty Development
2004-2020	Director, Medical Student Research Training Program

2003-2014	Educational Program for the M.D. Degree Steering Committee (LCME Committee)
2002-2005	Student Promotions Committee
2002-2012	Curriculum Management and Policy Committee
2001-2012	Curriculum Advisory Committee
1998-2013	Second Year Curriculum Committee, Chairman 2001-2013
1999-2002	Curriculum Integration Committee, Chairman 2000-2002

### **Administrative Activities**

2013-present	Chief, Division of Gastroenterology & Hepatology
2005-2020	Director, UNC Office of Medical Student Research
2002-2020	Director, UNC Center for Esophageal Diseases and Swallowing
2002-2010	Co-Director, UNC GI Motility Laboratory
2004-2009	Director, GI Fellowship Training Program